m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00007)
| Regulator Name | Methyltransferase-like 3 (METTL3) | ||||
|---|---|---|---|---|---|
| Synonyms |
N6-adenosine-methyltransferase catalytic subunit; hMETTL3; N6-adenosine-methyltransferase 70 kDa subunit; MT-A70; MTA70
Click to Show/Hide
|
||||
| Gene Name | METTL3 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Angiopoietin 1 receptor (TEK)
AKB-9778 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for AKB-9778. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AKB-9778 through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [2] | ||
DCC-2036 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for DCC-2036. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DCC-2036 through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [3] | ||
Altiratinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for Altiratinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Altiratinib through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [4] | ||
CEP-11981 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for CEP-11981. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEP-11981 through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [5] | ||
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for (4-Phenoxy-phenyl)-quinazolin-4-yl-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-Phenoxy-phenyl)-quinazolin-4-yl-amine through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [6] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [7] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [8] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [7] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [7] | ||
A-420983 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for A-420983. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-420983 through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [7] | ||
ABTAA [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for ABTAA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABTAA through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [9] | ||
AP-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for AP-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AP-101 through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [10] | ||
ARRY-614 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Angiopoietin 1 receptor (TEK) is a therapeutic target for ARRY-614. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARRY-614 through regulating the expression of Angiopoietin 1 receptor (TEK). | [1], [11] | ||
Apoptosis mediating surface antigen FAS (FAS)
VB-111 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for VB-111. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VB-111 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [13] | ||
APG-101 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-101 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [14] | ||
DE-098 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for DE-098. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DE-098 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [15] | ||
APO-010 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APO-010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APO-010 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [16] | ||
2-aminophenoxazine-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for 2-aminophenoxazine-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-aminophenoxazine-3-one through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [17] | ||
APG-103 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for APG-103. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-103 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [18] | ||
F61F12 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for F61F12. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of F61F12 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [19] | ||
ISIS 17020 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis mediating surface antigen FAS (FAS) is a therapeutic target for ISIS 17020. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 17020 through regulating the expression of Apoptosis mediating surface antigen FAS (FAS). | [12], [20] | ||
Apoptosis regulator BAX (BAX)
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator BAX (BAX) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator BAX (BAX). | [21], [22] | ||
Apoptosis regulator Bcl-2 (BCL-2)
MCI-186 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [24] | ||
Venetoclax [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [25] | ||
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [26] | ||
Oblimersen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [27] | ||
RG7601 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [28] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [29] | ||
APG-1252 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [30] | ||
APG-2575 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [31] | ||
AZD0466 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [32] | ||
Beclanorsen [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [33] | ||
Gossypol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [34] | ||
Obatoclax [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [18], [23] | ||
PNT-2258 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [35] | ||
AI-850 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [5], [23] | ||
BCL201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [36] | ||
BGB-11417 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [37] | ||
BP1002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [38] | ||
LP-108 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [39] | ||
Pc4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [40] | ||
VOB560 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [41] | ||
2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [42] | ||
4,5-dibenzylbenzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [43] | ||
5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [44] | ||
Apogossypol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [45] | ||
BP-100-1.02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [46] | ||
modified HA14-1 compounds (cancer) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [44] | ||
N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [44] | ||
QEDIIRNIARHLAQVGDSMDR [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [44] | ||
TW-37 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [47] | ||
WL-276 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [48] | ||
ABT-737 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [23], [49] | ||
ATM serine/threonine kinase (ATM)
KU-60019 [Clinical trial]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATM serine/threonine kinase (ATM) is a therapeutic target for KU-60019. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KU-60019 through regulating the expression of ATM serine/threonine kinase (ATM). | [5], [50] | ||
AZD0156 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATM serine/threonine kinase (ATM) is a therapeutic target for AZD0156. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD0156 through regulating the expression of ATM serine/threonine kinase (ATM). | [50], [51] | ||
AZD1390 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATM serine/threonine kinase (ATM) is a therapeutic target for AZD1390. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD1390 through regulating the expression of ATM serine/threonine kinase (ATM). | [5], [50] | ||
M3541 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATM serine/threonine kinase (ATM) is a therapeutic target for M3541. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M3541 through regulating the expression of ATM serine/threonine kinase (ATM). | [5], [50] | ||
CGK733 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATM serine/threonine kinase (ATM) is a therapeutic target for CGK733. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGK733 through regulating the expression of ATM serine/threonine kinase (ATM). | [50], [52] | ||
ATP-citrate synthase (ACLY)
Bempedoic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATP-citrate synthase (ACLY) is a therapeutic target for Bempedoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bempedoic acid through regulating the expression of ATP-citrate synthase (ACLY). | [53], [54] | ||
(-)-hydroxycitrate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATP-citrate synthase (ACLY) is a therapeutic target for (-)-hydroxycitrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (-)-hydroxycitrate through regulating the expression of ATP-citrate synthase (ACLY). | [53], [55] | ||
SB-201076 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ATP-citrate synthase (ACLY) is a therapeutic target for SB-201076. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-201076 through regulating the expression of ATP-citrate synthase (ACLY). | [53], [56] | ||
Beta-catenin (CTNNB1)
Recombinant human endostatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). | [57], [58] | ||
C 82 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for C 82. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). | [57], [59] | ||
CEQ-508 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). | [57], [60] | ||
Breast cancer resistance protein (ABCG2)
Abacavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Abacavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abacavir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [62] | ||
Acyclovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Acyclovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acyclovir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [63] | ||
Adefovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Adefovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Adefovir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [64] | ||
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Afatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Afatinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [65] | ||
Alfuzosin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Alfuzosin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alfuzosin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [66] | ||
Apatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Apatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apatinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [67] | ||
Apixaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Apixaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apixaban through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [68] | ||
Baricitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Baricitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Baricitinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [69] | ||
Bicalutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Bicalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bicalutamide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [70] | ||
Binimetinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Binimetinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Binimetinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [71] | ||
Brigatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Brigatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Brigatinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [72] | ||
Bupropion [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Bupropion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bupropion through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [73] | ||
Canagliflozin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Canagliflozin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Canagliflozin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [74] | ||
Cephalothin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cephalothin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cephalothin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [75] | ||
Cerivastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cerivastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cerivastatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Chlorothiazide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Chlorothiazide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chlorothiazide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [77] | ||
Cholic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cholic acid through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [78] | ||
Cimetidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cimetidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cimetidine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [79] | ||
Ciprofloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Ciprofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ciprofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [80] | ||
Cisplatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cisplatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cisplatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [81] | ||
Cladribine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cladribine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cladribine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [82] | ||
Clofarabine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Clofarabine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clofarabine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [82] | ||
Cyclosporine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cyclosporine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclosporine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Dabrafenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Dabrafenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dabrafenib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [83] | ||
Dactinomycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Dactinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dactinomycin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [84] | ||
Daidzein [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Daidzein. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Daidzein through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [85] | ||
Dehydroepiandrosterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Dehydroepiandrosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydroepiandrosterone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [86] | ||
Dehydroepiandrosterone sulfate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Dehydroepiandrosterone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydroepiandrosterone sulfate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [87] | ||
Delavirdine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Delavirdine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Delavirdine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Deoxycholic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Deoxycholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Deoxycholic acid through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [75] | ||
Diclofenac [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Diclofenac. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diclofenac through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [88] | ||
Dipyridamole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Dipyridamole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dipyridamole through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [89] | ||
Dirithromycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Dirithromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dirithromycin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [75] | ||
Docetaxel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Docetaxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Docetaxel through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [90] | ||
Eltrombopag [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Eltrombopag. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eltrombopag through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [91] | ||
Empagliflozin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Empagliflozin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Empagliflozin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [92] | ||
Entacapone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Entacapone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Entacapone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [93] | ||
Entecavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Entecavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Entecavir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [94] | ||
Epirubicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Epirubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epirubicin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Erythromycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Erythromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [89] | ||
Estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [95] | ||
Estrone sulfate [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Estrone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone sulfate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [96] | ||
| Breast cancer resistance protein (ABCG2) is a therapeutic target for Estrone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone sulfate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [97] | |||
Etoposide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Etoposide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etoposide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [98] | ||
Ezetimibe [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Ezetimibe. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ezetimibe through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [99] | ||
Fluvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Fluvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluvastatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [100] | ||
Folic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Folic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Folic acid through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [101] | ||
Ganciclovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Ganciclovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ganciclovir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [102] | ||
Glibenclamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Glibenclamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glibenclamide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [103] | ||
Glutathione [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Glutathione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glutathione through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [104] | ||
Grepafloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Grepafloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Grepafloxacin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [105] | ||
Hesperetin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Hesperetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hesperetin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [106] | ||
Hydroxychloroquine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Hydroxychloroquine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydroxychloroquine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [107] | ||
Hypericin [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Hypericin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hypericin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [108] | ||
Idarubicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Idarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Idarubicin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [109] | ||
Idelalisib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Idelalisib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Idelalisib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [110] | ||
Imatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Imatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imatinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [111] | ||
Irinotecan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Irinotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Irinotecan through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [112] | ||
Lamivudine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Lamivudine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lamivudine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [113] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Lapatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lapatinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [114] | ||
Leflunomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Leflunomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Leflunomide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [115] | ||
Lopinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Lopinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lopinavir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Menadione [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Menadione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Menadione through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [116] | ||
Mercaptopurine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Mercaptopurine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mercaptopurine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [64] | ||
Methotrexate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Methotrexate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [117] | ||
Mitoxantrone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Mitoxantrone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mitoxantrone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [118] | ||
Moxidectin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Moxidectin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Moxidectin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [119] | ||
Mycophenolate mofetil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Mycophenolate mofetil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [120] | ||
Nelfinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Nelfinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nelfinavir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Nicardipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Nicardipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicardipine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Nifurtimox [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Nifurtimox. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nifurtimox through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [121] | ||
Nilotinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Nilotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nilotinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [122] | ||
Nitrofurantoin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Nitrofurantoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nitrofurantoin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [123] | ||
Norfloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Norfloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Norfloxacin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [124] | ||
Ofloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Ofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Olmesartan medoxomil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Olmesartan medoxomil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olmesartan medoxomil through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [92] | ||
Oxaliplatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Oxaliplatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxaliplatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [125] | ||
Palbociclib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Palbociclib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palbociclib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [126] | ||
Pantoprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pantoprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pantoprazole through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [127] | ||
Pazopanib hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pazopanib hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pazopanib hydrochloride through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [128] | ||
Pemetrexed [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pemetrexed. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pemetrexed through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [129] | ||
Pirarubicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pirarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirarubicin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [130] | ||
Pitavastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pitavastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pitavastatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [89] | ||
Pitavastatin calcium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pitavastatin calcium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pitavastatin calcium through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [131] | ||
Ponatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Ponatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ponatinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [132] | ||
Pravastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pravastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pravastatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Prazosin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Prazosin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prazosin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [133] | ||
Progesterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [95] | ||
Pyrimethamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pyrimethamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pyrimethamine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [134] | ||
Quercetin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Rabeprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Rabeprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rabeprazole through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [135] | ||
Raltitrexed [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Raltitrexed. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Raltitrexed through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Regorafenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Regorafenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Regorafenib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [92] | ||
Reserpine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Reserpine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Reserpine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Riboflavin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Riboflavin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riboflavin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [137] | ||
Rifampicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Rifampicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rifampicin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [75] | ||
Riluzole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Riluzole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riluzole through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [138] | ||
Riociguat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Riociguat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riociguat through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [92] | ||
Rivaroxaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Rivaroxaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rivaroxaban through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [139] | ||
Rosiglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Rosiglitazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosiglitazone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [140] | ||
Rosuvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Rosuvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosuvastatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [141] | ||
Saquinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Saquinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Saquinavir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [142] | ||
Simvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Simvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Simvastatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [86] | ||
Sofosbuvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Sofosbuvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sofosbuvir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [92] | ||
Sulfasalazine [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Sulfasalazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfasalazine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [143] | ||
| Breast cancer resistance protein (ABCG2) is a therapeutic target for Sulfasalazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfasalazine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [144] | |||
Talazoparib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Talazoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Talazoparib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [145] | ||
Tenofovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Tenofovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [92] | ||
Teriflunomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Teriflunomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Teriflunomide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [107] | ||
Testosterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Testosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [146] | ||
Tetracycline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Tetracycline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tetracycline through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [75] | ||
Thioguanine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Thioguanine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thioguanine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [64] | ||
Topotecan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Topotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Topotecan through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [147] | ||
Trimetrexate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Trimetrexate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimetrexate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [134] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Vandetanib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vandetanib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [148] | ||
Verteporfin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Verteporfin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Verteporfin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [149] | ||
Vinblastine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Vinblastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vinblastine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [90] | ||
Vincristine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Vincristine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vincristine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [134] | ||
Zidovudine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Zidovudine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zidovudine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
AG 337 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for AG 337. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG 337 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [134] | ||
Belotecan [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Belotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Belotecan through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [150] | ||
BNP-1350 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for BNP-1350. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BNP-1350 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Butyrate [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Butyrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Butyrate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [151] | ||
Camptothecin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Camptothecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Camptothecin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [152] | ||
Exatecan mesylate [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Exatecan mesylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Exatecan mesylate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Glycocholic acid [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Glycocholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glycocholic acid through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [78] | ||
J-107088 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for J-107088. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of J-107088 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Phenethyl isothiocyanate [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Phenethyl isothiocyanate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenethyl isothiocyanate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [87] | ||
Tenofovir alafenamide [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Tenofovir alafenamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir alafenamide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [153] | ||
Uric acid [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Uric acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Uric acid through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [154] | ||
9-Aminocamptothecin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for 9-Aminocamptothecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Aminocamptothecin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Bisantrene [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Bisantrene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisantrene through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
BN-80915 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for BN-80915. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BN-80915 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
C-1311 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for C-1311. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-1311 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [155] | ||
Cholesterol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Cholesterol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cholesterol through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [95] | ||
Flavopiridol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Flavopiridol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flavopiridol through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [156] | ||
Genistein [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Genistein. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Genistein through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [97] | ||
Gimatecan [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Gimatecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gimatecan through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
HPPH [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for HPPH. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HPPH through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [157] | ||
Ortataxel [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Ortataxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ortataxel through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Oxfendazole [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Oxfendazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxfendazole through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [158] | ||
Phosphatidylserine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Phosphatidylserine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phosphatidylserine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [159] | ||
Piritrexim [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Piritrexim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Piritrexim through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [134] | ||
Quinacrine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Quinacrine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinacrine through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [75] | ||
SJG-136 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for SJG-136. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SJG-136 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [160] | ||
SN-38 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for SN-38. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SN-38 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [161] | ||
UCN-01 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for UCN-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UCN-01 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Benzo(a)pyrene [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Benzo(a)pyrene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzo(a)pyrene through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [87] | ||
Benzoylphenylurea [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Benzoylphenylurea. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzoylphenylurea through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [162] | ||
CP-724714 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for CP-724714. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-724714 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [163] | ||
Mycophenolic acid glucuronide [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Mycophenolic acid glucuronide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mycophenolic acid glucuronide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [120] | ||
YP-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for YP-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YP-005 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [164] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for AG1478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG1478 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [81] | ||
AZD-1152-HQPA [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for AZD-1152-HQPA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-1152-HQPA through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [165] | ||
Azidothymidine monophosphate [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Azidothymidine monophosphate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azidothymidine monophosphate through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [166] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [167] | ||
Coumestrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Coumestrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Coumestrol through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [85] | ||
Enrofloxacin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Enrofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enrofloxacin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [168] | ||
Homocamptothecin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Homocamptothecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Homocamptothecin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [169] | ||
JNJ 7706621 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for JNJ 7706621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ 7706621 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [170] | ||
N-desethyl sunitinib [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for N-desethyl sunitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-desethyl sunitinib through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [171] | ||
Pancratistatin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Pancratistatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pancratistatin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [172] | ||
Protoporphyrin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Protoporphyrin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Protoporphyrin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Puromycin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Puromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Puromycin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [87] | ||
Scutellarin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Scutellarin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Scutellarin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [173] | ||
Chrysin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Chrysin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chrysin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [76] | ||
Estradiol-17beta-glucuronide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Estradiol-17beta-glucuronide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol-17beta-glucuronide through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [174] | ||
Hematoporphyrin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Hematoporphyrin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hematoporphyrin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [175] | ||
Becatecarin [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Becatecarin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Becatecarin through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [176] | ||
Befloxatone [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Befloxatone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Befloxatone through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [177] | ||
E3040 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for E3040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E3040 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [166] | ||
Lurtotecan [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Lurtotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lurtotecan through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [87] | ||
NB-506 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for NB-506. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NB-506 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [136] | ||
Parabis [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Parabis. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Parabis through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [178] | ||
Rhodamine 123 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Rhodamine 123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rhodamine 123 through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [179] | ||
Taurocholic acid [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Breast cancer resistance protein (ABCG2) is a therapeutic target for Taurocholic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Taurocholic acid through regulating the expression of Breast cancer resistance protein (ABCG2). | [61], [78] | ||
Bromodomain-containing protein 4 (BRD4)
CPI-0610 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for CPI-0610. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPI-0610 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [181] | ||
INCB57643 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for INCB57643. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INCB57643 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [182] | ||
OTX-015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for OTX-015. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OTX-015 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [5], [180] | ||
PLX2853 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for PLX2853. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PLX2853 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [182] | ||
ABBV-744 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for ABBV-744. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABBV-744 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [5], [180] | ||
AZD5153 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for AZD5153. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD5153 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [182] | ||
GSK525762 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for GSK525762. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK525762 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [182] | ||
TEN010 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for TEN010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TEN010 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [5], [180] | ||
BzT-7 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for BzT-7. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BzT-7 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [183] | ||
CPI-203 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for CPI-203. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPI-203 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [184] | ||
GW841819X [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for GW841819X. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW841819X through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [185] | ||
I-BET151 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for I-BET151. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of I-BET151 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [186] | ||
isoxazole azepine compound 3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for isoxazole azepine compound 3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of isoxazole azepine compound 3 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [187] | ||
MS417 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for MS417. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MS417 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [188] | ||
MS436 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for MS436. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MS436 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [189] | ||
PFI-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for PFI-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PFI-1 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [190] | ||
XD1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for XD1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XD1 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [190] | ||
XD14 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Bromodomain-containing protein 4 (BRD4) is a therapeutic target for XD14. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XD14 through regulating the expression of Bromodomain-containing protein 4 (BRD4). | [180], [184] | ||
C-X-C motif chemokine 10 (CXCL10)
Anti-IP10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for Anti-IP10. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-IP10 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [60], [191] | ||
BMS-936557 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for BMS-936557. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-936557 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [191], [192] | ||
JT02 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for JT02. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JT02 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [191], [193] | ||
MDX-1100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for MDX-1100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MDX-1100 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [191], [194] | ||
NI-0801 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for NI-0801. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NI-0801 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [191], [195] | ||
NG-641 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for NG-641. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NG-641 through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [191], [194] | ||
N-Methylleucine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 10 (CXCL10) is a therapeutic target for N-Methylleucine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Methylleucine through regulating the expression of C-X-C motif chemokine 10 (CXCL10). | [191], [196] | ||
C-X-C motif chemokine 9 (CXCL9)
NG-641 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | C-X-C motif chemokine 9 (CXCL9) is a therapeutic target for NG-641. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NG-641 through regulating the expression of C-X-C motif chemokine 9 (CXCL9). | [191], [197] | ||
Caspase-3 (CASP3)
PAC1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for PAC1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PAC1 through regulating the expression of Caspase-3 (CASP3). | [198], [199] | ||
2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
2-allylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-allylisoquinoline-1,3,4-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-allylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
2-benzylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-benzylisoquinoline-1,3,4-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-benzylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
2-methylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-methylisoquinoline-1,3,4-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-methylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [198], [201] | ||
2-phenethylisoquinoline-1,3,4-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 2-phenethylisoquinoline-1,3,4-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-phenethylisoquinoline-1,3,4-trione through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
5-(azepan-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(azepan-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(azepan-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [198], [201] | ||
5-(azetidin-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [198], [201] | ||
5-(piperidin-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [198], [201] | ||
5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione through regulating the expression of Caspase-3 (CASP3). | [198], [202] | ||
Ac-Asp-Glu-Val-Asp-CHO [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Ac-Asp-Glu-Val-Asp-CHO. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ac-Asp-Glu-Val-Asp-CHO through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
Ac-DEVD-CHO [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Ac-DEVD-CHO. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ac-DEVD-CHO through regulating the expression of Caspase-3 (CASP3). | [198], [203] | ||
AZ10417808 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for AZ10417808. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZ10417808 through regulating the expression of Caspase-3 (CASP3). | [198], [204] | ||
Glionitrin A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Glionitrin A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glionitrin A through regulating the expression of Caspase-3 (CASP3). | [198], [205] | ||
Isoquinoline-1,3,4(2H)-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for Isoquinoline-1,3,4(2H)-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Isoquinoline-1,3,4(2H)-trione through regulating the expression of Caspase-3 (CASP3). | [198], [200] | ||
M826 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for M826. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M826 through regulating the expression of Caspase-3 (CASP3). | [198], [206] | ||
PETCM [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for PETCM. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PETCM through regulating the expression of Caspase-3 (CASP3). | [198], [207] | ||
SJ-8002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caspase-3 (CASP3) is a therapeutic target for SJ-8002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SJ-8002 through regulating the expression of Caspase-3 (CASP3). | [198], [208] | ||
Caterpiller protein 1.1 (NLRP3)
Dapansutrile [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caterpiller protein 1.1 (NLRP3) is a therapeutic target for Dapansutrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dapansutrile through regulating the expression of Caterpiller protein 1.1 (NLRP3). | [209], [210] | ||
BMS-986299 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caterpiller protein 1.1 (NLRP3) is a therapeutic target for BMS-986299. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-986299 through regulating the expression of Caterpiller protein 1.1 (NLRP3). | [209], [211] | ||
MCC950 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caterpiller protein 1.1 (NLRP3) is a therapeutic target for MCC950. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MCC950 through regulating the expression of Caterpiller protein 1.1 (NLRP3). | [209], [212] | ||
Cellular tumor antigen p53 (TP53)
Contusugene ladenovec [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Contusugene ladenovec. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Contusugene ladenovec through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [214] | ||
QPI-1002 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for QPI-1002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of QPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [215] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [216] | ||
Ad-p53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Ad-p53. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ad-p53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [217] | ||
ALT-801 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ALT-801. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALT-801 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [218] | ||
APG-115 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APG-115. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-115 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [219] | ||
APR-246 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APR-246. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APR-246 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [220] | ||
Cenersen [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Cenersen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cenersen through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [221] | ||
INGN-225 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-225. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INGN-225 through regulating the expression of Cellular tumor antigen p53 (TP53). | [5], [213] | ||
ISA-P53-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ISA-P53-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISA-P53-01 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [222] | ||
Kevetrin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Kevetrin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Kevetrin through regulating the expression of Cellular tumor antigen p53 (TP53). | [18], [213] | ||
OPI-1002 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for OPI-1002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [223] | ||
SGT-53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SGT-53. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SGT-53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [5], [213] | ||
CGM097 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for CGM097. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGM097 through regulating the expression of Cellular tumor antigen p53 (TP53). | [5], [213] | ||
COTI-2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for COTI-2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of COTI-2 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [224] | ||
Dendritic cell vaccine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Dendritic cell vaccine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dendritic cell vaccine through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [225] | ||
HDM201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for HDM201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HDM201 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [226] | ||
ONYX-015 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ONYX-015. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ONYX-015 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [227] | ||
SAR-405838 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SAR-405838. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAR-405838 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [214] | ||
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [228] | ||
AHL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for AHL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AHL through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [229] | ||
NU-8231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NU-8231. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NU-8231 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [230] | ||
NUTLIN-3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NUTLIN-3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NUTLIN-3 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [231] | ||
INGN-234 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-234. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INGN-234 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [232] | ||
Pifithrin-alpha [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Pifithrin-alpha. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pifithrin-alpha through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [233] | ||
TAR-1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for TAR-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAR-1 through regulating the expression of Cellular tumor antigen p53 (TP53). | [213], [234] | ||
Clusterin messenger RNA (Clusterin mRNA)
Custirsen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Clusterin messenger RNA (Clusterin mRNA) is a therapeutic target for Custirsen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Custirsen through regulating the expression of Clusterin messenger RNA (Clusterin mRNA). | [235], [236] | ||
Cyclin-dependent kinase 1 (CDK1)
P-276 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for P-276. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of P-276 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [238] | ||
P276-00 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for P276-00. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of P276-00 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [239] | ||
Ro 31-7453 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Ro 31-7453. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [240] | ||
Roscovitine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Roscovitine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Roscovitine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [241] | ||
AG-024322 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for AG-024322. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [242] | ||
PHA-793887 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for PHA-793887. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [239] | ||
RGB-286638 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for RGB-286638. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [239] | ||
L-751250 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for L-751250. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-751250 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [239] | ||
ON-01135 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for ON-01135. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ON-01135 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [243] | ||
(2,6-Diamino-pyridin-3-yl)-phenyl-methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for (2,6-Diamino-pyridin-3-yl)-phenyl-methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (2,6-Diamino-pyridin-3-yl)-phenyl-methanone through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [244] | ||
10Z-Hymenialdisine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 10Z-Hymenialdisine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 10Z-Hymenialdisine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [245] | ||
2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [246] | ||
3,4-bis(indol-3-yl)maleimide derivative [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-bis(indol-3-yl)maleimide derivative. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-bis(indol-3-yl)maleimide derivative through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [244] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [7], [237] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [7], [237] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [247] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [7], [237] | ||
4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [248] | ||
4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [249] | ||
4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [250] | ||
9-Nitropaullone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for 9-Nitropaullone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Nitropaullone through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [251] | ||
aloisine A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for aloisine A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of aloisine A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [22], [237] | ||
alsterpaullone 2-cyanoethyl [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for alsterpaullone 2-cyanoethyl. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of alsterpaullone 2-cyanoethyl through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [22], [237] | ||
aminopurvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for aminopurvalanol A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of aminopurvalanol A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [252] | ||
AZAKENPAULLONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for AZAKENPAULLONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZAKENPAULLONE through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [253] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Bisindolylmaleimide-I. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [253] | ||
BMS-265246 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for BMS-265246. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-265246 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [22], [237] | ||
Cdk1 inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Cdk1 inhibitor. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cdk1 inhibitor through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [254] | ||
CGP74514A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for CGP74514A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGP74514A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [243] | ||
CVT-313 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for CVT-313. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CVT-313 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [255] | ||
IN1535 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for IN1535. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IN1535 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [256] | ||
Indirubin-3'-monoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Indirubin-3'-monoxime. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indirubin-3'-monoxime through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [210], [237] | ||
Indirubin-5-sulfonate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Indirubin-5-sulfonate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indirubin-5-sulfonate through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [257] | ||
JNJ 7706621 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for JNJ 7706621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ 7706621 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [7], [237] | ||
K00024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for K00024. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [258] | ||
Microxine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Microxine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Microxine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [259] | ||
NU6140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for NU6140. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [260] | ||
PF-228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for PF-228. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-228 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [249] | ||
Purvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Purvalanol A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Purvalanol A through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [243] | ||
Quinoxaline1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Quinoxaline1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinoxaline1 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [22], [237] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for RO-316233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-316233 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [244] | ||
SU9516 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for SU9516. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SU9516 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [261] | ||
Thieno analogue of kenpaullone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Thieno analogue of kenpaullone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thieno analogue of kenpaullone through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [250] | ||
BAY 10-00394 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for BAY 10-00394. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [262] | ||
CGP-60474 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for CGP-60474. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGP-60474 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [263] | ||
Olomoucine [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for Olomoucine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olomoucine through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [264] | ||
R547 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for R547. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [239] | ||
SCH 727965 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for SCH 727965. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SCH 727965 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [265] | ||
ZK 304709 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 1 (CDK1) is a therapeutic target for ZK 304709. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 1 (CDK1). | [237], [239] | ||
Cysteines of Keap1 (KEAP1 Cysteines)
CXA10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cysteines of Keap1 (KEAP1 Cysteines) is a therapeutic target for CXA10. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CXA10 through regulating the expression of Cysteines of Keap1 (KEAP1 Cysteines). | [266], [267] | ||
VCB101 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cysteines of Keap1 (KEAP1 Cysteines) is a therapeutic target for VCB101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VCB101 through regulating the expression of Cysteines of Keap1 (KEAP1 Cysteines). | [266], [268] | ||
VCB102 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cysteines of Keap1 (KEAP1 Cysteines) is a therapeutic target for VCB102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VCB102 through regulating the expression of Cysteines of Keap1 (KEAP1 Cysteines). | [266], [269] | ||
Cystine/glutamate transporter (SLC7A11)
L-glutamic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cystine/glutamate transporter (SLC7A11) is a therapeutic target for L-glutamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-glutamic acid through regulating the expression of Cystine/glutamate transporter (SLC7A11). | [270], [271] | ||
SXC-2023 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11). | [270], [272] | ||
Cytochrome P450 1B1 (CYP1B1)
Amodiaquine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Amodiaquine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amodiaquine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [274] | ||
Caffeine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Caffeine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Caffeine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [275] | ||
Erythromycin stearate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Erythromycin stearate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin stearate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [276] | ||
Estrone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Estrone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [277] | ||
Flutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Flutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flutamide through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [278] | ||
Hydrogen peroxide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Hydrogen peroxide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydrogen peroxide through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [279] | ||
Melatonin [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Melatonin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Melatonin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [280] | ||
Oxaliplatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Oxaliplatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxaliplatin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [281] | ||
Procarbazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Procarbazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Procarbazine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [282] | ||
Progesterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [283] | ||
Rosuvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Rosuvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosuvastatin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [284] | ||
Testosterone cypionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Testosterone cypionate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone cypionate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [283] | ||
Theophylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Theophylline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Theophylline through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [275] | ||
Estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [285] | ||
HSDB-3466 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for HSDB-3466. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HSDB-3466 through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [286] | ||
NSC-122758 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for NSC-122758. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-122758 through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [287] | ||
PINOCEMBRIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for PINOCEMBRIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PINOCEMBRIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [288] | ||
Naringenin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Naringenin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naringenin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [290] | ||
3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [290] | ||
4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [290] | ||
ACACETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ACACETIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ACACETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
APIGENIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for APIGENIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APIGENIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
Chrysin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Chrysin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chrysin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
CHRYSOERIOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for CHRYSOERIOL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CHRYSOERIOL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
Dibutylphthalate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Dibutylphthalate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dibutylphthalate through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [291] | ||
DIOSMETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for DIOSMETIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DIOSMETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
ERIODICTYOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ERIODICTYOL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ERIODICTYOL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
Galangin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Galangin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Galangin through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [290] | ||
HOMOERIODICTYOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for HOMOERIODICTYOL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HOMOERIODICTYOL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
ISORHAMNETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ISORHAMNETIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISORHAMNETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
ISOSAKUTANETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for ISOSAKUTANETIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISOSAKUTANETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
KAEMPFERIDE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for KAEMPFERIDE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KAEMPFERIDE through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
KAEMPFEROL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for KAEMPFEROL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KAEMPFEROL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
TAMARIXETIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for TAMARIXETIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAMARIXETIN through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [289] | ||
TRISMETHOXYRESVERATROL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of Cytochrome P450 1B1 (CYP1B1). | [273], [290] | ||
Cytochrome P450 2C8 (CYP2C8)
Almotriptan malate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Almotriptan malate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Almotriptan malate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [293] | ||
Aminophenazone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Aminophenazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aminophenazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [294] | ||
Amiodarone hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amiodarone hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amiodarone hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [295] | ||
Amitriptyline hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amitriptyline hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amitriptyline hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [296] | ||
Amodiaquine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Amodiaquine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amodiaquine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [297] | ||
Anastrozole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Anastrozole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anastrozole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [298] | ||
Apalutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Apalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apalutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [299] | ||
Apixaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Apixaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apixaban through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [300] | ||
Atorvastatin calcium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Atorvastatin calcium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Atorvastatin calcium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Azelastine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Azelastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azelastine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [302] | ||
Benzyl alcohol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Benzyl alcohol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzyl alcohol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [303] | ||
Beraprost [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Beraprost. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Beraprost through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [304] | ||
Brigatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Brigatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Brigatinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [305] | ||
Bromfenac [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Bromfenac. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bromfenac through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [306] | ||
Buprenorphine hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Buprenorphine hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Buprenorphine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [307] | ||
Cabazitaxel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cabazitaxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cabazitaxel through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [308] | ||
Caffeine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Caffeine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Caffeine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [309] | ||
Capsaicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Capsaicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Capsaicin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [310] | ||
Carbamazepine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Carbamazepine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carbamazepine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [311] | ||
Cefaloridine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cefaloridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cefaloridine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [312] | ||
Celecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Celecoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Celecoxib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [313] | ||
Cerivastatin sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cerivastatin sodium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cerivastatin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Cisapride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cisapride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cisapride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [314] | ||
Clozapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Clozapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clozapine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [315] | ||
Cyclophosphamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cyclophosphamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclophosphamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [316] | ||
Dabrafenib mesylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dabrafenib mesylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dabrafenib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Dapsone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dapsone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dapsone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [317] | ||
Desloratadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Desloratadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Desloratadine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [318] | ||
Dexibuprofen [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dexibuprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dexibuprofen through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [319] | ||
Diazepam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diazepam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diazepam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [320] | ||
Diclofenac sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diclofenac sodium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diclofenac sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [321] | ||
Diethylstilbestrol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diethylstilbestrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diethylstilbestrol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [322] | ||
Diltiazem hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Diltiazem hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diltiazem hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [323] | ||
Eltrombopag olamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Eltrombopag olamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eltrombopag olamine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [324] | ||
Enasidenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Enasidenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enasidenib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [325] | ||
Enzalutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Enzalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enzalutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Estradiol acetate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol acetate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol acetate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Estradiol cypionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol cypionate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol cypionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [326] | ||
Estradiol valerate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol valerate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol valerate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [326] | ||
Eszopiclone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Eszopiclone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eszopiclone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [327] | ||
Ethinyl estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ethinyl estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ethinyl estradiol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [328] | ||
Fluvastatin sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Fluvastatin sodium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluvastatin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [329] | ||
Glasdegib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Glasdegib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glasdegib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [330] | ||
Halofantrine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Halofantrine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Halofantrine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [331] | ||
Ibuprofen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ibuprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ibuprofen through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [319] | ||
Ifosfamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ifosfamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ifosfamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [316] | ||
Imatinib mesylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Imatinib mesylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imatinib mesylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Irbesartan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Irbesartan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Irbesartan through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [328] | ||
Istradefylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Istradefylline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Istradefylline through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [332] | ||
Ixazomib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ixazomib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ixazomib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [333] | ||
Ketobemidone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketobemidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ketobemidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [334] | ||
Ketorolac [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ketorolac. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ketorolac through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [335] | ||
Lansoprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lansoprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lansoprazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [336] | ||
Lapatinib ditosylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lapatinib ditosylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lapatinib ditosylate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [337] | ||
Levomilnacipran [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Levomilnacipran. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Levomilnacipran through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [338] | ||
Lidocaine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lidocaine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lidocaine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [339] | ||
Loperamide hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Loperamide hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Loperamide hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [340] | ||
Loratadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Loratadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Loratadine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Lorlatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lorlatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lorlatinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [341] | ||
Losartan potassium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Losartan potassium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Losartan potassium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [342] | ||
Lovastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Lovastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lovastatin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [343] | ||
Mefenamic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mefenamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mefenamic acid through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Meloxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Meloxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Meloxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [344] | ||
Mephenytoin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mephenytoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mephenytoin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [345] | ||
Mestranol [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mestranol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mestranol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [346] | ||
Methadone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Methadone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methadone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [347] | ||
Mirtazapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mirtazapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mirtazapine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [339] | ||
Montelukast sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Montelukast sodium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Montelukast sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [348] | ||
Morphine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Morphine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Morphine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [349] | ||
Mycophenolate mofetil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Mycophenolate mofetil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [350] | ||
Naloxone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Naloxone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naloxone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [307] | ||
Naproxen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Naproxen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naproxen through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [351] | ||
Nicardipine hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nicardipine hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicardipine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [339] | ||
Nicotine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nicotine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicotine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [352] | ||
Nilotinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Nilotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nilotinib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Ombitasvir [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Ombitasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ombitasvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [353] | ||
Omeprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Omeprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Omeprazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [354] | ||
Pazopanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pazopanib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pazopanib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [355] | ||
Pentamidine isethionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pentamidine isethionate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pentamidine isethionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [356] | ||
Perphenazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Perphenazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Perphenazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [357] | ||
Phenobarbital [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenobarbital. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenobarbital through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [358] | ||
Phenprocoumon [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenprocoumon. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenprocoumon through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [359] | ||
Phenytoin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Phenytoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenytoin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [339] | ||
Pioglitazone hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pioglitazone hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pioglitazone hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [360] | ||
Piroxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Piroxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Piroxicam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [361] | ||
Pitavastatin calcium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Pitavastatin calcium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pitavastatin calcium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [362] | ||
Propofol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Propofol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Propofol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [363] | ||
Quinidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Quinidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinidine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Quinine sulfate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Quinine sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinine sulfate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Repaglinide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Repaglinide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Repaglinide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [364] | ||
Riociguat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Riociguat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riociguat through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [365] | ||
Rofecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rofecoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rofecoxib through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Rosiglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rosiglitazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosiglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [366] | ||
Selegiline hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Selegiline hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Selegiline hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [367] | ||
Selexipag [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Selexipag. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Selexipag through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [368] | ||
Simvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Simvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Simvastatin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [369] | ||
Sitagliptin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sitagliptin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sitagliptin through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [370] | ||
Sulfadiazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfadiazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfadiazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [371] | ||
Sulfamethoxazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfamethoxazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfamethoxazole through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [372] | ||
Sulfinpyrazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Sulfinpyrazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sulfinpyrazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [339] | ||
Tazarotene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tazarotene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tazarotene through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [373] | ||
Tegafur [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tegafur. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tegafur through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [374] | ||
Temazepam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Temazepam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Temazepam through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [375] | ||
Terbinafine hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Terbinafine hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Terbinafine hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [327] | ||
Testosterone cypionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone cypionate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone cypionate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Testosterone enanthate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone enanthate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone enanthate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Testosterone undecanoate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Testosterone undecanoate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone undecanoate through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Thalidomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thalidomide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [376] | ||
Tolbutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Tolbutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tolbutamide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [377] | ||
Torasemide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Torasemide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Torasemide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [378] | ||
Treprostinil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Treprostinil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Treprostinil through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [379] | ||
Trifarotene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trifarotene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trifarotene through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [380] | ||
Trimethadione [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethadione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimethadione through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [381] | ||
Trimethoprim [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Trimethoprim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimethoprim through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [382] | ||
Troglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Troglitazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Troglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [383] | ||
Velpatasvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Velpatasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Velpatasvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [384] | ||
Verapamil hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Verapamil hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Verapamil hydrochloride through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [385] | ||
Vortioxetine hydrobromide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Vortioxetine hydrobromide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vortioxetine hydrobromide through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [386] | ||
Voxilaprevir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Voxilaprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Voxilaprevir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [384] | ||
Warfarin sodium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Warfarin sodium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Warfarin sodium through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [351] | ||
Zafirlukast [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zafirlukast. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zafirlukast through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [382] | ||
Zidovudine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zidovudine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zidovudine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [339] | ||
Zopiclone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Zopiclone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zopiclone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [387] | ||
BMS-298585 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for BMS-298585. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-298585 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [388] | ||
BNP-1350 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for BNP-1350. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BNP-1350 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [389] | ||
CKD-501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for CKD-501. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CKD-501 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [390] | ||
CYT-387 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for CYT-387. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYT-387 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [391] | ||
Dasabuvir [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Dasabuvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dasabuvir through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [392] | ||
Domperidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Domperidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Domperidone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [393] | ||
DRF-2593 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for DRF-2593. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DRF-2593 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [390] | ||
EMD-128130 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for EMD-128130. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EMD-128130 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [394] | ||
Estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [301] | ||
LAS-17177 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LAS-17177. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LAS-17177 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [395] | ||
LAU-7b [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LAU-7b. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LAU-7b through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [396] | ||
LY-2484595 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for LY-2484595. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-2484595 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [397] | ||
NSC-122758 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for NSC-122758. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-122758 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [398] | ||
QLT-091001 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for QLT-091001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of QLT-091001 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [398] | ||
Rivoglitazone [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Rivoglitazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rivoglitazone through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [399] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AZD-2014. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-2014 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [400] | ||
GSK-1278863 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for GSK-1278863. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK-1278863 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [401] | ||
TAK-652 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for TAK-652. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-652 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [402] | ||
AG-1549 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AG-1549. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG-1549 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [403] | ||
AZD-9496 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for AZD-9496. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-9496 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [404] | ||
H3B-6545 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for H3B-6545. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of H3B-6545 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [405] | ||
M-813 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for M-813. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M-813 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [406] | ||
MK-0822 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for MK-0822. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-0822 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [407] | ||
Antipyrine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Antipyrine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Antipyrine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [327] | ||
Cyamemazine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Cyamemazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyamemazine through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [408] | ||
Paraoxon [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Paraoxon. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Paraoxon through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [409] | ||
ABT-001 [Discontinued]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ABT-001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-001 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [410] | ||
ADD-3878 [Discontinued]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ADD-3878. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ADD-3878 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [390] | ||
Aleglitazar [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for Aleglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aleglitazar through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [411] | ||
ML-3000 [Discontinued]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cytochrome P450 2C8 (CYP2C8) is a therapeutic target for ML-3000. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ML-3000 through regulating the expression of Cytochrome P450 2C8 (CYP2C8). | [292], [327] | ||
Delta-like protein 3 (DLL3)
Rova-T [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Delta-like protein 3 (DLL3) is a therapeutic target for Rova-T. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rova-T through regulating the expression of Delta-like protein 3 (DLL3). | [412], [413] | ||
HPN328 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Delta-like protein 3 (DLL3) is a therapeutic target for HPN328. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HPN328 through regulating the expression of Delta-like protein 3 (DLL3). | [412], [414] | ||
AMG 119 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Delta-like protein 3 (DLL3) is a therapeutic target for AMG 119. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 119 through regulating the expression of Delta-like protein 3 (DLL3). | [412], [415] | ||
AMG 757 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Delta-like protein 3 (DLL3) is a therapeutic target for AMG 757. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 757 through regulating the expression of Delta-like protein 3 (DLL3). | [412], [416] | ||
Diacylglycerol O-acyltransferase 2 (DGAT2)
Vitamin B3 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Diacylglycerol O-acyltransferase 2 (DGAT2) is a therapeutic target for Vitamin B3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vitamin B3 through regulating the expression of Diacylglycerol O-acyltransferase 2 (DGAT2). | [53], [417] | ||
ARI-3037MO [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Diacylglycerol O-acyltransferase 2 (DGAT2) is a therapeutic target for ARI-3037MO. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARI-3037MO through regulating the expression of Diacylglycerol O-acyltransferase 2 (DGAT2). | [53], [418] | ||
ION 224 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Diacylglycerol O-acyltransferase 2 (DGAT2) is a therapeutic target for ION 224. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ION 224 through regulating the expression of Diacylglycerol O-acyltransferase 2 (DGAT2). | [53], [419] | ||
PF-06427878 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Diacylglycerol O-acyltransferase 2 (DGAT2) is a therapeutic target for PF-06427878. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-06427878 through regulating the expression of Diacylglycerol O-acyltransferase 2 (DGAT2). | [53], [420] | ||
DNA repair protein RAD51 homolog 1 (RAD51)
CYT-0851 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA repair protein RAD51 homolog 1 (RAD51) is a therapeutic target for CYT-0851. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYT-0851 through regulating the expression of DNA repair protein RAD51 homolog 1 (RAD51). | [210], [421] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA repair protein RAD51 homolog 1 (RAD51) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of DNA repair protein RAD51 homolog 1 (RAD51). | [421], [422] | ||
DNA-binding factor KBF1 (p105)
CAT 1004 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA-binding factor KBF1 (p105) is a therapeutic target for CAT 1004. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CAT 1004 through regulating the expression of DNA-binding factor KBF1 (p105). | [423], [424] | ||
P54 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DNA-binding factor KBF1 (p105) is a therapeutic target for P54. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of P54 through regulating the expression of DNA-binding factor KBF1 (p105). | [423], [425] | ||
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
KH-CB19 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for KH-CB19. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KH-CB19 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [426], [427] | ||
leucettine L41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for leucettine L41. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of leucettine L41 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [426], [428] | ||
ML315 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for ML315. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ML315 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [426], [429] | ||
WO2013026806C72 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for WO2013026806C72 . The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WO2013026806C72 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). | [426], [428] | ||
DUSP5 messenger RNA (DUSP5 mRNA)
ISIS 133206 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133206. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133206 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133207 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133207. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133207 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133208 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133208. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133208 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133211 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133211. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133211 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133242 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133242. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133242 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133243 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133243. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133243 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133244 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133244. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133244 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [431] | ||
ISIS 133245 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | DUSP5 messenger RNA (DUSP5 mRNA) is a therapeutic target for ISIS 133245. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 133245 through regulating the expression of DUSP5 messenger RNA (DUSP5 mRNA). | [430], [432] | ||
E2F transcription factor 1 (E2F1)
ARQ-171 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ARQ-171. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARQ-171 through regulating the expression of E2F transcription factor 1 (E2F1). | [433], [434] | ||
ISIS 113019 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113019. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113019 through regulating the expression of E2F transcription factor 1 (E2F1). | [433], [435] | ||
ISIS 113020 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113020. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113020 through regulating the expression of E2F transcription factor 1 (E2F1). | [433], [435] | ||
ISIS 113021 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113021. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113021 through regulating the expression of E2F transcription factor 1 (E2F1). | [433], [435] | ||
ISIS 113022 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113022. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113022 through regulating the expression of E2F transcription factor 1 (E2F1). | [433], [435] | ||
ISIS 113048 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113048. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113048 through regulating the expression of E2F transcription factor 1 (E2F1). | [433], [436] | ||
EIF4E messenger RNA (EIF4E mRNA)
7-Methyl-Gpppa [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | EIF4E messenger RNA (EIF4E mRNA) is a therapeutic target for 7-Methyl-Gpppa. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Methyl-Gpppa through regulating the expression of EIF4E messenger RNA (EIF4E mRNA). | [210], [437] | ||
7-Methyl-Guanosine-5'-Triphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | EIF4E messenger RNA (EIF4E mRNA) is a therapeutic target for 7-Methyl-Guanosine-5'-Triphosphate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Methyl-Guanosine-5'-Triphosphate through regulating the expression of EIF4E messenger RNA (EIF4E mRNA). | [210], [437] | ||
7n-Methyl-8-Hydroguanosine-5'-Diphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | EIF4E messenger RNA (EIF4E mRNA) is a therapeutic target for 7n-Methyl-8-Hydroguanosine-5'-Diphosphate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7n-Methyl-8-Hydroguanosine-5'-Diphosphate through regulating the expression of EIF4E messenger RNA (EIF4E mRNA). | [437], [438] | ||
Endoplasmic reticulum chaperone BiP (HSPA5)
IT-139 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for IT-139. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IT-139 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). | [439], [440] | ||
NKP-1339 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for NKP-1339. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NKP-1339 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). | [439], [441] | ||
SAM-6 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for SAM-6. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAM-6 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). | [439], [442] | ||
Enhancer of zeste homolog 2 (EZH2)
Tazemetostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for Tazemetostat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tazemetostat through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [444] | ||
CPI-0209 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for CPI-0209. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPI-0209 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [445] | ||
CPI-1205 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for CPI-1205. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPI-1205 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [446] | ||
DS-3201b [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for DS-3201b. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-3201b through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [447] | ||
SHR2554 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for SHR2554. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SHR2554 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [448] | ||
DS-3201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for DS-3201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-3201 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [449] | ||
GSK2816126 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for GSK2816126. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK2816126 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [5], [443] | ||
HH2853 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for HH2853. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HH2853 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [5], [443] | ||
PF-06821497 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for PF-06821497. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-06821497 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [450] | ||
EI1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for EI1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EI1 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [451] | ||
EPZ005687 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for EPZ005687. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EPZ005687 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [452] | ||
GSK343 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for GSK343. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK343 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [453] | ||
MS1943 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for MS1943. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MS1943 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [454] | ||
UNC1999 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for UNC1999. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UNC1999 through regulating the expression of Enhancer of zeste homolog 2 (EZH2). | [443], [455] | ||
Ephrin type-A receptor 2 (EPHA2)
BT5528 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for BT5528. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BT5528 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [456], [457] | ||
CAR-T cells targeting EphA2 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for CAR-T cells targeting EphA2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CAR-T cells targeting EphA2 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [456], [458] | ||
DS-8895 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for DS-8895. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-8895 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [456], [459] | ||
MEDI-547 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-547. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI-547 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [456], [460] | ||
MEDI-543 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-543. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI-543 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [456], [461] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [456], [462] | ||
Ephrin type-A receptor 3 (EPHA3)
Ifabotuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 3 (EPHA3) is a therapeutic target for Ifabotuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ifabotuzumab through regulating the expression of Ephrin type-A receptor 3 (EPHA3). | [434], [463] | ||
KB-004 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 3 (EPHA3) is a therapeutic target for KB-004. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KB-004 through regulating the expression of Ephrin type-A receptor 3 (EPHA3). | [435], [463] | ||
Ephrin type-B receptor 2 (EPHB2)
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [464], [465] | ||
SEphB4-HSA [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SEphB4-HSA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SEphB4-HSA through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [464], [466] | ||
KO-947 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for KO-947. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KO-947 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [5], [464] | ||
MK-8353 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for MK-8353. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-8353 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [5], [464] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [464], [467] | ||
SNEWIQPRLPQH [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SNEWIQPRLPQH. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SNEWIQPRLPQH through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [5], [464] | ||
Epidermal growth factor (EGF)
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor (EGF) is a therapeutic target for Epidermal growth factor. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor (EGF). | [421], [468] | ||
Hebervis [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor (EGF) is a therapeutic target for Hebervis. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hebervis through regulating the expression of Epidermal growth factor (EGF). | [421], [469] | ||
Epidermal growth factor receptor (EGFR)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Afatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Afatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [241], [470] | ||
Cetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cetuximab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cetuximab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [471] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Dacomitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dacomitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [472] | ||
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epidermal growth factor. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [473] | ||
HEGF [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HEGF. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [474] | ||
Icotinib hydrochloride [Registered]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Icotinib hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Icotinib hydrochloride through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [475] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Lapatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lapatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [476] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Merimepodib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Merimepodib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [477] | ||
Necitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Necitumumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Necitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [478] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NERATINIB MALEATE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [479] | ||
Nitroglycerin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Nitroglycerin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nitroglycerin through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [477] | ||
Panitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Panitumumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Panitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [480] | ||
SKI-758 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SKI-758. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SKI-758 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Vandetanib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vandetanib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [482] | ||
AC0010 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AC0010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AC0010 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [483] | ||
Almonertinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Almonertinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Almonertinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [484] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Amivantamab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amivantamab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [485] | ||
ASP1929 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP1929. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ASP1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [486] | ||
CO-1686 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CO-1686. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CO-1686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
DE-766 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for DE-766. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DE-766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [487] | ||
EGF816 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGF816. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EGF816 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
HKI-272 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-272. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HKI-272 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [488] | ||
Indium-111 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Indium-111. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indium-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [214], [470] | ||
Rindopepimut [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Rindopepimut. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rindopepimut through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [489] | ||
SYM-004 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-004. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SYM-004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [490] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Varlitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Varlitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [29], [470] | ||
Zalutumumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Zalutumumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zalutumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [472] | ||
ABT-414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABT-414. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-414 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [471] | ||
ABX-EGF [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABX-EGF. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABX-EGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [491] | ||
AFM24 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM24. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AFM24 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [492] | ||
ASP8273 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP8273. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ASP8273 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [493] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BDTX-189. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BDTX-189 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [494] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-599626. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-599626 through regulating the expression of Epidermal growth factor receptor (EGFR). | [241], [470] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-690514. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-690514 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [489] | ||
CART-EGFR [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CART-EGFR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CART-EGFR through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [495] | ||
CetuGEX [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CetuGEX. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CetuGEX through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [496] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CI-1033. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CI-1033 through regulating the expression of Epidermal growth factor receptor (EGFR). | [5], [470] | ||
CK-101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CK-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CK-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [5], [470] | ||
Depatuxizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Depatuxizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Depatuxizumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [5], [470] | ||
EGFR antisense DNA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR antisense DNA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EGFR antisense DNA through regulating the expression of Epidermal growth factor receptor (EGFR). | [5], [470] | ||
EGFR CART [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR CART. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EGFR CART through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [497] | ||
EMB-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMB-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EMB-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [498] | ||
EMD 55900 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMD 55900. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EMD 55900 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [499] | ||
HER1-VSSP vaccine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HER1-VSSP vaccine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HER1-VSSP vaccine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [500] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-78136B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HM-78136B through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [501] | ||
Matuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Matuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Matuzumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [502] | ||
MEHD-7945A [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MEHD-7945A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEHD-7945A through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [503] | ||
Pelitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pelitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pelitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [504] | ||
RM-1929 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-1929. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RM-1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [505] | ||
SN-32793 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SN-32793. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SN-32793 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [506] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym013. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sym013 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [507] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym015. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sym015 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [497] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Tarloxotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tarloxotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [508] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TT-100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TT-100 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [509] | ||
VATALANIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for VATALANIB. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VATALANIB through regulating the expression of Epidermal growth factor receptor (EGFR). | [214], [470] | ||
ZN-e4 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ZN-e4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZN-e4 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [510] | ||
AMG 595 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AMG 595. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 595 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [511] | ||
Anti-EGFR CAR T [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR CAR T. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-EGFR CAR T through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [512] | ||
AP32788 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AP32788. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AP32788 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [513] | ||
AST-1306 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AST-1306. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AST-1306 through regulating the expression of Epidermal growth factor receptor (EGFR). | [214], [470] | ||
BCA101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BCA101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BCA101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [514] | ||
BIBX-1382 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BIBX-1382. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BIBX-1382 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [515] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cipatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cipatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [516] | ||
CLN-081 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CLN-081. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CLN-081 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [517] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CUDC-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CUDC-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [518] | ||
D2C7 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for D2C7. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of D2C7 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [519] | ||
EGFR806-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR806-specific CAR T cell. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EGFR806-specific CAR T cell through regulating the expression of Epidermal growth factor receptor (EGFR). | [414], [470] | ||
IMGN289 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IMGN289. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMGN289 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for JNJ-26483327. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ-26483327 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [520] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LY3164530. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3164530 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [521] | ||
MCLA-158 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MCLA-158. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MCLA-158 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [522] | ||
MM-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MM-151. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MM-151 through regulating the expression of Epidermal growth factor receptor (EGFR). | [5], [470] | ||
MR1-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MR1-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MR1-1 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [523] | ||
PF-05230907 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF-05230907. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-05230907 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [497] | ||
Pyrotinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pyrotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pyrotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [524] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for S-222611. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-222611 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
SI-B001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SI-B001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SI-B001 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [525] | ||
SYN004 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYN004. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SYN004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [497] | ||
111In-hEGF [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 111In-hEGF. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 111In-hEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [526] | ||
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-quinazolin-4-yl-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (3-Bromo-phenyl)-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [528] | ||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [529] | ||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [530] | ||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [531] | ||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
2-methoxy-4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-methoxy-4-(2-nitrovinyl)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-methoxy-4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [7], [470] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [532] | ||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [533] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [534] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [535] | ||
3-Pyridin-4-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-Pyridin-4-yl-quinoline-6,7-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-6,7-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [536] | ||
4-(2-nitroprop-1-enyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitroprop-1-enyl)benzene-1,2-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-nitroprop-1-enyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
4-(2-nitrovinyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)benzene-1,2-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-nitrovinyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [537] | ||
4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [538] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [528] | ||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [539] | ||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [540] | ||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4557W. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4557W through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [542] | ||
5,6-Bis-p-tolylamino-isoindole-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5,6-Bis-p-tolylamino-isoindole-1,3-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,6-Bis-p-tolylamino-isoindole-1,3-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [543] | ||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [544] | ||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
6,7-diethoxy-4-styrylquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-styrylquinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-diethoxy-4-styrylquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [22], [470] | ||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-N-m-tolylquinazolin-4-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-dimethoxy-N-m-tolylquinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [534] | ||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [534] | ||
AFM-21 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM-21. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AFM-21 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
AG 112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 112. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG 112 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [545] | ||
AG 9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 9. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG 9 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-213. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG-213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [527] | ||
AG-538 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-538. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG-538 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [546] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG1478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG1478 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [547] | ||
AGT-2000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AGT-2000. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AGT-2000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
AL-6802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AL-6802. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AL-6802 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
Anti-EGFR humanized mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR humanized mabs. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-EGFR humanized mabs through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
Anti-EGFR mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR mab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-EGFR mab through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
ARX-AHD [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ARX-AHD. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARX-AHD through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [538] | ||
Benzyl-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzyl-quinazolin-4-yl-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzyl-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [539] | ||
Bmab-200 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Bmab-200. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bmab-200 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
BPIQ-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BPIQ-I. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BPIQ-I through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [548] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CL-387785. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CL-387785 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [540] | ||
Cochliobolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cochliobolic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cochliobolic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [549] | ||
EDP-13 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EDP-13. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EDP-13 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
EGFR inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR inhibitor. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EGFR inhibitor through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [550] | ||
Epitinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
FHT-2107 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for FHT-2107. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FHT-2107 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
GI-3000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for GI-3000. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GI-3000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HDS-029. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HDS-029 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [551] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-9924129. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HKI-9924129 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [552] | ||
HM-61713B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-61713B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HM-61713B through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
HTS-00213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-00213. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HTS-00213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [534] | ||
HTS-02876 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-02876. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HTS-02876 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [553] | ||
HTS-05058 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-05058. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HTS-05058 through regulating the expression of Epidermal growth factor receptor (EGFR). | [7], [470] | ||
ICR 62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ICR 62. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ICR 62 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [554] | ||
IPS-01003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IPS-01003. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IPS-01003 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
LA22-radioimmunoconjugates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LA22-radioimmunoconjugates. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LA22-radioimmunoconjugates through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
LAVENDUSTIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LAVENDUSTIN A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LAVENDUSTIN A through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [541] | ||
mabionHER2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for mabionHER2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of mabionHER2 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
MDP-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MDP-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MDP-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
MG-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MG-111. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MG-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [555] | ||
MT-062 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MT-062. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MT-062 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [556] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [557] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [558] | ||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [546] | ||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-(phenylamino)quinazolin-6-yl)acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-(phenylamino)quinazolin-6-yl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [554] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [530] | ||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [528] | ||
N4-(3-chlorophenyl)quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-chlorophenyl)quinazoline-4,6-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N4-(3-chlorophenyl)quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [556] | ||
N4-(3-methylphenyl)-4,6-quinazolinediamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-methylphenyl)-4,6-quinazolinediamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N4-(3-methylphenyl)-4,6-quinazolinediamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [7], [470] | ||
NRC-2694 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NRC-2694. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NRC-2694 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
ON-128 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ON-128. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ON-128 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [528] | ||
OSI-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for OSI-75. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OSI-75 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [559] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0166326. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0166326 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [529] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0173956. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0173956 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [529] | ||
PD-158780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-158780. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-158780 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [528] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-168393. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-168393 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [558] | ||
PD182905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD182905. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD182905 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [506] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF 5208766. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF 5208766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [560] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PP121. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PP121 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [561] | ||
RG-50810 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG-50810. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG-50810 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [553] | ||
RM-6427 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-6427. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RM-6427 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [7], [470] | ||
RX-1792 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RX-1792. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RX-1792 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
SYM-011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-011. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SYM-011 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
TGF alpha [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TGF alpha. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TGF alpha through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
Theliatinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Theliatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Theliatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [562] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WHI-P154. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WHI-P154 through regulating the expression of Epidermal growth factor receptor (EGFR). | [22], [470] | ||
WZ-3146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WZ-3146. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WZ-3146 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [481] | ||
AZD-9935 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD-9935. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-9935 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [563] | ||
AZD4769 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD4769. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD4769 through regulating the expression of Epidermal growth factor receptor (EGFR). | [241], [470] | ||
CGP-52411 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-52411. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGP-52411 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [564] | ||
CGP-53353 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-53353. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CGP-53353 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [506] | ||
Heparin-EGF-like factor [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Heparin-EGF-like factor. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Heparin-EGF-like factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [565] | ||
PD-153035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-153035. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-153035 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [566] | ||
PKI166 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PKI166. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PKI166 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [567] | ||
RG7160 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG7160. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG7160 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [568] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TAK165. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK165 through regulating the expression of Epidermal growth factor receptor (EGFR). | [470], [569] | ||
Extracellular matrix receptor III (CD44)
A-6 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular matrix receptor III (CD44) is a therapeutic target for A-6. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-6 through regulating the expression of Extracellular matrix receptor III (CD44). | [570], [571] | ||
SPL-108 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular matrix receptor III (CD44) is a therapeutic target for SPL-108. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SPL-108 through regulating the expression of Extracellular matrix receptor III (CD44). | [570], [572] | ||
BIWA 4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular matrix receptor III (CD44) is a therapeutic target for BIWA 4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BIWA 4 through regulating the expression of Extracellular matrix receptor III (CD44). | [570], [573] | ||
Bivatuzumab mertansine [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular matrix receptor III (CD44) is a therapeutic target for Bivatuzumab mertansine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bivatuzumab mertansine through regulating the expression of Extracellular matrix receptor III (CD44). | [570], [574] | ||
Fatty acid synthase (FASN)
Cerulenin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for Cerulenin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cerulenin through regulating the expression of Fatty acid synthase (FASN). | [53], [575] | ||
TVB-2640 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for TVB-2640. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TVB-2640 through regulating the expression of Fatty acid synthase (FASN). | [53], [576] | ||
| Fatty acid synthase (FASN) is a therapeutic target for TVB-2640. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TVB-2640 through regulating the expression of Fatty acid synthase (FASN). | [53], [577] | |||
FAS1 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for FAS1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FAS1 through regulating the expression of Fatty acid synthase (FASN). | [53], [575] | ||
FSA2 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for FSA2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FSA2 through regulating the expression of Fatty acid synthase (FASN). | [53], [578] | ||
(-)-CATECHINGALLATE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for (-)-CATECHINGALLATE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (-)-CATECHINGALLATE through regulating the expression of Fatty acid synthase (FASN). | [53], [579] | ||
2-Hexadecynoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for 2-Hexadecynoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Hexadecynoic acid through regulating the expression of Fatty acid synthase (FASN). | [53], [575] | ||
3,7,3',4'-TETRAHYDROXYFLAVONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for 3,7,3',4'-TETRAHYDROXYFLAVONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,7,3',4'-TETRAHYDROXYFLAVONE through regulating the expression of Fatty acid synthase (FASN). | [53], [577] | ||
4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one through regulating the expression of Fatty acid synthase (FASN). | [53], [577] | ||
4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one through regulating the expression of Fatty acid synthase (FASN). | [53], [580] | ||
Anti-Fas mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for Anti-Fas mabs. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-Fas mabs through regulating the expression of Fatty acid synthase (FASN). | [53], [581] | ||
biochanin A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for biochanin A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of biochanin A through regulating the expression of Fatty acid synthase (FASN). | [53], [577] | ||
C75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for C75. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C75 through regulating the expression of Fatty acid synthase (FASN). | [53], [577] | ||
FAS-031 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for FAS-031. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FAS-031 through regulating the expression of Fatty acid synthase (FASN). | [53], [581] | ||
GALLOCATECHIN GALLATE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for GALLOCATECHIN GALLATE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GALLOCATECHIN GALLATE through regulating the expression of Fatty acid synthase (FASN). | [53], [579] | ||
GSK2194069 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for GSK2194069. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK2194069 through regulating the expression of Fatty acid synthase (FASN). | [53], [582] | ||
MG-28 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for MG-28. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MG-28 through regulating the expression of Fatty acid synthase (FASN). | [53], [583] | ||
MORIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for MORIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MORIN through regulating the expression of Fatty acid synthase (FASN). | [53], [577] | ||
MT-061 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fatty acid synthase (FASN) is a therapeutic target for MT-061. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MT-061 through regulating the expression of Fatty acid synthase (FASN). | [53], [581] | ||
Forkhead box protein O1A (FOXO1)
AS-1708727 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for AS-1708727. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AS-1708727 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [584] | ||
ISIS 188755 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188755. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188755 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188757 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188757. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188757 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188759 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188759. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188759 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188761 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188761. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188761 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188763. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188763 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188778 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188778. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188778 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188780. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188780 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188781 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188781. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188781 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [585] | ||
ISIS 188782 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein O1A (FOXO1) is a therapeutic target for ISIS 188782. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 188782 through regulating the expression of Forkhead box protein O1A (FOXO1). | [53], [586] | ||
G1/S-specific cyclin-D1 (CCND1)
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for ABT-263. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-263 through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [587], [588] | ||
Briciclib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [5], [587] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [7], [587] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [7], [587] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [587], [589] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [7], [587] | ||
7-hydroxycoumarin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 7-hydroxycoumarin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-hydroxycoumarin through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [587], [590] | ||
G1/S-specific cyclin-E1 (CCNE1)
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [7], [591] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [7], [591] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [591], [592] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [7], [591] | ||
aloisine A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for aloisine A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of aloisine A through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [590], [591] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [591], [593] | ||
PD-0183812 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-E1 (CCNE1) is a therapeutic target for PD-0183812. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0183812 through regulating the expression of G1/S-specific cyclin-E1 (CCNE1). | [591], [594] | ||
Glucose transporter type 1 (SLC2A1)
D-glucose [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for D-glucose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of D-glucose through regulating the expression of Glucose transporter type 1 (SLC2A1). | [595], [596] | ||
Quercetin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of Glucose transporter type 1 (SLC2A1). | [595], [597] | ||
2-Deoxyglucose [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for 2-Deoxyglucose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Deoxyglucose through regulating the expression of Glucose transporter type 1 (SLC2A1). | [595], [598] | ||
WZB-117 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for WZB-117. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WZB-117 through regulating the expression of Glucose transporter type 1 (SLC2A1). | [595], [599] | ||
Arsenite [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for Arsenite. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Arsenite through regulating the expression of Glucose transporter type 1 (SLC2A1). | [595], [600] | ||
Dehydroascorbic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for Dehydroascorbic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydroascorbic acid through regulating the expression of Glucose transporter type 1 (SLC2A1). | [595], [601] | ||
Heat shock protein 90 alpha (HSP90A)
Amlexanox [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Amlexanox. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amlexanox through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
Cromoglicate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Cromoglicate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cromoglicate through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
BIIB-021 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for BIIB-021. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BIIB-021 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [603] | ||
Efungumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Efungumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Efungumab through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
KW-2478 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for KW-2478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KW-2478 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [605] | ||
NVP-AUY922 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for NVP-AUY922. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NVP-AUY922 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [606] | ||
SNX-5422 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for SNX-5422. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SNX-5422 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
Tanespimycin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Tanespimycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tanespimycin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [607] | ||
VER 50589 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for VER 50589. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VER 50589 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [608] | ||
Alvespimycin hydrochloride [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Alvespimycin hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alvespimycin hydrochloride through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [609] | ||
AT13387 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for AT13387. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AT13387 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
BIIB 028 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for BIIB 028. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BIIB 028 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [211], [602] | ||
Debio 0932 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Debio 0932. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Debio 0932 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [610] | ||
PU-AD [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for PU-AD. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PU-AD through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [605] | ||
PU3 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for PU3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PU3 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [611] | ||
RTA-901 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for RTA-901. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RTA-901 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [612] | ||
CCT-018159 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for CCT-018159. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CCT-018159 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [613] | ||
KOS-2484 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for KOS-2484. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KOS-2484 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
17-desmethoxy-17-aminogeldanamycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 17-desmethoxy-17-aminogeldanamycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 17-desmethoxy-17-aminogeldanamycin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [436], [602] | ||
2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
2-Methyl-2,4-Pentanediol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 2-Methyl-2,4-Pentanediol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Methyl-2,4-Pentanediol through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [220], [602] | ||
Geldanamycin-estradiol hybrid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Geldanamycin-estradiol hybrid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Geldanamycin-estradiol hybrid through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [614] | ||
GNF-PF-67 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for GNF-PF-67. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GNF-PF-67 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [436], [602] | ||
KOSN1559 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for KOSN1559. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KOSN1559 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [604] | ||
Macbecin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Macbecin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Macbecin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [615] | ||
PU24S [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for PU24S. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PU24S through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [210], [602] | ||
Radicicol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Radicicol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Radicicol through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [616] | ||
RHEIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for RHEIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RHEIN through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [617] | ||
SNX-2112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for SNX-2112. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SNX-2112 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [614] | ||
VER-49009 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for VER-49009. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VER-49009 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [618] | ||
ZEARALANONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for ZEARALANONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZEARALANONE through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [436], [602] | ||
EC-154 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for EC-154. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EC-154 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [619] | ||
Geldanamycin [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for Geldanamycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Geldanamycin through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [620] | ||
HBP-347 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for HBP-347. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HBP-347 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [621] | ||
IPI-493 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein 90 alpha (HSP90A) is a therapeutic target for IPI-493. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IPI-493 through regulating the expression of Heat shock protein 90 alpha (HSP90A). | [602], [622] | ||
Heat shock protein beta-1 (HSPB1)
AZX-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein beta-1 (HSPB1) is a therapeutic target for AZX-100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZX-100 through regulating the expression of Heat shock protein beta-1 (HSPB1). | [623], [624] | ||
SB-242235 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heat shock protein beta-1 (HSPB1) is a therapeutic target for SB-242235. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-242235 through regulating the expression of Heat shock protein beta-1 (HSPB1). | [623], [625] | ||
Hepatocyte nuclear factor 1-alpha (HNF1A)
Norleucine [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hepatocyte nuclear factor 1-alpha (HNF1A) is a therapeutic target for Norleucine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Norleucine through regulating the expression of Hepatocyte nuclear factor 1-alpha (HNF1A). | [626], [627] | ||
Herpesvirus ubiquitin-specific protease (HAUSP)
ADC-01 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Herpesvirus ubiquitin-specific protease (HAUSP) is a therapeutic target for ADC-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ADC-01 through regulating the expression of Herpesvirus ubiquitin-specific protease (HAUSP). | [628], [629] | ||
ADC-03 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Herpesvirus ubiquitin-specific protease (HAUSP) is a therapeutic target for ADC-03. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ADC-03 through regulating the expression of Herpesvirus ubiquitin-specific protease (HAUSP). | [628], [630] | ||
HBX19818 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Herpesvirus ubiquitin-specific protease (HAUSP) is a therapeutic target for HBX19818. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HBX19818 through regulating the expression of Herpesvirus ubiquitin-specific protease (HAUSP). | [628], [631] | ||
P22077 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Herpesvirus ubiquitin-specific protease (HAUSP) is a therapeutic target for P22077. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of P22077 through regulating the expression of Herpesvirus ubiquitin-specific protease (HAUSP). | [628], [632] | ||
Hexokinase-2 (HK2)
VDA-1102 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). | [595], [633] | ||
HIF-1 responsive protein RTP801 (DDIT4)
PF-04523655 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | HIF-1 responsive protein RTP801 (DDIT4) is a therapeutic target for PF-04523655. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-04523655 through regulating the expression of HIF-1 responsive protein RTP801 (DDIT4). | [423], [634] | ||
PF-4523655 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | HIF-1 responsive protein RTP801 (DDIT4) is a therapeutic target for PF-4523655. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-4523655 through regulating the expression of HIF-1 responsive protein RTP801 (DDIT4). | [423], [635] | ||
Histone deacetylase 2 (HDAC2)
CHR-3996 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for CHR-3996. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CHR-3996 through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [636] | ||
(E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [637] | ||
1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [637] | ||
1,1,1-Trifluoro-8-phenoxy-octan-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 1,1,1-Trifluoro-8-phenoxy-octan-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,1,1-Trifluoro-8-phenoxy-octan-2-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [639] | ||
2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [639] | ||
2-(methylsulfonylthio)ethyl 2-propylpentanoate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 2-(methylsulfonylthio)ethyl 2-propylpentanoate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(methylsulfonylthio)ethyl 2-propylpentanoate through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [640] | ||
4-Benzoylamino-N-hydroxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Benzoylamino-N-hydroxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Benzoylamino-N-hydroxy-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [641] | ||
4-Butyrylamino-N-hydroxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Butyrylamino-N-hydroxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Butyrylamino-N-hydroxy-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [643] | ||
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [644] | ||
4-Phenylbutyrohydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 4-Phenylbutyrohydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Phenylbutyrohydroxamic acid through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [645] | ||
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [644] | ||
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [646] | ||
5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [647] | ||
5-Mercapto-pentanoic acid phenylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 5-Mercapto-pentanoic acid phenylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Mercapto-pentanoic acid phenylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
6-(2-Bromo-acetylamino)-hexanoic acid phenylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [649] | ||
6-benzenesulfinylhexanoic acid hydroxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 6-benzenesulfinylhexanoic acid hydroxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-benzenesulfinylhexanoic acid hydroxamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [650] | ||
6-benzenesulfonylhexanoic acid hydroxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 6-benzenesulfonylhexanoic acid hydroxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-benzenesulfonylhexanoic acid hydroxamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [646] | ||
6-Mercapto-hexanoic acid phenylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 6-Mercapto-hexanoic acid phenylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Mercapto-hexanoic acid phenylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
6-Phenoxy-hexane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 6-Phenoxy-hexane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Phenoxy-hexane-1-thiol through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
6-phenylsulfanylhexanoic acid hydroxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 6-phenylsulfanylhexanoic acid hydroxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-phenylsulfanylhexanoic acid hydroxamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [646] | ||
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [637] | ||
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [651] | ||
7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [637] | ||
7-Biphenyl-4-yl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Biphenyl-4-yl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Biphenyl-4-yl-heptanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [652] | ||
7-Mercapto-heptanoic acid benzothiazol-2-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid benzothiazol-2-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid benzothiazol-2-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
7-Mercapto-heptanoic acid biphenyl-3-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid biphenyl-3-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid biphenyl-3-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
7-Mercapto-heptanoic acid biphenyl-4-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid biphenyl-4-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid biphenyl-4-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
7-Mercapto-heptanoic acid phenylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid phenylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid phenylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
7-Mercapto-heptanoic acid pyridin-3-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid pyridin-3-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid pyridin-3-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
7-Mercapto-heptanoic acid quinolin-3-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Mercapto-heptanoic acid quinolin-3-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Mercapto-heptanoic acid quinolin-3-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
7-Phenoxy-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 7-Phenoxy-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Phenoxy-heptanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [653] | ||
8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [653] | ||
8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [654] | ||
8-Mercapto-octanoic acid phenylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-Mercapto-octanoic acid phenylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Mercapto-octanoic acid phenylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
8-Oxo-8-phenyl-octanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-Oxo-8-phenyl-octanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Oxo-8-phenyl-octanoic acid through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [644] | ||
8-Oxo-8-phenyl-octanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-Oxo-8-phenyl-octanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Oxo-8-phenyl-octanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [655] | ||
8-Phenyl-octanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 8-Phenyl-octanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Phenyl-octanoic acid hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [653] | ||
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [644] | ||
9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
Cyclostellettamine derivative [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for Cyclostellettamine derivative. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclostellettamine derivative through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [654] | ||
KAR-1880 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for KAR-1880. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KAR-1880 through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [656] | ||
N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(2-amino-5-(furan-2-yl)phenyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-amino-5-(furan-2-yl)phenyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-amino-5-(furan-2-yl)phenyl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(2-amino-5-(furan-3-yl)phenyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-amino-5-(furan-3-yl)phenyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-amino-5-(furan-3-yl)phenyl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [655] | ||
N-(2-aminophenyl)-4-methoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-aminophenyl)-4-methoxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-aminophenyl)-4-methoxybenzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [658] | ||
N-(2-aminophenyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-aminophenyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-aminophenyl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [647] | ||
N-(2-aminophenyl)nicotinamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-aminophenyl)nicotinamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-aminophenyl)nicotinamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [659] | ||
N-(2-aminophenyl)quinoxaline-6-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-aminophenyl)quinoxaline-6-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-aminophenyl)quinoxaline-6-carboxamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [640] | ||
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [649] | ||
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(2-Mercapto-ethyl)-N'-phenyl-succinamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(2-Mercapto-ethyl)-N'-phenyl-succinamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-amino-3'-methylbiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-amino-3'-methylbiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-3'-methylbiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-amino-4'-bromobiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-amino-4'-bromobiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-4'-bromobiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-aminobiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-aminobiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-aminobiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
N-(4-aminobiphenyl-3-yl)nicotinamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-aminobiphenyl-3-yl)nicotinamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-aminobiphenyl-3-yl)nicotinamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [659] | ||
N-(4-hydroxybiphenyl-3-yl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(4-hydroxybiphenyl-3-yl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-hydroxybiphenyl-3-yl)benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [659] | ||
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [643] | ||
N-(6-Hydroxycarbamoyl-hexyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(6-Hydroxycarbamoyl-hexyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(6-Hydroxycarbamoyl-hexyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
N-(6-Mercapto-hexyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-(6-Mercapto-hexyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(6-Mercapto-hexyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [652] | ||
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [660] | ||
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-(pentanoylamino-methyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(pentanoylamino-methyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [642] | ||
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [652] | ||
N-Hydroxy-4-phenylacetylamino-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-4-phenylacetylamino-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-phenylacetylamino-benzamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [639] | ||
N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [659] | ||
N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [647] | ||
N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [647] | ||
N7-hydroxy-2-methoxy-N1-phenylheptanediamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N7-hydroxy-2-methoxy-N1-phenylheptanediamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N7-hydroxy-2-methoxy-N1-phenylheptanediamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [658] | ||
N7-hydroxy-N1-phenyl-2-propoxyheptanediamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N7-hydroxy-N1-phenyl-2-propoxyheptanediamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N7-hydroxy-N1-phenyl-2-propoxyheptanediamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [639] | ||
N8,2-dihydroxy-N1-phenyloctanediamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N8,2-dihydroxy-N1-phenyloctanediamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N8,2-dihydroxy-N1-phenyloctanediamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [639] | ||
N8-hydroxy-2-methoxy-N1-phenyloctanediamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for N8-hydroxy-2-methoxy-N1-phenyloctanediamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N8-hydroxy-2-methoxy-N1-phenyloctanediamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [639] | ||
Octanedioic acid bis-hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for Octanedioic acid bis-hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Octanedioic acid bis-hydroxyamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [657] | ||
Octanedioic acid hydroxyamide pyridin-2-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for Octanedioic acid hydroxyamide pyridin-2-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Octanedioic acid hydroxyamide pyridin-2-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [643] | ||
Octanedioic acid hydroxyamide pyridin-4-ylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for Octanedioic acid hydroxyamide pyridin-4-ylamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Octanedioic acid hydroxyamide pyridin-4-ylamide through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [644] | ||
PSAMMAPLIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for PSAMMAPLIN A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PSAMMAPLIN A through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
santacruzamate A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for santacruzamate A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of santacruzamate A through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [638] | ||
ST-2986 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for ST-2986. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ST-2986 through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [653] | ||
ST-2987 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for ST-2987. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ST-2987 through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [661] | ||
Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 2 (HDAC2) is a therapeutic target for Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester through regulating the expression of Histone deacetylase 2 (HDAC2). | [235], [648] | ||
Histone deacetylase 5 (HDAC5)
TMP269 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone deacetylase 5 (HDAC5) is a therapeutic target for TMP269. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TMP269 through regulating the expression of Histone deacetylase 5 (HDAC5). | [636], [662] | ||
Histone-lysine N-methyltransferase SETD7 (SETD7)
(R)-PFI-2 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Histone-lysine N-methyltransferase SETD7 (SETD7) is a therapeutic target for (R)-PFI-2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (R)-PFI-2 through regulating the expression of Histone-lysine N-methyltransferase SETD7 (SETD7). | [434], [663] | ||
Hypoxia-inducible factor 1 alpha (HIF-1A)
HIF-1alpha [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for HIF-1alpha. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HIF-1alpha through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [665] | ||
IT-101 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for IT-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IT-101 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [666] | ||
2-Methoxyestradiol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for 2-Methoxyestradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Methoxyestradiol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [667] | ||
PT2385 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PT2385. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PT2385 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [668] | ||
ENMD-1198 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ENMD-1198. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ENMD-1198 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [669] | ||
EZN-2968 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for EZN-2968. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EZN-2968 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [670] | ||
PX-478 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for PX-478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PX-478 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [671] | ||
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [5], [664] | ||
ISIS 175510 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 175510. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 175510 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298697 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298697. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298697 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298699 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298699. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298699 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298700 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298700. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298700 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298701 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298701. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298701 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298702 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298702. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298702 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298711 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298711. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298711 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298712 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298712. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298712 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298743 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298743. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298743 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298744 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298744. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298744 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298745 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298745. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298745 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [672] | ||
ISIS 298746 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hypoxia-inducible factor 1 alpha (HIF-1A) is a therapeutic target for ISIS 298746. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 298746 through regulating the expression of Hypoxia-inducible factor 1 alpha (HIF-1A). | [664], [673] | ||
Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)
5-Bromo-6-methoxy-9H-beta-carboline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for 5-Bromo-6-methoxy-9H-beta-carboline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Bromo-6-methoxy-9H-beta-carboline through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). | [674], [675] | ||
IKI-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for IKI-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IKI-1 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). | [674], [676] | ||
ISIS 23544 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for ISIS 23544. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 23544 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). | [674], [677] | ||
ISIS 23559 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for ISIS 23559. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 23559 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). | [674], [678] | ||
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). | [674], [679] | ||
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
Arsenic trioxide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for Arsenic trioxide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Arsenic trioxide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [681] | ||
IMD-1041 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for IMD-1041. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMD-1041 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [682] | ||
Parthenolide [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for Parthenolide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Parthenolide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [683] | ||
SAR-113945 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for SAR-113945. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAR-113945 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [684] | ||
IMD-0354 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for IMD-0354. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMD-0354 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [685] | ||
2-amino-5-phenylthiophene-3-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 2-amino-5-phenylthiophene-3-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-amino-5-phenylthiophene-3-carboxamide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
2-amino-quinoline-3-carboxylic acid amide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 2-amino-quinoline-3-carboxylic acid amide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-amino-quinoline-3-carboxylic acid amide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [247], [680] | ||
3-amino-benzo[b]thiophene-2-carboxylic acid amide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 3-amino-benzo[b]thiophene-2-carboxylic acid amide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-amino-benzo[b]thiophene-2-carboxylic acid amide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
4-amino-biphenyl-3-carboxylic acid amide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 4-amino-biphenyl-3-carboxylic acid amide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-amino-biphenyl-3-carboxylic acid amide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
5-amino-2-phenyl-oxazole-4-carboxylic acid amide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 5-amino-2-phenyl-oxazole-4-carboxylic acid amide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-amino-2-phenyl-oxazole-4-carboxylic acid amide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
5-Bromo-6-methoxy-9H-beta-carboline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 5-Bromo-6-methoxy-9H-beta-carboline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Bromo-6-methoxy-9H-beta-carboline through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [686] | ||
PF-228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for PF-228. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-228 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [687] | ||
SC-514 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for SC-514. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-514 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [677], [680] | ||
Staurosporine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for Staurosporine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Staurosporine through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [688] | ||
MLN0415 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Inhibitor of nuclear factor kappa-B kinase beta (IKKB) is a therapeutic target for MLN0415. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MLN0415 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase beta (IKKB). | [680], [689] | ||
Insulin-like growth factor I receptor (IGF1R)
Mecasermin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Mecasermin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mecasermin through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [691] | ||
Somatomedin-1 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Somatomedin-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Somatomedin-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [5], [690] | ||
Teprotumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Teprotumumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Teprotumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [692] | ||
Rinfabate [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Rinfabate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rinfabate through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [693] | ||
AMG 479 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMG 479. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 479 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [29], [690] | ||
AXL-1717 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AXL-1717. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AXL-1717 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [500], [690] | ||
Cixutumumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cixutumumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cixutumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [694] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for MM-141. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MM-141 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [3], [690] | ||
R1507 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for R1507. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of R1507 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [695] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for TT-100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TT-100 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [696] | ||
VPI-2690B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for VPI-2690B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VPI-2690B through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [697] | ||
AEW-541 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AEW-541. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AEW-541 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [698] | ||
BIIB 022 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BIIB 022. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BIIB 022 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [699] | ||
Cyclolignan picropodophyllin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cyclolignan picropodophyllin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclolignan picropodophyllin through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [241], [690] | ||
FPI-1434 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for FPI-1434. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FPI-1434 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [700] | ||
HF-0299 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for HF-0299. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HF-0299 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [701] | ||
RG-7010 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for RG-7010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG-7010 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [702] | ||
ATL-1101 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for ATL-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ATL-1101 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [703] | ||
BMS-695735 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS-695735. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-695735 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [526], [690] | ||
4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [704] | ||
4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [705] | ||
AG 1024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AG 1024. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG 1024 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [706] | ||
Alpha-D-Mannose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Alpha-D-Mannose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alpha-D-Mannose through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [210], [690] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [210], [690] | ||
AZD3463 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AZD3463. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD3463 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [707] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [704] | ||
Fucose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Fucose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fucose through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [26], [690] | ||
GSK-1838705A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK-1838705A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK-1838705A through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [708] | ||
GSK1511931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK1511931. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK1511931 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [709] | ||
JB-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for JB-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JB-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [710] | ||
NVP-ADW742 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for NVP-ADW742. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NVP-ADW742 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [26], [690] | ||
PQ401 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for PQ401. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PQ401 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [711] | ||
AVE-1642 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AVE-1642. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVE-1642 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [712] | ||
Figitumumab [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Figitumumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Figitumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [214], [690] | ||
KW-2450 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for KW-2450. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KW-2450 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [690], [713] | ||
Insulin-like growth factor-I (IGF1)
Xentuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). | [714], [715] | ||
BI-836845 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for BI-836845. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI-836845 through regulating the expression of Insulin-like growth factor-I (IGF1). | [497], [714] | ||
MEDI-573 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for MEDI-573. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI-573 through regulating the expression of Insulin-like growth factor-I (IGF1). | [714], [716] | ||
Insulin-like growth factor-II (IGF2)
Dusigitumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-II (IGF2) is a therapeutic target for Dusigitumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dusigitumab through regulating the expression of Insulin-like growth factor-II (IGF2). | [235], [717] | ||
Xentuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-II (IGF2) is a therapeutic target for Xentuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-II (IGF2). | [235], [497] | ||
Integrin beta-1 (ITGB1)
131I-radretumab [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for 131I-radretumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 131I-radretumab through regulating the expression of Integrin beta-1 (ITGB1). | [718], [719] | ||
JSM 6427 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for JSM 6427. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JSM 6427 through regulating the expression of Integrin beta-1 (ITGB1). | [718], [720] | ||
OS2966 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for OS2966. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OS2966 through regulating the expression of Integrin beta-1 (ITGB1). | [718], [721] | ||
C(-GRGDfL-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for C(-GRGDfL-). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C(-GRGDfL-) through regulating the expression of Integrin beta-1 (ITGB1). | [718], [722] | ||
MK-0668 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for MK-0668. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-0668 through regulating the expression of Integrin beta-1 (ITGB1). | [718], [723] | ||
SB-265123 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Integrin beta-1 (ITGB1) is a therapeutic target for SB-265123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-265123 through regulating the expression of Integrin beta-1 (ITGB1). | [718], [724] | ||
Intercellular adhesion molecule ICAM-1 (ICAM1)
ISIS 1570 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 1570. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 1570 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [726] | ||
lifitegrast [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for lifitegrast. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of lifitegrast through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [727] | ||
Alicaforsen [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for Alicaforsen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alicaforsen through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [728] | ||
| Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for Alicaforsen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alicaforsen through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [729] | |||
APC-8015F [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for APC-8015F. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APC-8015F through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [730] | ||
BI-505 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for BI-505. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI-505 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [731] | ||
AIC100 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for AIC100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AIC100 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [732] | ||
A-286982 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for A-286982. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-286982 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [733] | ||
Dehydropipernonaline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for Dehydropipernonaline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dehydropipernonaline through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [733] | ||
ISIS 11158 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 11158. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 11158 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [734] | ||
ISIS 11159 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 11159. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 11159 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [735] | ||
ISIS 11665 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 11665. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 11665 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [735] | ||
ISIS 1931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 1931. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 1931 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [728] | ||
ISIS 2974 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 2974. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 2974 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [735] | ||
ISIS 3067 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 3067. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 3067 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [735] | ||
ISIS 3224 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS 3224. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 3224 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [735] | ||
ISIS-1939 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for ISIS-1939. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS-1939 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [736] | ||
Pellitorin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for Pellitorin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pellitorin through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [733] | ||
PIPERNONALINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for PIPERNONALINE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PIPERNONALINE through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [737] | ||
PIPERROLEIN B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for PIPERROLEIN B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PIPERROLEIN B through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [733] | ||
A-252444.0 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for A-252444.0. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-252444.0 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [738] | ||
GI-270384X [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for GI-270384X. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GI-270384X through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [739] | ||
INXC-ICAM1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for INXC-ICAM1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INXC-ICAM1 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [728] | ||
MOR-102 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Intercellular adhesion molecule ICAM-1 (ICAM1) is a therapeutic target for MOR-102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MOR-102 through regulating the expression of Intercellular adhesion molecule ICAM-1 (ICAM1). | [725], [740] | ||
Interferon-gamma (IFNG)
Emapalumab [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for Emapalumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Emapalumab through regulating the expression of Interferon-gamma (IFNG). | [191], [741] | ||
| Interferon-gamma (IFNG) is a therapeutic target for Emapalumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Emapalumab through regulating the expression of Interferon-gamma (IFNG). | [191], [624] | |||
Fumaric acid [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for Fumaric acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fumaric acid through regulating the expression of Interferon-gamma (IFNG). | [191], [742] | ||
VIR-201 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for VIR-201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VIR-201 through regulating the expression of Interferon-gamma (IFNG). | [191], [743] | ||
AMG 811 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for AMG 811. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 811 through regulating the expression of Interferon-gamma (IFNG). | [191], [744] | ||
CIGB-128 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for CIGB-128. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CIGB-128 through regulating the expression of Interferon-gamma (IFNG). | [191], [745] | ||
VPM-4-001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for VPM-4-001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VPM-4-001 through regulating the expression of Interferon-gamma (IFNG). | [191], [746] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for CRx-191. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRx-191 through regulating the expression of Interferon-gamma (IFNG). | [191], [747] | ||
Fontolizumab [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for Fontolizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fontolizumab through regulating the expression of Interferon-gamma (IFNG). | [191], [748] | ||
TAK-603 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for TAK-603. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-603 through regulating the expression of Interferon-gamma (IFNG). | [191], [749] | ||
TG-1042 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interferon-gamma (IFNG) is a therapeutic target for TG-1042. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TG-1042 through regulating the expression of Interferon-gamma (IFNG). | [191], [750] | ||
Interleukin-6 (IL6)
Siltuximab [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Siltuximab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Siltuximab through regulating the expression of Interleukin-6 (IL6). | [751], [752] | ||
| Interleukin-6 (IL6) is a therapeutic target for Siltuximab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Siltuximab through regulating the expression of Interleukin-6 (IL6). | [751], [754] | |||
Olokizumab [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Olokizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olokizumab through regulating the expression of Interleukin-6 (IL6). | [60], [751] | ||
| Interleukin-6 (IL6) is a therapeutic target for Olokizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olokizumab through regulating the expression of Interleukin-6 (IL6). | [751], [753] | |||
Sirukumab [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Sirukumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sirukumab through regulating the expression of Interleukin-6 (IL6). | [751], [755] | ||
| Interleukin-6 (IL6) is a therapeutic target for Sirukumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sirukumab through regulating the expression of Interleukin-6 (IL6). | [751], [758] | |||
ALD-518 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for ALD-518. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALD-518 through regulating the expression of Interleukin-6 (IL6). | [60], [751] | ||
CDP-6038 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for CDP-6038. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CDP-6038 through regulating the expression of Interleukin-6 (IL6). | [214], [751] | ||
Clazakizumab [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Clazakizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clazakizumab through regulating the expression of Interleukin-6 (IL6). | [60], [751] | ||
| Interleukin-6 (IL6) is a therapeutic target for Clazakizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clazakizumab through regulating the expression of Interleukin-6 (IL6). | [751], [756] | |||
PF-04236921 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for PF-04236921. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-04236921 through regulating the expression of Interleukin-6 (IL6). | [751], [757] | ||
YSIL6 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for YSIL6. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YSIL6 through regulating the expression of Interleukin-6 (IL6). | [214], [751] | ||
C326 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for C326. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C326 through regulating the expression of Interleukin-6 (IL6). | [751], [759] | ||
Gerilimzumab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for Gerilimzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gerilimzumab through regulating the expression of Interleukin-6 (IL6). | [751], [760] | ||
MEDI5117 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for MEDI5117. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI5117 through regulating the expression of Interleukin-6 (IL6). | [751], [761] | ||
OP-R003 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-6 (IL6) is a therapeutic target for OP-R003. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OP-R003 through regulating the expression of Interleukin-6 (IL6). | [60], [751] | ||
ITGB3 messenger RNA (ITGB3 mRNA)
3-(3-(benzamido)-5-nitrobenzamido)propanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [763] | ||
3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [763] | ||
3-(3-(carbamoyl)benzamido)propanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for 3-(3-(carbamoyl)benzamido)propanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3-(carbamoyl)benzamido)propanoic acid through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Ac-Asp-Arg-Leu-Asp-Ser-OH [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Ac-Asp-Arg-Leu-Asp-Ser-OH. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ac-Asp-Arg-Leu-Asp-Ser-OH through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [724], [762] | ||
AcDRGDS [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for AcDRGDS. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AcDRGDS through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
C(-GRGDfL-) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C(-GRGDfL-). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C(-GRGDfL-) through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [766] | ||
C(Arg-Gly-Asp-D-Phe-Val) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C(Arg-Gly-Asp-D-Phe-Val). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C(Arg-Gly-Asp-D-Phe-Val) through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [767] | ||
C(RGDfF) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C(RGDfF). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C(RGDfF) through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [767] | ||
C(RGDfMeF) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C(RGDfMeF). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C(RGDfMeF) through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C-[-Arg-Gly-Asp-Acpca30-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C-[-Arg-Gly-Asp-Acpca30-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-[-Arg-Gly-Asp-Acpca30-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C-[-Arg-Gly-Asp-Acpca31-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C-[-Arg-Gly-Asp-Acpca31-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-[-Arg-Gly-Asp-Acpca31-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C-[-Arg-Gly-Asp-Acpca32-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C-[-Arg-Gly-Asp-Acpca32-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-[-Arg-Gly-Asp-Acpca32-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C-[-Arg-Gly-Asp-Acpca33-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C-[-Arg-Gly-Asp-Acpca33-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-[-Arg-Gly-Asp-Acpca33-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
Cyclo(RGDfV) (control) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo(RGDfV) (control). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo(RGDfV) (control) through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Cyclo-[-Arg-Gly-Asp-Amp21-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp21-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp21-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
Cyclo-[-Arg-Gly-Asp-Amp22-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp22-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp22-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
Cyclo-[-Arg-Gly-Asp-Amp23-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp23-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp23-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
Cyclo-[-Arg-Gly-Asp-Amp24-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp24-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp24-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
Cyclo-[-Arg-Gly-Asp-Amp25-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp25-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp25-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [770] | ||
Cyclo-[-Arg-Gly-Asp-Amp26-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp26-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp26-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
Cyclo-[-Arg-Gly-Asp-Amp27-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp27-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp27-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
Cyclo-[-Arg-Gly-Asp-Amp28-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo-[-Arg-Gly-Asp-Amp28-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo-[-Arg-Gly-Asp-Amp28-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
CYCLORGDFV [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for CYCLORGDFV. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYCLORGDFV through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [771] | ||
Cyclo[RGDfK(cypate)] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cyclo[RGDfK(cypate)]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclo[RGDfK(cypate)] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [772] | ||
Cypate-[(RGD)2-NH2]1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cypate-[(RGD)2-NH2]1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cypate-[(RGD)2-NH2]1 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Cypate-[(RGD)2-NH2]2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cypate-[(RGD)2-NH2]2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cypate-[(RGD)2-NH2]2 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Cypate-[(RGD)3-NH2]1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cypate-[(RGD)3-NH2]1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cypate-[(RGD)3-NH2]1 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Cypate-[(RGD)3-NH2]2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cypate-[(RGD)3-NH2]2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cypate-[(RGD)3-NH2]2 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Cypate-[(RGD)4-NH2]1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cypate-[(RGD)4-NH2]1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cypate-[(RGD)4-NH2]1 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
Cypate-[(RGD)4-NH2]2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Cypate-[(RGD)4-NH2]2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cypate-[(RGD)4-NH2]2 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [764] | ||
C[-Arg-Gly-Asp-Acpca19-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca19-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca19-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[-Arg-Gly-Asp-Acpca20-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca20-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca20-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[-Arg-Gly-Asp-Acpca21-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca21-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca21-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[-Arg-Gly-Asp-Acpca22-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca22-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca22-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[-Arg-Gly-Asp-Acpca34-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca34-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca34-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[-Arg-Gly-Asp-Acpca35-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca35-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca35-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[-Arg-Gly-Asp-Acpca36-] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[-Arg-Gly-Asp-Acpca36-]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[-Arg-Gly-Asp-Acpca36-] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
C[RGD-(R)-alpha-TfmfV] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGD-(R)-alpha-TfmfV]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGD-(R)-alpha-TfmfV] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGD-(S)-alpha-TfmfV] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGD-(S)-alpha-TfmfV]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGD-(S)-alpha-TfmfV] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(R)-alpha-TfmF] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(R)-alpha-TfmF]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(R)-alpha-TfmF] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(R)-alpha-TfmV] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(R)-alpha-TfmV]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(R)-alpha-TfmV] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(R)-N-Me-alpha-TfmF] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(R)-N-Me-alpha-TfmF]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(R)-N-Me-alpha-TfmF] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(S)-alpha-TfmF] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(S)-alpha-TfmF]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(S)-alpha-TfmF] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(S)-alpha-TfmV] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(S)-alpha-TfmV]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(S)-alpha-TfmV] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(S)-N-Me-alpha-TfmF] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(S)-N-Me-alpha-TfmF]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(S)-N-Me-alpha-TfmF] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
C[RGDf-(S,R)-alpha-Dfm-F] [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for C[RGDf-(S,R)-alpha-Dfm-F]. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C[RGDf-(S,R)-alpha-Dfm-F] through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [768] | ||
E[c(RGDyK)]2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for E[c(RGDyK)]2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E[c(RGDyK)]2 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [773] | ||
E[c(RGDyK)]2-PTX conjugate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for E[c(RGDyK)]2-PTX conjugate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E[c(RGDyK)]2-PTX conjugate through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [774] | ||
Gly-Arg-Gly-Asp-Ser [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Gly-Arg-Gly-Asp-Ser. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gly-Arg-Gly-Asp-Ser through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [775] | ||
Gly-Arg-Gly-Asp-Ser-Pro-Lys [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Gly-Arg-Gly-Asp-Ser-Pro-Lys. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gly-Arg-Gly-Asp-Ser-Pro-Lys through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
ISIS 196103 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for ISIS 196103. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 196103 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [769] | ||
ISIS 25237 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for ISIS 25237. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 25237 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [777] | ||
ISONIPECOTAMIDE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for ISONIPECOTAMIDE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISONIPECOTAMIDE through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [778] | ||
L-734115 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-734115. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-734115 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
L-739758 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-739758. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-739758 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
L-746233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-746233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-746233 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
L-750034 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-750034. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-750034 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
L-756568 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-756568. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-756568 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [779] | ||
L-767679 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-767679. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-767679 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [780] | ||
N-(3,5-dichlorophenyl)imidodicarbonimidic diamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for N-(3,5-dichlorophenyl)imidodicarbonimidic diamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3,5-dichlorophenyl)imidodicarbonimidic diamide through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [781] | ||
RGDechi [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for RGDechi. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RGDechi through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [763] | ||
ROXIFIBAN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for ROXIFIBAN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ROXIFIBAN through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [782] | ||
RWJ-53419 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for RWJ-53419. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RWJ-53419 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
SB-207043 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SB-207043. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-207043 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [765] | ||
SB-265123 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SB-265123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-265123 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [783] | ||
SC-54701A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SC-54701A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-54701A through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [784] | ||
ST-1646 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for ST-1646. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ST-1646 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [773] | ||
DMP-757 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for DMP-757. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DMP-757 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
DMP-802 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for DMP-802. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DMP-802 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
L-709780 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-709780. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-709780 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [785] | ||
L-738167 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for L-738167. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-738167 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [786] | ||
Ro-43-5054 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Ro-43-5054. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-43-5054 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
Ro-43-8857 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for Ro-43-8857. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-43-8857 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [783] | ||
SB-223245 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SB-223245. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-223245 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [776] | ||
SC-47643 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SC-47643. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-47643 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [787] | ||
SKF-107260 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for SKF-107260. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SKF-107260 through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [210], [762] | ||
XEMILOFIBAN [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | ITGB3 messenger RNA (ITGB3 mRNA) is a therapeutic target for XEMILOFIBAN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XEMILOFIBAN through regulating the expression of ITGB3 messenger RNA (ITGB3 mRNA). | [762], [788] | ||
Jagged2 messenger RNA (JAG2 mRNA)
ISIS 148715 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Jagged2 messenger RNA (JAG2 mRNA) is a therapeutic target for ISIS 148715. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 148715 through regulating the expression of Jagged2 messenger RNA (JAG2 mRNA). | [412], [789] | ||
Janus kinase 2 (JAK-2)
Baricitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Baricitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Baricitinib through regulating the expression of Janus kinase 2 (JAK-2). | [790], [791] | ||
Fedratinib [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Fedratinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fedratinib through regulating the expression of Janus kinase 2 (JAK-2). | [790], [792] | ||
| Janus kinase 2 (JAK-2) is a therapeutic target for Fedratinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fedratinib through regulating the expression of Janus kinase 2 (JAK-2). | [790], [809] | |||
Ruxolitinib [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Ruxolitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ruxolitinib through regulating the expression of Janus kinase 2 (JAK-2). | [790], [793] | ||
| Janus kinase 2 (JAK-2) is a therapeutic target for Ruxolitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ruxolitinib through regulating the expression of Janus kinase 2 (JAK-2). | [60], [790] | |||
CYT-387 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for CYT-387. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYT-387 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [794] | ||
ITF2357 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for ITF2357. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ITF2357 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [795] | ||
Pacritinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Pacritinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pacritinib through regulating the expression of Janus kinase 2 (JAK-2). | [790], [796] | ||
XL019 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for XL019. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XL019 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [797] | ||
AZD1480 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AZD1480. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD1480 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [798] | ||
BMS-911543 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for BMS-911543. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-911543 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [799] | ||
Cerdulatinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Cerdulatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cerdulatinib through regulating the expression of Janus kinase 2 (JAK-2). | [790], [800] | ||
CTP-543 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for CTP-543. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CTP-543 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [801] | ||
| Janus kinase 2 (JAK-2) is a therapeutic target for CTP-543. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CTP-543 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [797] | |||
INCB039110 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for INCB039110. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INCB039110 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [802] | ||
LY2784544 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for LY2784544. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY2784544 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [803] | ||
NS-018 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for NS-018. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NS-018 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [801] | ||
AC430 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AC430. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AC430 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [804] | ||
Peginterferon beta [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Peginterferon beta. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Peginterferon beta through regulating the expression of Janus kinase 2 (JAK-2). | [790], [793] | ||
SB-1578 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for SB-1578. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-1578 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [805] | ||
1,2,3,4,5,6-hexabromocyclohexane [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for 1,2,3,4,5,6-hexabromocyclohexane. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,2,3,4,5,6-hexabromocyclohexane through regulating the expression of Janus kinase 2 (JAK-2). | [790], [806] | ||
5-phenyl-1H-indazol-3-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for 5-phenyl-1H-indazol-3-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-phenyl-1H-indazol-3-amine through regulating the expression of Janus kinase 2 (JAK-2). | [790], [807] | ||
AMG-JAK2-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AMG-JAK2-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG-JAK2-01 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [801] | ||
Atropisomer 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for Atropisomer 1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Atropisomer 1 through regulating the expression of Janus kinase 2 (JAK-2). | [436], [790] | ||
AZ960 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AZ960. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZ960 through regulating the expression of Janus kinase 2 (JAK-2). | [220], [790] | ||
BVB-808 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for BVB-808. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BVB-808 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [808] | ||
CMP-6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for CMP-6. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CMP-6 through regulating the expression of Janus kinase 2 (JAK-2). | [562], [790] | ||
K-454 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for K-454. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of K-454 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [810] | ||
NSC-1771 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for NSC-1771. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-1771 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [811] | ||
ON-044580 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for ON-044580. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ON-044580 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [801] | ||
SGI-1252 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for SGI-1252. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SGI-1252 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [812] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for WHI-P154. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WHI-P154 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [813] | ||
AG490 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Janus kinase 2 (JAK-2) is a therapeutic target for AG490. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG490 through regulating the expression of Janus kinase 2 (JAK-2). | [790], [793] | ||
Kruppel like factor 4 (KLF4)
APTO-253 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Kruppel like factor 4 (KLF4) is a therapeutic target for APTO-253. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APTO-253 through regulating the expression of Kruppel like factor 4 (KLF4). | [223], [663] | ||
Leukocyte surface antigen CD47 (CD47)
Hu5F9-G4 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for Hu5F9-G4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hu5F9-G4 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [815] | ||
ALX148 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for ALX148. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALX148 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [816] | ||
AO-176 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for AO-176. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AO-176 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [5], [814] | ||
DSP-107 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for DSP-107. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DSP-107 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [817] | ||
CC-90002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for CC-90002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CC-90002 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [818] | ||
IBI188 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for IBI188. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IBI188 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [819] | ||
IMC-002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for IMC-002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMC-002 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [820] | ||
SL-172154 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for SL-172154. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SL-172154 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [5], [814] | ||
TG-1801 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TG-1801. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TG-1801 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [821] | ||
TJC4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TJC4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TJC4 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [822] | ||
TTI-621 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TTI-621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TTI-621 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [823] | ||
TTI-622 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TTI-622. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TTI-622 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [824] | ||
ZL-1201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Leukocyte surface antigen CD47 (CD47) is a therapeutic target for ZL-1201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZL-1201 through regulating the expression of Leukocyte surface antigen CD47 (CD47). | [814], [825] | ||
M-phase inducer phosphatase 2 (MPIP2)
2-Sulfhydryl-Ethanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 2-Sulfhydryl-Ethanol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Sulfhydryl-Ethanol through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [827] | ||
3-isopropyl-4-(phenylamino)naphthalene-1,2-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [828] | ||
3-isopropyl-4-(phenylthio)naphthalene-1,2-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [827] | ||
3-isopropyl-4-phenylnaphthalene-1,2-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 3-isopropyl-4-phenylnaphthalene-1,2-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-isopropyl-4-phenylnaphthalene-1,2-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [828] | ||
4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [828] | ||
4-ethoxynaphthalene-1,2-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 4-ethoxynaphthalene-1,2-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-ethoxynaphthalene-1,2-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [829] | ||
5,6,7,8-tetrahydroanthracene-1,4-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 5,6,7,8-tetrahydroanthracene-1,4-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,6,7,8-tetrahydroanthracene-1,4-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [830] | ||
6,7-dibromoquinoline-5,8-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for 6,7-dibromoquinoline-5,8-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-dibromoquinoline-5,8-dione through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [827] | ||
ADOCIAQUINONE B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for ADOCIAQUINONE B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ADOCIAQUINONE B through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [829] | ||
ANTHRAQUINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for ANTHRAQUINONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ANTHRAQUINONE through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [829] | ||
Cysteine Sulfenic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for Cysteine Sulfenic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cysteine Sulfenic Acid through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [210], [826] | ||
Cysteinesulfonic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for Cysteinesulfonic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cysteinesulfonic Acid through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [210], [826] | ||
Double Oxidized Cysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for Double Oxidized Cysteine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [831] | ||
Methyl Mercury Ion [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for Methyl Mercury Ion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methyl Mercury Ion through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [210], [826] | ||
NSC-95397 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for NSC-95397. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-95397 through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [828] | ||
MX-7065 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for MX-7065. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MX-7065 through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). | [826], [829] | ||
Mammalian target of rapamycin complex 1 (mTORC1)
RBT-101 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for RBT-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RBT-101 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [832], [833] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for AZD-2014. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-2014 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [832], [834] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for ME-344. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ME-344 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [5], [832] | ||
NV-5138 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for NV-5138. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NV-5138 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [832], [835] | ||
Palomid-529 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for Palomid-529. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palomid-529 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [5], [832] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mammalian target of rapamycin complex 1 (mTORC1) is a therapeutic target for VS-5584. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VS-5584 through regulating the expression of Mammalian target of rapamycin complex 1 (mTORC1). | [832], [836] | ||
MAP kinase signal-integrating kinase 2 (MKNK2)
EFT508 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAP kinase signal-integrating kinase 2 (MKNK2) is a therapeutic target for EFT508. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EFT508 through regulating the expression of MAP kinase signal-integrating kinase 2 (MKNK2). | [464], [837] | ||
MAPK-activated protein kinase 2 (MAPKAPK2)
CBP-501 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for CBP-501. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CBP-501 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). | [235], [838] | ||
MMI-0100 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for MMI-0100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI-0100 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). | [235], [839] | ||
CMPD1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for CMPD1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CMPD1 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). | [235], [840] | ||
PF-3644022 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for PF-3644022. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-3644022 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). | [235], [841] | ||
MAPK/ERK kinase kinase 3 (MAP3K3)
ISIS 122970 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122970. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122970 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122971 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122971. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122971 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122974 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122974. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122974 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122975 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122975. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122975 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122976 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122976. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122976 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122984 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122984. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122984 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122985 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122985. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122985 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122986 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122986. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122986 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122990 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122990. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122990 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [272], [426] | ||
ISIS 122991 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122991. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122991 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). | [426], [842] | ||
Matrix metalloproteinase-1 (MMP-1)
Prinomastat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for Prinomastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prinomastat through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [844] | ||
CIPEMASTAT [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for CIPEMASTAT. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CIPEMASTAT through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [845] | ||
Marimastat [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for Marimastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Marimastat through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [846] | ||
Apratastat [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for Apratastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apratastat through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [847] | ||
3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [848] | ||
3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [849] | ||
3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [850] | ||
3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [850] | ||
3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [851] | ||
3-Benzenesulfinyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-Benzenesulfinyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfinyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [852] | ||
3-Benzenesulfonyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [852] | ||
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [853] | ||
4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [853] | ||
4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [854] | ||
4-Butoxy-N-hydroxycarbamoylmethyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [853] | ||
METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [852] | ||
MMI270 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for MMI270. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [855] | ||
N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [856] | ||
N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [853] | ||
N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [853] | ||
N-Hydroxycarbamoylmethyl-4-methoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-Hydroxycarbamoylmethyl-4-methoxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxycarbamoylmethyl-4-methoxy-benzamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [853] | ||
N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [854] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for PKF-242-484. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PKF-242-484 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [857] | ||
Ro-37-9790 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for Ro-37-9790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [850] | ||
RS-39066 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for RS-39066. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-39066 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [850] | ||
SR-973 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for SR-973. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SR-973 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [858] | ||
BB-1101 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for BB-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [859] | ||
BB-3644 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for BB-3644. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-3644 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [860] | ||
BMS 275291 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for BMS 275291. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 275291 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [861] | ||
GM6001 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for GM6001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [220], [843] | ||
L-696418 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for L-696418. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-696418 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [862] | ||
Ro-31-4724 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for Ro-31-4724. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-31-4724 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [863] | ||
RO-319790 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for RO-319790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-319790 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [864] | ||
RS-130830 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for RS-130830. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [865] | ||
SC-44463 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for SC-44463. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-44463 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [866] | ||
XL784 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for XL784. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XL784 through regulating the expression of Matrix metalloproteinase-1 (MMP-1). | [843], [867] | ||
Matrix metalloproteinase-12 (MMP-12)
FP-025 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for FP-025. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FP-025 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [866], [868] | ||
Neovastat [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for Neovastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Neovastat through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [869] | ||
2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
2-(2-(biphenyl-4-yl)ethylthio)acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 2-(2-(biphenyl-4-yl)ethylthio)acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(biphenyl-4-yl)ethylthio)acetic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [871] | ||
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [872] | ||
3-(4-Phenylethynylbenzoyl)nonanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 3-(4-Phenylethynylbenzoyl)nonanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenylethynylbenzoyl)nonanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [872] | ||
3-Benzenesulfonyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [852], [868] | ||
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [872] | ||
4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [873] | ||
5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [874] | ||
5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
5-(biphenyl-4-yl)-3-methoxypentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 5-(biphenyl-4-yl)-3-methoxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(biphenyl-4-yl)-3-methoxypentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
5-(biphenyl-4-yl)-3-oxopentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 5-(biphenyl-4-yl)-3-oxopentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(biphenyl-4-yl)-3-oxopentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
Acetate Ion [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for Acetate Ion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acetate Ion through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [210], [868] | ||
AGELADINE A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for AGELADINE A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AGELADINE A through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [871] | ||
CP-271485 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for CP-271485. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-271485 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [831], [868] | ||
MMP-408 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for MMP-408. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMP-408 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [875] | ||
N-(biphenyl-4-ylsulfonyl)-D-leucine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-(biphenyl-4-ylsulfonyl)-D-leucine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(biphenyl-4-ylsulfonyl)-D-leucine through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [220], [868] | ||
N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [220], [868] | ||
N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [870] | ||
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [871] | ||
N-oxo-2-(phenylsulfonylamino)ethanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-oxo-2-(phenylsulfonylamino)ethanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-oxo-2-(phenylsulfonylamino)ethanamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [220], [868] | ||
N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [220], [868] | ||
N-[(4-methoxyphenyl)sulfonyl]-D-alanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for N-[(4-methoxyphenyl)sulfonyl]-D-alanine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-[(4-methoxyphenyl)sulfonyl]-D-alanine through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [852], [868] | ||
PF-00356231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for PF-00356231. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-00356231 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [220], [868] | ||
PUP-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for PUP-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PUP-1 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [869] | ||
RXP-470 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for RXP-470. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RXP-470 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [869] | ||
RXP470.1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for RXP470.1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RXP470.1 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [876] | ||
WAY-644 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for WAY-644. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WAY-644 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [869] | ||
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [871] | ||
AZD1236 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for AZD1236. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD1236 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [877] | ||
GM6001 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for GM6001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [868], [878] | ||
V85546 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for V85546. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of V85546 through regulating the expression of Matrix metalloproteinase-12 (MMP-12). | [613], [868] | ||
Matrix metalloproteinase-13 (MMP-13)
Curcumin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [866], [879] | ||
Apratastat [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Apratastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apratastat through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [880] | ||
PMID17935984C1 [Clinical trial]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for PMID17935984C1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMID17935984C1 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [861], [879] | ||
1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [850], [879] | ||
1-Methyloxy-4-Sulfone-Benzene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 1-Methyloxy-4-Sulfone-Benzene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-Methyloxy-4-Sulfone-Benzene through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [852], [879] | ||
2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [870], [879] | ||
2-(biphenyl-4-ylsulfonamido)pentanedioic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 2-(biphenyl-4-ylsulfonamido)pentanedioic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(biphenyl-4-ylsulfonamido)pentanedioic acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [880] | ||
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [871], [879] | ||
3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [848], [879] | ||
3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [881] | ||
3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [849], [879] | ||
3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [850], [879] | ||
3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [854], [879] | ||
3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [850], [879] | ||
3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [850], [879] | ||
3-Benzenesulfonyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-Benzenesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzenesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [852], [879] | ||
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [854], [879] | ||
3-Methylpyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 3-Methylpyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Methylpyridine through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [210], [879] | ||
4-(2,2'-bithiophen-5-ylmethyleneamino)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 4-(2,2'-bithiophen-5-ylmethyleneamino)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2,2'-bithiophen-5-ylmethyleneamino)phenol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [882] | ||
4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [854], [879] | ||
4-(methyl(4-phenylthiazol-2-yl)amino)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 4-(methyl(4-phenylthiazol-2-yl)amino)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(methyl(4-phenylthiazol-2-yl)amino)phenol through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [883] | ||
4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [880] | ||
5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [884] | ||
CL82198 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for CL82198. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CL82198 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [885] | ||
Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [883] | ||
Hydroxyaminovaline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Hydroxyaminovaline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydroxyaminovaline through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [210], [879] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for IK-862. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IK-862 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [850], [879] | ||
MMI270 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for MMI270. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [867], [879] | ||
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [870], [879] | ||
N1,N3-bis(3-methoxybenzyl)isophthalamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for N1,N3-bis(3-methoxybenzyl)isophthalamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N1,N3-bis(3-methoxybenzyl)isophthalamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [886] | ||
N4,N6-dibenzylpyrimidine-4,6-dicarboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for N4,N6-dibenzylpyrimidine-4,6-dicarboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N4,N6-dibenzylpyrimidine-4,6-dicarboxamide through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [880] | ||
PD-156 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for PD-156. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-156 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [887] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for PKF-242-484. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PKF-242-484 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [857], [879] | ||
Ro-37-9790 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for Ro-37-9790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [850], [879] | ||
SL422 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for SL422. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SL422 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [888] | ||
SR-973 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for SR-973. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SR-973 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [871], [879] | ||
UK-356618 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for UK-356618. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UK-356618 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [210], [879] | ||
WAY-151693 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for WAY-151693. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WAY-151693 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [210], [879] | ||
WAY170523 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for WAY170523. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WAY170523 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [888] | ||
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [871], [879] | ||
GM6001 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for GM6001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [889] | ||
RS-130830 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for RS-130830. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-13 (MMP-13). | [879], [890] | ||
Matrix metalloproteinase-2 (MMP-2)
Amylin [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Amylin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amylin through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [892] | ||
Prinomastat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Prinomastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prinomastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [844], [891] | ||
Marimastat [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Marimastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Marimastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [846], [891] | ||
Metastat [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Metastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Metastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [893] | ||
Neovastat [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Neovastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Neovastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [862], [891] | ||
RO-26-2853 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for RO-26-2853. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-26-2853 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [867], [891] | ||
2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [872], [891] | ||
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [871], [891] | ||
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [894] | ||
3-(4-Phenylethynylbenzoyl)nonanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 3-(4-Phenylethynylbenzoyl)nonanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenylethynylbenzoyl)nonanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [872], [891] | ||
4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [895] | ||
5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [896] | ||
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [881], [891] | ||
5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [897] | ||
5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [897] | ||
Cis-2-aminocyclohexylcarbamoylphosphonic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Cis-2-aminocyclohexylcarbamoylphosphonic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cis-2-aminocyclohexylcarbamoylphosphonic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [898] | ||
Clinopodic acid C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Clinopodic acid C. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clinopodic acid C through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [899] | ||
Folate gamma-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Folate gamma-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Folate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [872], [891] | ||
Folate gamma-L-proline-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Folate gamma-L-proline-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Folate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [900] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for IK-862. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IK-862 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [849], [891] | ||
Lithospermic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Lithospermic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lithospermic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [901] | ||
Methotrexate gamma-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [898] | ||
Methotrexate gamma-L-proline-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [898] | ||
MMI270 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for MMI270. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [855], [891] | ||
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [870], [891] | ||
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [900] | ||
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [902] | ||
PD-169469 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for PD-169469. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-169469 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [857], [891] | ||
PNU-107859 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for PNU-107859. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PNU-107859 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [897] | ||
Ro-37-9790 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Ro-37-9790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [898] | ||
Roche 28-2653 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Roche 28-2653. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Roche 28-2653 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [897] | ||
SC-74020 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for SC-74020. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-74020 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [903] | ||
SR-973 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for SR-973. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SR-973 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [871], [891] | ||
UK-356618 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for UK-356618. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UK-356618 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [210], [891] | ||
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [871], [891] | ||
BB-1101 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BB-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [28], [891] | ||
BB-3644 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BB-3644. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-3644 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [904] | ||
BMS 275291 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for BMS 275291. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 275291 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [905] | ||
CDP-845 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for CDP-845. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CDP-845 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [860], [891] | ||
Galarubicin [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Galarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Galarubicin through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [906] | ||
GM6001 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for GM6001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [878], [891] | ||
L-696418 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for L-696418. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-696418 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [862], [891] | ||
RS-130830 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for RS-130830. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [891], [907] | ||
SC-44463 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for SC-44463. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-44463 through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [866], [891] | ||
Tanomastat [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Tanomastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tanomastat through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [865], [891] | ||
Matrix metalloproteinase-3 (MMP-3)
Batimastat [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for Batimastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Batimastat through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [889] | ||
1-Methyloxy-4-Sulfone-Benzene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for 1-Methyloxy-4-Sulfone-Benzene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-Methyloxy-4-Sulfone-Benzene through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [896] | ||
3-Methylpyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for 3-Methylpyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Methylpyridine through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [210], [751] | ||
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [881] | ||
8-chloro-quinoline-3-carbonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for 8-chloro-quinoline-3-carbonitrile. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-chloro-quinoline-3-carbonitrile through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [908] | ||
AM-2S [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for AM-2S. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AM-2S through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [905] | ||
CM-352 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for CM-352. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CM-352 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [862] | ||
FUTOENONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for FUTOENONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FUTOENONE through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [210], [751] | ||
Hydroxyaminovaline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for Hydroxyaminovaline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydroxyaminovaline through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [210], [751] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for IK-862. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IK-862 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [909] | ||
MMI270 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for MMI270. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [860] | ||
PD-169469 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for PD-169469. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-169469 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [910] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for PKF-242-484. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PKF-242-484 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [895] | ||
PNU-107859 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for PNU-107859. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PNU-107859 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [897] | ||
PNU-142372 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for PNU-142372. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PNU-142372 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [856] | ||
Ro-37-9790 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for Ro-37-9790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [848] | ||
RS-39066 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for RS-39066. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-39066 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [849] | ||
UK-356618 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for UK-356618. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UK-356618 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [911] | ||
BB-1101 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for BB-1101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BB-1101 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [859] | ||
GM6001 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for GM6001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [912] | ||
L-696418 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for L-696418. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-696418 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [913] | ||
PG-530742 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for PG-530742. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PG-530742 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [867] | ||
RO-319790 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for RO-319790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-319790 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [914] | ||
RS-130830 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for RS-130830. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [844] | ||
SC-44463 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-3 (MMP-3) is a therapeutic target for SC-44463. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-44463 through regulating the expression of Matrix metalloproteinase-3 (MMP-3). | [751], [866] | ||
Matrix metalloproteinase-9 (MMP-9)
Amylin [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Amylin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amylin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [892] | ||
Andecaliximab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Andecaliximab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Andecaliximab through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [915] | ||
Curcumin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [916] | ||
DP-b99 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for DP-b99. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DP-b99 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [917] | ||
GS-5745 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for GS-5745. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GS-5745 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [887] | ||
BLZ-100 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for BLZ-100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BLZ-100 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [497], [868] | ||
Neovastat [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Neovastat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Neovastat through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [918] | ||
DX-2802 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for DX-2802. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DX-2802 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [867], [868] | ||
2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [857], [868] | ||
2-(biphenyl-4-ylsulfonamido)pentanedioic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(biphenyl-4-ylsulfonamido)pentanedioic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(biphenyl-4-ylsulfonamido)pentanedioic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [883] | ||
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [871] | ||
2-Amino-N,3,3-Trimethylbutanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 2-Amino-N,3,3-Trimethylbutanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Amino-N,3,3-Trimethylbutanamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [903] | ||
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [919] | ||
3-(4-Phenylethynylbenzoyl)nonanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 3-(4-Phenylethynylbenzoyl)nonanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Phenylethynylbenzoyl)nonanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [872] | ||
4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [899] | ||
5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [897] | ||
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [881] | ||
5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [897] | ||
5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [897] | ||
5-Methyl-5-phenyl-pyrimidine-2,4,6-trione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [897] | ||
ARP100 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for ARP100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARP100 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [920] | ||
Carboxylated glucosamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Carboxylated glucosamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carboxylated glucosamine through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [894] | ||
Folate gamma-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Folate gamma-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Folate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [898] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for IK-862. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IK-862 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [849], [868] | ||
Methotrexate gamma-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [900] | ||
Methotrexate gamma-L-phenylalaninehydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-L-phenylalaninehydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-L-phenylalaninehydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [872] | ||
Methotrexate gamma-L-proline-hydroxamic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-L-proline-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-L-proline-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [898] | ||
MMI270 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for MMI270. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI270 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [904] | ||
N-hydroxy-2,3-bis(phenylsulfonamido)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-2,3-bis(phenylsulfonamido)propanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-2,3-bis(phenylsulfonamido)propanamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [871] | ||
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [870] | ||
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [900] | ||
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [898] | ||
Ro 28-2653 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Ro 28-2653. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro 28-2653 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [903] | ||
Ro-37-9790 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Ro-37-9790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-37-9790 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [898] | ||
Roche 28-2653 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Roche 28-2653. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Roche 28-2653 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [897] | ||
SL422 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for SL422. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SL422 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [921] | ||
SR-973 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for SR-973. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SR-973 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [871] | ||
UK-356618 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for UK-356618. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UK-356618 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [210], [868] | ||
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [922] | ||
CDP-845 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for CDP-845. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CDP-845 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [923] | ||
CT-1746 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for CT-1746. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CT-1746 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [859], [868] | ||
Galarubicin [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Galarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Galarubicin through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [924] | ||
GM6001 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for GM6001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GM6001 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [878] | ||
RO-319790 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for RO-319790. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-319790 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [925] | ||
RS-130830 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for RS-130830. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RS-130830 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [868], [907] | ||
SC-44463 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for SC-44463. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-44463 through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [866], [868] | ||
microRNA hsa-miR-17 (MIR17)
RGLS4326 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | microRNA hsa-miR-17 (MIR17) is a therapeutic target for RGLS4326. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RGLS4326 through regulating the expression of microRNA hsa-miR-17 (MIR17). | [268], [926] | ||
microRNA hsa-miR-191 (MIR191)
Anti-miR-191 modified oligonucleotide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | microRNA hsa-miR-191 (MIR191) is a therapeutic target for Anti-miR-191 modified oligonucleotide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-miR-191 modified oligonucleotide through regulating the expression of microRNA hsa-miR-191 (MIR191). | [926], [927] | ||
Mitochondrial matrix protein P1 (HSPD1)
DiaPep-277 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mitochondrial matrix protein P1 (HSPD1) is a therapeutic target for DiaPep-277. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DiaPep-277 through regulating the expression of Mitochondrial matrix protein P1 (HSPD1). | [623], [928] | ||
Mothers against decapentaplegic homolog 3 (SMAD3)
FLUORESCEIN [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for FLUORESCEIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FLUORESCEIN through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [929], [930] | ||
SIS-3 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for SIS-3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SIS-3 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [436], [929] | ||
ELLAGIC ACID [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for ELLAGIC ACID. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ELLAGIC ACID through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [436], [929] | ||
GNF-PF-2272 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 3 (SMAD3) is a therapeutic target for GNF-PF-2272. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GNF-PF-2272 through regulating the expression of Mothers against decapentaplegic homolog 3 (SMAD3). | [929], [931] | ||
Mothers against decapentaplegic homolog 7 (SMAD7)
GED-0301 [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [932], [933] | ||
| Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for GED-0301. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GED-0301 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [932], [934] | |||
ISIS 28465 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28465. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 28465 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [932], [935] | ||
ISIS 28466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28466. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 28466 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [932], [935] | ||
ISIS 28472 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28472. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 28472 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [932], [935] | ||
ISIS 28477 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Mothers against decapentaplegic homolog 7 (SMAD7) is a therapeutic target for ISIS 28477. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 28477 through regulating the expression of Mothers against decapentaplegic homolog 7 (SMAD7). | [932], [936] | ||
MST-1 protein kinase (STK4)
TAT-120 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MST-1 protein kinase (STK4) is a therapeutic target for TAT-120. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAT-120 through regulating the expression of MST-1 protein kinase (STK4). | [937], [938] | ||
NAD-dependent deacetylase sirtuin-1 (SIRT1)
GSK2245840 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for GSK2245840. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK2245840 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [939] | ||
MB-12066 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for MB-12066. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MB-12066 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [940] | ||
SEN-196 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SEN-196. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SEN-196 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [941] | ||
SRT2379 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT2379. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SRT2379 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [942] | ||
SRT3025 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT3025. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SRT3025 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [943] | ||
(R)-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for (R)-sirtinol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (R)-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [944] | ||
(S)-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for (S)-sirtinol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (S)-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [944] | ||
2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [945] | ||
2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [471] | ||
Meta-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Meta-sirtinol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Meta-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [946] | ||
Para-sirtinol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Para-sirtinol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Para-sirtinol through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [944] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for RO-316233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-316233 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [945] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for Ro31-8220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro31-8220 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [947] | ||
splitomicin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for splitomicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of splitomicin through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [948] | ||
SRT1720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for SRT1720. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SRT1720 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [944] | ||
YK-3237 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for YK-3237. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YK-3237 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [947] | ||
GSK184072 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NAD-dependent deacetylase sirtuin-1 (SIRT1) is a therapeutic target for GSK184072. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK184072 through regulating the expression of NAD-dependent deacetylase sirtuin-1 (SIRT1). | [53], [949] | ||
Neural cadherin (CDH2)
Exherin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Neural cadherin (CDH2) is a therapeutic target for Exherin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Exherin through regulating the expression of Neural cadherin (CDH2). | [950], [951] | ||
NF-kappa-B inhibitor alpha (NFKBIA)
I3C [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NF-kappa-B inhibitor alpha (NFKBIA) is a therapeutic target for I3C. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of I3C through regulating the expression of NF-kappa-B inhibitor alpha (NFKBIA). | [672], [674] | ||
Fucoxanthin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NF-kappa-B inhibitor alpha (NFKBIA) is a therapeutic target for Fucoxanthin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fucoxanthin through regulating the expression of NF-kappa-B inhibitor alpha (NFKBIA). | [674], [952] | ||
NLR pyrin domain containing 1 (NLRP1)
muramyl dipeptide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | NLR pyrin domain containing 1 (NLRP1) is a therapeutic target for muramyl dipeptide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of muramyl dipeptide through regulating the expression of NLR pyrin domain containing 1 (NLRP1). | [953], [954] | ||
Notch-1 receptor (NOTCH1)
LY3039478 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-1 receptor (NOTCH1) is a therapeutic target for LY3039478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3039478 through regulating the expression of Notch-1 receptor (NOTCH1). | [955], [956] | ||
OMP-52M51 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-1 receptor (NOTCH1) is a therapeutic target for OMP-52M51. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OMP-52M51 through regulating the expression of Notch-1 receptor (NOTCH1). | [5], [955] | ||
Notch-2 receptor (NOTCH2)
Tarextumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-2 receptor (NOTCH2) is a therapeutic target for Tarextumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tarextumab through regulating the expression of Notch-2 receptor (NOTCH2). | [957], [958] | ||
Notch-3 receptor (NOTCH3)
Tarextumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-3 receptor (NOTCH3) is a therapeutic target for Tarextumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tarextumab through regulating the expression of Notch-3 receptor (NOTCH3). | [412], [959] | ||
Notch-4 receptor (NOTCH4)
LY3039478 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Notch-4 receptor (NOTCH4) is a therapeutic target for LY3039478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3039478 through regulating the expression of Notch-4 receptor (NOTCH4). | [412], [960] | ||
Nuclear factor erythroid 2-related factor 2 (Nrf2)
ABT-RTA-408 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for ABT-RTA-408. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-RTA-408 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [961] | ||
CXA10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for CXA10. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CXA10 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [267] | ||
Omaveloxolone [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for Omaveloxolone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Omaveloxolone through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [962] | ||
OT-551 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for OT-551. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OT-551 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [963] | ||
OT551 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for OT551. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OT551 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [269] | ||
SFX-01 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for SFX-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SFX-01 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [964] | ||
HPP971 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for HPP971. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HPP971 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [965] | ||
CAT4001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for CAT4001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CAT4001 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [966] | ||
M102 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for M102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M102 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [967] | ||
TFM735 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for TFM735. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TFM735 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [266], [962] | ||
Nucleobindin-1 (NUCB1)
KML110 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nucleobindin-1 (NUCB1) is a therapeutic target for KML110. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KML110 through regulating the expression of Nucleobindin-1 (NUCB1). | [815], [968] | ||
MJN228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nucleobindin-1 (NUCB1) is a therapeutic target for MJN228. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MJN228 through regulating the expression of Nucleobindin-1 (NUCB1). | [968], [969] | ||
O-6-methylguanine-DNA-alkyltransferase (MGMT)
O6-Benzylguanine alkylade [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for O6-Benzylguanine alkylade. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of O6-Benzylguanine alkylade through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [970], [971] | ||
6-Allyloxy-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for 6-Allyloxy-9H-purin-2-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Allyloxy-9H-purin-2-ylamine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [970], [972] | ||
6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [970], [972] | ||
6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [970], [973] | ||
6-Benzyloxy-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for 6-Benzyloxy-9H-purin-2-ylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Benzyloxy-9H-purin-2-ylamine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [210], [970] | ||
Benzylcysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for Benzylcysteine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzylcysteine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [970], [972] | ||
S-Methylcysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for S-Methylcysteine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-Methylcysteine through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). | [970], [974] | ||
P-glycoprotein 1 (ABCB1)
Abacavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Abacavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abacavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [975] | ||
Acebutolol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Acebutolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acebutolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Acrivastine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Acrivastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acrivastine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Actinomycin D [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Actinomycin D. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Actinomycin D through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Afatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Afatinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [65] | ||
Ajmaline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ajmaline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ajmaline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [977] | ||
Albendazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Albendazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Albendazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [978] | ||
Aldosterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Aldosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aldosterone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [979] | ||
Aliskiren fumarate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Aliskiren fumarate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aliskiren fumarate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [980] | ||
Ambrisentan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ambrisentan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ambrisentan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [981] | ||
Amiodarone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Amiodarone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amiodarone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Amisulpride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Amisulpride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amisulpride through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Amitriptyline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Amitriptyline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amitriptyline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [983] | ||
Amoxicillin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Amoxicillin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amoxicillin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Amphotericin B [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Amphotericin B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amphotericin B through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [984] | ||
Amprenavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Amprenavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amprenavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Apixaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Apixaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apixaban through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [985] | ||
Apremilast [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Apremilast. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apremilast through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Aprepitant [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Aprepitant. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aprepitant through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Arsenic trioxide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Arsenic trioxide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Arsenic trioxide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [988] | ||
Aspirin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Aspirin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aspirin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [983] | ||
Atenolol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Atenolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Atenolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [989] | ||
Atomoxetine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Atomoxetine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Atomoxetine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Axitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Axitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Axitinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [990] | ||
Azasetron [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Azasetron. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azasetron through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Azathioprine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Azathioprine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azathioprine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [983] | ||
Azithromycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Azithromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azithromycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [991] | ||
Baloxavir marboxil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Baloxavir marboxil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Baloxavir marboxil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [992] | ||
Baricitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Baricitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Baricitinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [993] | ||
Beclomethasone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Beclomethasone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Beclomethasone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [994] | ||
Beclomethasone dipropionate [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Beclomethasone dipropionate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Beclomethasone dipropionate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [994] | ||
Bepridil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bepridil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bepridil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
beta-Acetyldigoxin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for beta-Acetyldigoxin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of beta-Acetyldigoxin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [995] | ||
beta-Carotene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for beta-Carotene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of beta-Carotene through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [984] | ||
Betamethasone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Betamethasone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Betamethasone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [996] | ||
Betrixaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Betrixaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Betrixaban through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [997] | ||
Bicalutamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bicalutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bicalutamide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [70] | ||
Binimetinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Binimetinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Binimetinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [71] | ||
Biotin [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Biotin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Biotin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [998] | ||
Boceprevir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Boceprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Boceprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [999] | ||
Bosutinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bosutinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bosutinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1000] | ||
Brilinta [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Brilinta. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Brilinta through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Bromocriptine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bromocriptine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bromocriptine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Bupropion [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bupropion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bupropion through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1002] | ||
Cabergoline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cabergoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cabergoline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1003] | ||
Canagliflozin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Canagliflozin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Canagliflozin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [74] | ||
Cannabidiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cannabidiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cannabidiol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Carfilzomib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Carfilzomib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carfilzomib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1004] | ||
Carvedilol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Carvedilol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carvedilol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Cefoperazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cefoperazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cefoperazone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Cefotetan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cefotetan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cefotetan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Ceftriaxone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ceftriaxone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ceftriaxone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Celiprolol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Celiprolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Celiprolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1005] | ||
Cepharanthine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cepharanthine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cepharanthine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1006] | ||
Ceritinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ceritinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ceritinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1007] | ||
Cerivastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cerivastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cerivastatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1008] | ||
Cetirizine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cetirizine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cetirizine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1009] | ||
Chlorambucil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Chlorambucil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chlorambucil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Chloramphenicol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Chloramphenicol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chloramphenicol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1010] | ||
Chlorpromazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Chlorpromazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Chlorpromazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ciclesonide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ciclesonide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ciclesonide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [994] | ||
Cimetidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cimetidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cimetidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Cinchonidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cinchonidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cinchonidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Cisplatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cisplatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cisplatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Citalopram [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Citalopram. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Citalopram through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1011] | ||
Clarithromycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clarithromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clarithromycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Clobazam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clobazam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clobazam through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Clofazimine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clofazimine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clofazimine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1012] | ||
Clomifene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clomifene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clomifene through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Clomiphene citrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clomiphene citrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clomiphene citrate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Clomipramine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clomipramine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clomipramine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Clonidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clonidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clonidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [983] | ||
Clopidogrel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clopidogrel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clopidogrel through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1014] | ||
Clozapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Clozapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Clozapine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Colchicine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Colchicine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Colchicine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1015] | ||
Cortisone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cortisone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cortisone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [996] | ||
Cyclosporine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cyclosporine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cyclosporine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1016] | ||
Cytarabine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cytarabine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cytarabine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Dabigatran [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dabigatran. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dabigatran through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1017] | ||
Dabrafenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dabrafenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dabrafenib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [83] | ||
Daclatasvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Daclatasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Daclatasvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1017] | ||
Dactinomycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dactinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dactinomycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1018] | ||
Darunavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Darunavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Darunavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1019] | ||
Debrisoquine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Debrisoquine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Debrisoquine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1020] | ||
Deflazacort [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Deflazacort. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Deflazacort through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Delavirdine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Delavirdine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Delavirdine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [975] | ||
Desipramine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Desipramine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Desipramine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Desloratadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Desloratadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Desloratadine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1022] | ||
Diazepam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Diazepam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diazepam through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1023] | ||
Dicloxacillin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dicloxacillin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dicloxacillin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1024] | ||
Diethylstilbestrol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Diethylstilbestrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diethylstilbestrol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Digitoxin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Digitoxin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Digitoxin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1025] | ||
Digoxin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Digoxin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Digoxin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1026] | ||
Dihydroergocristine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dihydroergocristine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dihydroergocristine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1027] | ||
Diltiazem [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Diltiazem. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diltiazem through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Dipyridamole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dipyridamole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dipyridamole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Docetaxel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Docetaxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Docetaxel through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1028] | ||
Dolutegravir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dolutegravir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dolutegravir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Domperidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Domperidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Domperidone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Doxycycline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Doxycycline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Doxycycline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ebastine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ebastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ebastine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Edoxaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Edoxaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Edoxaban through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1029] | ||
Efavirenz [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Efavirenz. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Efavirenz through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Eletriptan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Eletriptan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eletriptan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Eliglustat tartrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Eliglustat tartrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eliglustat tartrate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Emetine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Emetine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Emetine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1018] | ||
Empagliflozin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Empagliflozin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Empagliflozin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Epinastine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Epinastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epinastine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1030] | ||
Epirubicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Epirubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epirubicin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ergotamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ergotamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ergotamine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Erythromycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Erythromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Erythromycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1031] | ||
Eslicarbazepine acetate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Eslicarbazepine acetate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eslicarbazepine acetate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1032] | ||
Estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estradiol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Estriol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Estriol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estriol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1033] | ||
Estrone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Estrone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1033] | ||
Estrone sulfate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Estrone sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Estrone sulfate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1008] | ||
Ethinyl estradiol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ethinyl estradiol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ethinyl estradiol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1033] | ||
Etoposide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Etoposide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etoposide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1034] | ||
Ezetimibe [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ezetimibe. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ezetimibe through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1035] | ||
Famciclovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Famciclovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Famciclovir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Felodipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Felodipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Felodipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1036] | ||
Fentanyl [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fentanyl. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fentanyl through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Fesoterodine fumarate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fesoterodine fumarate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fesoterodine fumarate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1037] | ||
Fexofenadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fexofenadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fexofenadine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1038] | ||
Fluoxetine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluoxetine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluoxetine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1039] | ||
Flupentixol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Flupentixol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flupentixol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Fluphenazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluphenazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluphenazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Fluticasone propionate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluticasone propionate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluticasone propionate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [994] | ||
Fluvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluvastatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Fluvoxamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fluvoxamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluvoxamine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Folic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Folic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Folic acid through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1040] | ||
Fosamprenavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fosamprenavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fosamprenavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Gatifloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Gatifloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gatifloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1041] | ||
Gilteritinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Gilteritinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gilteritinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Glutathione [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Glutathione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glutathione through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1042] | ||
Gramicidin D [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Gramicidin D. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gramicidin D through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Grepafloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Grepafloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Grepafloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Guanabenz [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Guanabenz. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Guanabenz through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Guanfacine [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Guanfacine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Guanfacine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1043] | ||
Haloperidol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Haloperidol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Haloperidol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Hydrocortisone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Hydrocortisone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydrocortisone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [994] | ||
Hydroxyurea [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Hydroxyurea. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydroxyurea through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ibrutinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ibrutinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ibrutinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1044] | ||
Idarubicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Idarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Idarubicin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [109] | ||
Imatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Imatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imatinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1045] | ||
Imipramine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Imipramine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imipramine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [983] | ||
Indacaterol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Indacaterol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indacaterol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Indinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Indinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indinavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1046] | ||
Indomethacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Indomethacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indomethacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1047] | ||
Ingenol-3-angelate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ingenol-3-angelate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ingenol-3-angelate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1048] | ||
Irinotecan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Irinotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Irinotecan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1049] | ||
Itraconazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Itraconazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Itraconazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ivacaftor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ivacaftor. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ivacaftor through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1050] | ||
Ivermectin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ivermectin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ivermectin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1051] | ||
Ivosidenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ivosidenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ivosidenib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1052] | ||
Ixabepilone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ixabepilone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ixabepilone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [90] | ||
Ketoconazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ketoconazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ketoconazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
L-tryptophan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for L-tryptophan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-tryptophan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1053] | ||
Labetalol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Labetalol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Labetalol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Lamotrigine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lamotrigine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lamotrigine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1054] | ||
Lansoprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lansoprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lansoprazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lapatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lapatinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Ledipasvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ledipasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ledipasvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Lenalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lenalidomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lenalidomide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1055] | ||
Lenvatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lenvatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lenvatinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1056] | ||
Levetiracetam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Levetiracetam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Levetiracetam through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1057] | ||
Levodopa [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Levodopa. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Levodopa through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Levofloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Levofloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Levofloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Levomepromazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Levomepromazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Levomepromazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Levomilnacipran [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Levomilnacipran. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Levomilnacipran through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1058] | ||
Lidocaine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lidocaine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lidocaine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Linagliptin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Linagliptin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Linagliptin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Loperamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Loperamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Loperamide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1059] | ||
Lopinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lopinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lopinavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1060] | ||
Loratadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Loratadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Loratadine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1022] | ||
Losartan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Losartan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Losartan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1061] | ||
Lovastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lovastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lovastatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Lovastatin acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Lovastatin acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lovastatin acid through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Maraviroc [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Maraviroc. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Maraviroc through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Mefloquine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mefloquine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mefloquine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1062] | ||
Melphalan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Melphalan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Melphalan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1063] | ||
Meperidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Meperidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Meperidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1064] | ||
Mequitazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mequitazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mequitazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Methadone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Methadone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methadone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1065] | ||
Methotrexate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Methotrexate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Methylprednisolone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Methylprednisolone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methylprednisolone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1066] | ||
Methysergide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Methysergide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methysergide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Midazolam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Midazolam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Midazolam through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Midostaurin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Midostaurin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Midostaurin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Mitomycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mitomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mitomycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1067] | ||
Mitoxantrone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mitoxantrone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mitoxantrone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Morphine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Morphine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Morphine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1068] | ||
Moxidectin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Moxidectin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Moxidectin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [119] | ||
Mycophenolate mofetil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mycophenolate mofetil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mycophenolate mofetil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [120] | ||
Nadolol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nadolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nadolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Nalbuphine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nalbuphine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nalbuphine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Naloxegol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Naloxegol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naloxegol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Nelfinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nelfinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nelfinavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1069] | ||
Neostigmine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Neostigmine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Neostigmine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Nevirapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nevirapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nevirapine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Nicardipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nicardipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicardipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1070] | ||
Nifedipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nifedipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nifedipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Nilotinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nilotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nilotinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Nimodipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nimodipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nimodipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Nintedanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nintedanib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nintedanib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1071] | ||
Nisoldipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nisoldipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nisoldipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Nitrendipine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nitrendipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nitrendipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Nizatidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nizatidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nizatidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1072] | ||
Norfloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Norfloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Norfloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Olanzapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Olanzapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olanzapine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Olmesartan medoxomil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Olmesartan medoxomil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olmesartan medoxomil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Olopatadine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Olopatadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olopatadine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Omadacycline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Omadacycline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Omadacycline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1073] | ||
Ombitasvir [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ombitasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ombitasvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Omeprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Omeprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Omeprazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Ondansetron [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ondansetron. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ondansetron through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1062] | ||
Oseltamivir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Oseltamivir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oseltamivir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1074] | ||
Oxcarbazepine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Oxcarbazepine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxcarbazepine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1075] | ||
Palbociclib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Palbociclib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palbociclib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [126] | ||
Paliperidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Paliperidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Paliperidone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1076] | ||
Panobinostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Panobinostat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Panobinostat through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1077] | ||
Pantoprazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pantoprazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pantoprazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Paroxetine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Paroxetine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Paroxetine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Pazopanib hydrochloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pazopanib hydrochloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pazopanib hydrochloride through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [128] | ||
Pemirolast [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pemirolast. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pemirolast through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Pentazocine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pentazocine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pentazocine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Perazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Perazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Perazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Perphenazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Perphenazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Perphenazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Phenobarbital [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Phenobarbital. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenobarbital through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1075] | ||
Phenprocoumon [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Phenprocoumon. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenprocoumon through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1078] | ||
Phenytoin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Phenytoin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenytoin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1075] | ||
Pibrentasvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pibrentasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pibrentasvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Pimozide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pimozide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pimozide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Pirarubicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pirarubicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirarubicin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Pirenzepine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pirenzepine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirenzepine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Pomalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pomalidomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pomalidomide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1079] | ||
Ponatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ponatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ponatinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [132] | ||
Posaconazole [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Posaconazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Posaconazole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Pravastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pravastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pravastatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Prazosin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Prazosin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prazosin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1080] | ||
Prednisolone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Prednisolone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prednisolone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1081] | ||
Prednisone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Prednisone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prednisone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [996] | ||
Progesterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1023] | ||
Propafenone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Propafenone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Propafenone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Propranolol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Propranolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Propranolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Protriptyline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Protriptyline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Protriptyline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [976] | ||
Prucalopride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Prucalopride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prucalopride through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1082] | ||
Quercetin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1083] | ||
Quetiapine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Quetiapine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quetiapine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [982] | ||
Quinine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Quinine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Raloxifene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Raloxifene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Raloxifene through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1084] | ||
Ramosetron [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ramosetron. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ramosetron through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1085] | ||
Ranitidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ranitidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ranitidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ranolazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ranolazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ranolazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1086] | ||
Regorafenib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Regorafenib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Regorafenib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1087] | ||
Reserpine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Reserpine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Reserpine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Rifampicin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Rifampicin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rifampicin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Rifaximin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Rifaximin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rifaximin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1088] | ||
Riociguat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Riociguat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Riociguat through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1089] | ||
Risperidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Risperidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Risperidone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1090] | ||
Ritonavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ritonavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ritonavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1091] | ||
Rivaroxaban [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Rivaroxaban. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rivaroxaban through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1092] | ||
Romidepsin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Romidepsin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Romidepsin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1093] | ||
Rosuvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Rosuvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rosuvastatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [141] | ||
S-licarbazepine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for S-licarbazepine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-licarbazepine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1032] | ||
Saphris [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Saphris. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Saphris through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Saquinavir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Saquinavir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Saquinavir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1094] | ||
Saxagliptin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Saxagliptin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Saxagliptin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Sertraline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sertraline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sertraline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Silodosin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Silodosin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Silodosin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1095] | ||
Simeprevir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Simeprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Simeprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Simvastatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Simvastatin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Simvastatin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Sitagliptin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sitagliptin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sitagliptin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Sofosbuvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sofosbuvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sofosbuvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1096] | ||
Sparfloxacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sparfloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sparfloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Spiperone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Spiperone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Spiperone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Sumatriptan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sumatriptan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sumatriptan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1097] | ||
Sunitinib malate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sunitinib malate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sunitinib malate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1098] | ||
Tacrine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tacrine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tacrine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1099] | ||
Tacrolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tacrolimus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tacrolimus through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Tadalafil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tadalafil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tadalafil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1100] | ||
Talazoparib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Talazoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Talazoparib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [145] | ||
Telaprevir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Telaprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Telaprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [999] | ||
Telithromycin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Telithromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Telithromycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1101] | ||
Temsirolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Temsirolimus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Temsirolimus through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1102] | ||
Tenofovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Tenofovir disoproxil [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir disoproxil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir disoproxil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Tenoxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenoxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenoxicam through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Testosterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Testosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Testosterone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Tetracycline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tetracycline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tetracycline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Thiamphenicol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Thiamphenicol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thiamphenicol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1010] | ||
Thioridazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Thioridazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thioridazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Timolol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Timolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Timolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1005] | ||
Tolvaptan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tolvaptan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tolvaptan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1103] | ||
Topiramate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Topiramate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Topiramate through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1104] | ||
Topotecan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Topotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Topotecan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [150] | ||
Toremifene [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Toremifene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Toremifene through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Tramadol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tramadol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tramadol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1105] | ||
Trifluoperazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Trifluoperazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trifluoperazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Triflupromazine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Triflupromazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Triflupromazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Trimethoprim [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Trimethoprim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trimethoprim through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Triprolidine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Triprolidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Triprolidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1106] | ||
Trospium chloride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Trospium chloride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trospium chloride through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1107] | ||
Vecuronium [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Vecuronium. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vecuronium through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1062] | ||
Venetoclax [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Venetoclax. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Venetoclax through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1108] | ||
Verapamil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Verapamil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Verapamil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1109] | ||
vildagliptin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for vildagliptin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of vildagliptin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1110] | ||
Vinblastine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Vinblastine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vinblastine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1111] | ||
Vincristine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Vincristine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vincristine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1112] | ||
Vindesine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Vindesine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vindesine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Vinorelbine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Vinorelbine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vinorelbine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1113] | ||
Zidovudine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Zidovudine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zidovudine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [975] | ||
Ziprasidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ziprasidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ziprasidone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Zolmitriptan [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Zolmitriptan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zolmitriptan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
4-Hydroxytamoxifen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for 4-Hydroxytamoxifen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Hydroxytamoxifen through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Asimadoline [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Asimadoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Asimadoline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Asunaprevir [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Asunaprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Asunaprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Belotecan [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Belotecan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Belotecan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
CBT-1 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for CBT-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CBT-1 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [453] | ||
Corticosterone [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Corticosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Corticosterone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Dasabuvir [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dasabuvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dasabuvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Morphine-6-glucuronide [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Morphine-6-glucuronide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Morphine-6-glucuronide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Pazufloxacin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pazufloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pazufloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1114] | ||
Relugolix [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Relugolix. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Relugolix through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Simvastatin acid [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Simvastatin acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Simvastatin acid through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1115] | ||
Sitafloxacin [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Sitafloxacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sitafloxacin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Tenofovir alafenamide [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tenofovir alafenamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenofovir alafenamide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [153] | ||
Vibegron [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Vibegron. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Vibegron through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
(Z)-endoxifen [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for (Z)-endoxifen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (Z)-endoxifen through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1116] | ||
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for ABT-263. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-263 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1117] | ||
Bisantrene [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bisantrene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisantrene through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Cholesterol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cholesterol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cholesterol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1118] | ||
CP-122721 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for CP-122721. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-122721 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1119] | ||
Curcumin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Dihydrotestosterone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dihydrotestosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1120] | ||
Dolastatin 10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dolastatin 10. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dolastatin 10 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1121] | ||
Fucoxanthin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Fucoxanthin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fucoxanthin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [984] | ||
Gallopamil [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Gallopamil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gallopamil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Gepirone [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Gepirone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gepirone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Glecaprevir [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Glecaprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glecaprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Norverapamil [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Norverapamil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Norverapamil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1122] | ||
NSC325663 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for NSC325663. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC325663 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
Paritaprevir [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Paritaprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Paritaprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Roscovitine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Roscovitine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Roscovitine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1124] | ||
Staurosporine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Staurosporine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Staurosporine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
EDP-322 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for EDP-322. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EDP-322 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1125] | ||
Genz 644282 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Genz 644282. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Genz 644282 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1126] | ||
Naringenin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Naringenin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naringenin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1083] | ||
Norbuprenorphine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Norbuprenorphine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Norbuprenorphine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1127] | ||
Prostaglandin A2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Prostaglandin A2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prostaglandin A2 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1128] | ||
Substance P [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Substance P. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Substance P through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1129] | ||
Talinolol [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Talinolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Talinolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1130] | ||
Velpatasvir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Velpatasvir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Velpatasvir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
Voxilaprevir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Voxilaprevir. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Voxilaprevir through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [986] | ||
W-198 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for W-198. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of W-198 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1131] | ||
YP-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for YP-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YP-005 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1132] | ||
Abamectin B1A [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Abamectin B1A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abamectin B1A through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1133] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for AG1478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG1478 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [81] | ||
Bouvardin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bouvardin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bouvardin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
Bunitrolol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bunitrolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bunitrolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1134] | ||
Cephaeline [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cephaeline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cephaeline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
Coelenterazine [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Coelenterazine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Coelenterazine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1135] | ||
Cycloheximide [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Cycloheximide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cycloheximide through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [984] | ||
Desmethylsertraline [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Desmethylsertraline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Desmethylsertraline through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1002] | ||
E-guggulsterone [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for E-guggulsterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E-guggulsterone through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1136] | ||
Epothilone A [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Epothilone A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Epothilone A through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Geneticin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Geneticin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Geneticin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1137] | ||
Metildigoxin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Metildigoxin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Metildigoxin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1001] | ||
Metkephamid [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Metkephamid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Metkephamid through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
MG-132 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for MG-132. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MG-132 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1138] | ||
N-desethyl sunitinib [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for N-desethyl sunitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-desethyl sunitinib through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [171] | ||
Nafoxidine [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nafoxidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nafoxidine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1013] | ||
Nogalamycin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nogalamycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nogalamycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
Nonactin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Nonactin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nonactin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1018] | ||
Okadaic acid [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Okadaic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Okadaic acid through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
Pepstatin A [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pepstatin A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pepstatin A through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Puromycin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Puromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Puromycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1137] | ||
Selamectin [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Selamectin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Selamectin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1133] | ||
Silvestrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Silvestrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Silvestrol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1139] | ||
SNS-032 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for SNS-032. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SNS-032 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1140] | ||
6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1141] | ||
Azidopine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Azidopine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Azidopine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Bcecf-Am [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Bcecf-Am. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bcecf-Am through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Hoechst 33342 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Hoechst 33342. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hoechst 33342 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Leupeptin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Leupeptin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Leupeptin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Paraquat [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Paraquat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Paraquat through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Tiapamil [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tiapamil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tiapamil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
TRISMETHOXYRESVERATROL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for TRISMETHOXYRESVERATROL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TRISMETHOXYRESVERATROL through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1140] | ||
Valinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Valinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Valinomycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1070] | ||
XR-9456 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9456. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XR-9456 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1141] | ||
XR-9504 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9504. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XR-9504 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1141] | ||
XR-9544 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9544. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XR-9544 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1142] | ||
XR-9577 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for XR-9577. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XR-9577 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1141] | ||
[1,1':2',1'']-terphenyl-4,3'',5''-triol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for [1,1':2',1'']-terphenyl-4,3'',5''-triol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of [1,1':2',1'']-terphenyl-4,3'',5''-triol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1140] | ||
ABT-737 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for ABT-737. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-737 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1117] | ||
Alprenolol [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Alprenolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alprenolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Apafant [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Apafant. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apafant through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1143] | ||
Astemizole [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Astemizole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Astemizole through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [987] | ||
Biricodar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Biricodar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Biricodar through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1140] | ||
Calphostin C [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Calphostin C. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Calphostin C through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Dexniguldipine [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Dexniguldipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dexniguldipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1123] | ||
Droloxifene [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Droloxifene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Droloxifene through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
ELACRIDAR [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for ELACRIDAR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ELACRIDAR through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1144] | ||
Flesinoxan [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Flesinoxan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flesinoxan through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1145] | ||
Hydroxybupropion [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Hydroxybupropion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hydroxybupropion through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1002] | ||
Isoxicam [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Isoxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Isoxicam through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
LY335979 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for LY335979. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY335979 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1146] | ||
Melagatran [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Melagatran. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Melagatran through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Mibefradil [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mibefradil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mibefradil through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Mithramycin [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Mithramycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mithramycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Niguldipine [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Niguldipine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Niguldipine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
ONT-093 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for ONT-093. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ONT-093 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1147] | ||
Pafenolol [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Pafenolol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pafenolol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Rhodamine 123 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Rhodamine 123. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rhodamine 123 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1070] | ||
Roxithromycin [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Roxithromycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Roxithromycin through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1101] | ||
S9788 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for S9788. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S9788 through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
Tariquidar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tariquidar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tariquidar through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1148] | ||
Terfenadine [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Terfenadine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Terfenadine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Tolafentrine [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Tolafentrine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tolafentrine through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [1021] | ||
Trans-flupentixol [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Trans-flupentixol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Trans-flupentixol through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Valspodar [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Valspodar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Valspodar through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [76] | ||
Ximelagatran [Withdrawn]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | P-glycoprotein 1 (ABCB1) is a therapeutic target for Ximelagatran. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ximelagatran through regulating the expression of P-glycoprotein 1 (ABCB1). | [61], [86] | ||
p53-binding protein Mdm4 (MDM4)
ALRN-6924 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | p53-binding protein Mdm4 (MDM4) is a therapeutic target for ALRN-6924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALRN-6924 through regulating the expression of p53-binding protein Mdm4 (MDM4). | [12], [1149] | ||
NSC-207895 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | p53-binding protein Mdm4 (MDM4) is a therapeutic target for NSC-207895. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-207895 through regulating the expression of p53-binding protein Mdm4 (MDM4). | [12], [1150] | ||
Parathyroid hormone 1 receptor (PTH1R)
Abaloparatide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Parathyroid hormone 1 receptor (PTH1R) is a therapeutic target for Abaloparatide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abaloparatide through regulating the expression of Parathyroid hormone 1 receptor (PTH1R). | [1151], [1152] | ||
PCO371 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Parathyroid hormone 1 receptor (PTH1R) is a therapeutic target for PCO371. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PCO371 through regulating the expression of Parathyroid hormone 1 receptor (PTH1R). | [1151], [1153] | ||
Peroxisome proliferator-activated receptor alpha (PPARA)
Bezafibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Bezafibrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bezafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1155] | ||
Ciprofibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ciprofibrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ciprofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1156] | ||
Fenofibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fenofibrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1157] | ||
Lobeglitazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Lobeglitazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lobeglitazone through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1158] | ||
Pemafibrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Pemafibrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pemafibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1155] | ||
BMS-298585 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-298585. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-298585 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [833], [1154] | ||
CS-038 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-038. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CS-038 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1159] | ||
GFT-505 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT-505. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GFT-505 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1160] | ||
Imiglitazar [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Imiglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Imiglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1161] | ||
Ragaglitazar [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Ragaglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ragaglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1162] | ||
TESAGLITAZAR [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TESAGLITAZAR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TESAGLITAZAR through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1163] | ||
ZYH-1 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZYH-1 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1164] | ||
GFT14 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GFT14. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GFT14 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1165] | ||
LY-518674 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-518674. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-518674 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1166] | ||
Naveglitazar [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Naveglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naveglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [214], [1154] | ||
ONO-5129 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ONO-5129. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ONO-5129 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1167] | ||
ZYH7 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZYH7. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZYH7 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1168] | ||
AVE0897 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE0897. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVE0897 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1169] | ||
CDT-fenofibrate [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CDT-fenofibrate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CDT-fenofibrate through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1170] | ||
GW-409544 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-409544. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW-409544 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1171] | ||
Oxeglitazar [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Oxeglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1172] | ||
TPST-1120 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TPST-1120. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TPST-1120 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1173] | ||
MC-3001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MC-3001 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1174] | ||
MC-3002 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MC-3002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MC-3002 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1175] | ||
PIRINIXIC ACID [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for PIRINIXIC ACID. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PIRINIXIC ACID through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1176] | ||
Romazarit [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Romazarit. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Romazarit through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [214], [1154] | ||
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1177] | ||
(E)-12-Nitrooctadec-12-enoic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-12-Nitrooctadec-12-enoic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-12-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1178] | ||
(E)-13-Nitrooctadec-12-enoic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-13-Nitrooctadec-12-enoic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-13-Nitrooctadec-12-enoic Acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1178] | ||
(E)-4-(3,5-dimethoxystyryl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for (E)-4-(3,5-dimethoxystyryl)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-4-(3,5-dimethoxystyryl)phenol through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1179] | ||
8S-HETE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for 8S-HETE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8S-HETE through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1164] | ||
AD-5061 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AD-5061. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AD-5061 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1180] | ||
BMS-687453 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BMS-687453. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-687453 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1181] | ||
CP-775146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CP-775146. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-775146 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [210], [1154] | ||
DB-900 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DB-900. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DB-900 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1182] | ||
Deoxy-Bigchap [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Deoxy-Bigchap. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Deoxy-Bigchap through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1183] | ||
DRF 2519 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 2519. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DRF 2519 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1184] | ||
eicosatetranoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for eicosatetranoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of eicosatetranoic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1185] | ||
Fibrates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Fibrates. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fibrates through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1186] | ||
GSK-9578 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-9578. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK-9578 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1178] | ||
GW-2331 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW-2331. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW-2331 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1187] | ||
GW7647 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GW7647. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW7647 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1188] | ||
L-165461 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-165461. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-165461 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1186] | ||
L-796449 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for L-796449. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-796449 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1155] | ||
LL-6531 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LL-6531. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LL-6531 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1189] | ||
LY-465608 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-465608. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-465608 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1190] | ||
N-oleoylethanolamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for N-oleoylethanolamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-oleoylethanolamide through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1191] | ||
pristanic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for pristanic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of pristanic acid through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1192] | ||
reglitazar [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for reglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of reglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1193] | ||
TZD18 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for TZD18. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TZD18 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1194] | ||
ZY H2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for ZY H2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZY H2 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1195] | ||
Aleglitazar [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Aleglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aleglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1196] | ||
AR-H049020 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AR-H049020. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AR-H049020 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1192] | ||
AVE-0847 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-0847. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVE-0847 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1197] | ||
AVE-8134 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for AVE-8134. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVE-8134 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1198] | ||
BM-17.0744 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BM-17.0744. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BM-17.0744 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [214], [1154] | ||
BVT-142 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for BVT-142. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BVT-142 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1199] | ||
CS-204 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-204. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CS-204 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1200] | ||
CS-207 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for CS-207. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CS-207 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1201] | ||
DRF 10945 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for DRF 10945. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DRF 10945 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1202] | ||
E-3030 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for E-3030. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E-3030 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1203] | ||
GSK-677954 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for GSK-677954. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK-677954 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1204] | ||
Indeglitazar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Indeglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indeglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [29], [1154] | ||
KRP-101 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KRP-101 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1205] | ||
KRP-105 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-105. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KRP-105 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1163] | ||
KRP-297 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for KRP-297. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KRP-297 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1192] | ||
LG-101280 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LG-101280. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LG-101280 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1206] | ||
LY-929 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for LY-929. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-929 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1207] | ||
MP-136 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for MP-136. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MP-136 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1208] | ||
NS-220 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for NS-220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NS-220 through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1209] | ||
Reglixane [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Reglixane. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Reglixane through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1210] | ||
Sipoglitazar [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sipoglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sipoglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1211] | ||
Sodelglitazar [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Peroxisome proliferator-activated receptor alpha (PPARA) is a therapeutic target for Sodelglitazar. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sodelglitazar through regulating the expression of Peroxisome proliferator-activated receptor alpha (PPARA). | [1154], [1212] | ||
PI3-kinase alpha (PIK3CA)
Alpelisib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for Alpelisib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alpelisib through regulating the expression of PI3-kinase alpha (PIK3CA). | [482], [1213] | ||
BAY 80-6946 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for BAY 80-6946. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BAY 80-6946 through regulating the expression of PI3-kinase alpha (PIK3CA). | [665], [1213] | ||
Buparlisib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for Buparlisib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Buparlisib through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1214] | ||
GDC-0032 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for GDC-0032. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GDC-0032 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1215] | ||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for LY3023414. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3023414 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1216] | ||
MLN1117 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for MLN1117. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MLN1117 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1217] | ||
PA-799 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for PA-799. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PA-799 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1218] | ||
BLY719 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for BLY719. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BLY719 through regulating the expression of PI3-kinase alpha (PIK3CA). | [214], [1213] | ||
HHCYH33 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for HHCYH33. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HHCYH33 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1219] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for PWT-33597. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PWT-33597 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1220] | ||
ETP-46321 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PI3-kinase alpha (PIK3CA) is a therapeutic target for ETP-46321. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ETP-46321 through regulating the expression of PI3-kinase alpha (PIK3CA). | [1213], [1221] | ||
Pigment epithelium-derived factor (SERPINF1)
AdPEDR [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Pigment epithelium-derived factor (SERPINF1) is a therapeutic target for AdPEDR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AdPEDR through regulating the expression of Pigment epithelium-derived factor (SERPINF1). | [963], [1222] | ||
PEDF gene therapy [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Pigment epithelium-derived factor (SERPINF1) is a therapeutic target for PEDF gene therapy. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PEDF gene therapy through regulating the expression of Pigment epithelium-derived factor (SERPINF1). | [1222], [1223] | ||
PKC-eta messenger RNA (PRKCH mRNA)
8-Octyl-benzolactam-V9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for 8-Octyl-benzolactam-V9. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Octyl-benzolactam-V9 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1225] | ||
ISIS 6431 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6431. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6431 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6432 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6432. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6432 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6434 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6434. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6434 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6435 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6435. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6435 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6442 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6442. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6442 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6443 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6443. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6443 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6445 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6445. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6445 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6553 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6553. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6553 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6581 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6581. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6581 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1226] | ||
ISIS 6603 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for ISIS 6603. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 6603 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1227] | ||
LY-326449 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for LY-326449. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-326449 through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1228] | ||
PROSTRATIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for PROSTRATIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PROSTRATIN through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1229] | ||
BALANOL [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | PKC-eta messenger RNA (PRKCH mRNA) is a therapeutic target for BALANOL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BALANOL through regulating the expression of PKC-eta messenger RNA (PRKCH mRNA). | [1224], [1230] | ||
Platelet-derived growth factor receptor alpha (PDGFRA)
Avapritinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Avapritinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Avapritinib through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1231] | ||
Olaratumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Olaratumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Olaratumab through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
Ripretinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Ripretinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ripretinib through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1233] | ||
Romiplostim [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Romiplostim. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Romiplostim through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1234] | ||
CP-868596 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for CP-868596. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-868596 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1235] | ||
E-3810 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for E-3810. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E-3810 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1236] | ||
Famitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Famitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Famitinib through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1237] | ||
MEDI-575 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for MEDI-575. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI-575 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1238] | ||
MP470 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for MP470. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MP470 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1239] | ||
XL-820 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for XL-820. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XL-820 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1240] | ||
(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
1-Phenyl-1H-benzoimidazol-5-ol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 1-Phenyl-1H-benzoimidazol-5-ol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-Phenyl-1H-benzoimidazol-5-ol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1242] | ||
1-Phenyl-1H-benzoimidazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 1-Phenyl-1H-benzoimidazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-Phenyl-1H-benzoimidazole through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1243] | ||
3-((E)-Styryl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-((E)-Styryl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-((E)-Styryl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-(1H-Indol-3-yl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(1H-Indol-3-yl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(1H-Indol-3-yl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Benzyloxy-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Benzyloxy-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Benzyloxy-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Cyclohexylethynyl-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Cyclopentyl-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Cyclopentyl-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Cyclopentyl-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Pyridin-3-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Pyridin-3-yl-quinoline-6,7-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Pyridin-3-yl-quinoline-6,7-diol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Pyridin-4-yl-quinolin-7-ol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Pyridin-4-yl-quinolin-7-ol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Pyridin-4-yl-quinolin-7-ol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
3-Pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
3-Pyridin-4-yl-quinoline-5,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Pyridin-4-yl-quinoline-5,7-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-5,7-diol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
3-Thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 3-Thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1244] | ||
4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1245] | ||
4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
4-(6,7-Dimethoxy-quinolin-3-yl)-phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
4-Benzoimidazol-1-yl-phenylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 4-Benzoimidazol-1-yl-phenylamine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Benzoimidazol-1-yl-phenylamine through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1245] | ||
5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1246] | ||
5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
5,7-Dimethoxy-3-pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5,7-Dimethoxy-3-pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,7-Dimethoxy-3-pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
5,7-Dimethoxy-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5,7-Dimethoxy-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,7-Dimethoxy-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
5,7-Dimethyl-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5,7-Dimethyl-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,7-Dimethyl-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
5-Fluoro-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5-Fluoro-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Fluoro-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
5-Methoxy-1-phenyl-1H-benzoimidazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 5-Methoxy-1-phenyl-1H-benzoimidazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Methoxy-1-phenyl-1H-benzoimidazole through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1245] | ||
6,7-Dichloro-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dichloro-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dichloro-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Difluoro-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Difluoro-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Difluoro-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-((E)-styryl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-((E)-styryl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-((E)-styryl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
6,7-Dimethoxy-3-p-tolyl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-p-tolyl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-p-tolyl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-phenyl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-phenyl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-phenyl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-phenylethynyl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-phenylethynyl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-phenylethynyl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-pyridin-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-pyridin-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-pyridin-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6,7-Dimethoxy-3-pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
6,7-Dimethoxy-3-thiophen-2-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6,7-Dimethoxy-3-thiophen-2-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7-Dimethoxy-3-thiophen-2-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
6-Methoxy-3-pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6-Methoxy-3-pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Methoxy-3-pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
6-Methoxy-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 6-Methoxy-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Methoxy-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
7-Chloro-3-pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 7-Chloro-3-pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Chloro-3-pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [531], [1224] | ||
7-Fluoro-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 7-Fluoro-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Fluoro-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
7-Methoxy-3-pyridin-4-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 7-Methoxy-3-pyridin-4-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Methoxy-3-pyridin-4-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
7-Methoxy-3-thiophen-3-yl-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 7-Methoxy-3-thiophen-3-yl-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Methoxy-3-thiophen-3-yl-quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
Bis-(5-hydroxy-1H-indol-2-yl)-methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Bis-(5-hydroxy-1H-indol-2-yl)-methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bis-(5-hydroxy-1H-indol-2-yl)-methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1247] | ||
CP-673451 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for CP-673451. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CP-673451 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [586], [1224] | ||
D-65476 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for D-65476. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of D-65476 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [551], [1224] | ||
Di(1H-indol-2-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Di(1H-indol-2-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Di(1H-indol-2-yl)methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [535], [1224] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for HKI-9924129. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HKI-9924129 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1245] | ||
JNJ-10198409 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for JNJ-10198409. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ-10198409 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1233] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PD-0166326. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0166326 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
PD-0173952 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PD-0173952. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0173952 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
PD-0173955 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PD-0173955. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0173955 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PD-0173956. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0173956 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
PD-0173958 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PD-0173958. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0173958 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
PD-0179483 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PD-0179483. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0179483 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for PP121. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PP121 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [10], [1224] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Ro-4396686. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-4396686 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [529], [1224] | ||
RPR-101511 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for RPR-101511. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RPR-101511 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
RPR-108514A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for RPR-108514A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RPR-108514A through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1232] | ||
SU-11652 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for SU-11652. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SU-11652 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [538], [1224] | ||
AG1295 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for AG1295. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG1295 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1248] | ||
CEP-2563 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for CEP-2563. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEP-2563 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1249] | ||
RG-13022 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for RG-13022. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG-13022 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1241] | ||
SRI-62-834 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for SRI-62-834. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SRI-62-834 through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). | [1224], [1250] | ||
Polo-like kinase 1 (PLK1)
Rigosertib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for Rigosertib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rigosertib through regulating the expression of Polo-like kinase 1 (PLK1). | [181], [1251] | ||
Volasertib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for Volasertib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Volasertib through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1252] | ||
BI 2536 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for BI 2536. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI 2536 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1253] | ||
PCM-075 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for PCM-075. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PCM-075 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1254] | ||
TKM-PLK1 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for TKM-PLK1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TKM-PLK1 through regulating the expression of Polo-like kinase 1 (PLK1). | [497], [1251] | ||
CYC140 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for CYC140. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYC140 through regulating the expression of Polo-like kinase 1 (PLK1). | [5], [1251] | ||
GSK461364 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for GSK461364. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK461364 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1255] | ||
MK-1496 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for MK-1496. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-1496 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1256] | ||
TAK-960 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for TAK-960. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-960 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1257] | ||
CYC-800 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for CYC-800. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYC-800 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1254] | ||
DAP-81 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for DAP-81. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DAP-81 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1254] | ||
ZK-thiazolidinone [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for ZK-thiazolidinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZK-thiazolidinone through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1254] | ||
CHR-4125 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for CHR-4125. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CHR-4125 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1258] | ||
GSK579289A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for GSK579289A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK579289A through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1258] | ||
GW853606 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for GW853606. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW853606 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1259] | ||
MLN-0905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for MLN-0905. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MLN-0905 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1253] | ||
NMS-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for NMS-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NMS-1 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1253] | ||
Ro5203280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for Ro5203280. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro5203280 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1254] | ||
HMN-214 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Polo-like kinase 1 (PLK1) is a therapeutic target for HMN-214. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HMN-214 through regulating the expression of Polo-like kinase 1 (PLK1). | [1251], [1254] | ||
Poly [ADP-ribose] polymerase 1 (PARP1)
KU-0058948 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for KU-0058948. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KU-0058948 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1153], [1260] | ||
Nicotinamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Nicotinamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicotinamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1261] | ||
Niraparib Tosylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Niraparib Tosylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Niraparib Tosylate through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [220], [1260] | ||
CC-486 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for CC-486. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CC-486 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1262] | ||
Nicaraven [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Nicaraven. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicaraven through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1263] | ||
AG140699 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AG140699. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG140699 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1264] | ||
AMXI 5001 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AMXI 5001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMXI 5001 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1265] | ||
PMID27841036-Compound-37 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for PMID27841036-Compound-37. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMID27841036-Compound-37 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1266] | ||
Stenoparib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Stenoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Stenoparib through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1267] | ||
NMS-03305293 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for NMS-03305293. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NMS-03305293 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1268] | ||
CPH-102 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for CPH-102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPH-102 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1269] | ||
PJ34 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for PJ34. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PJ34 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
(E)-N-(4-Phenylthiazol-2-yl) cinnamamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for (E)-N-(4-Phenylthiazol-2-yl) cinnamamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-N-(4-Phenylthiazol-2-yl) cinnamamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1272] | ||
2,3-dihydro-1H-benzo[de]isoquinolin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2,3-dihydro-1H-benzo[de]isoquinolin-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,3-dihydro-1H-benzo[de]isoquinolin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
2,8-Dimethyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2,8-Dimethyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,8-Dimethyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
2-(2-Chlorophenyl)-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [220], [1260] | ||
2-(3-Chlorophenyl)-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1276] | ||
2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1277] | ||
2-(4-Chlorophenyl)-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [220], [1260] | ||
2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
2-(4-methoxyphenyl)quinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-methoxyphenyl)quinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-methoxyphenyl)quinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
2-Benzyl-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-Benzyl-2H-indazole-7-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Benzyl-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
2-ethylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-ethylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-ethylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
2-Methylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-Methylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Methylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
2-phenyl-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenyl-2H-indazole-7-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-phenyl-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1278] | ||
2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
2-phenylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-phenylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
2H-Isoquinolin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2H-Isoquinolin-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2H-Isoquinolin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
3-(4-aminophenyl)quinoxaline-5-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-(4-aminophenyl)quinoxaline-5-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-aminophenyl)quinoxaline-5-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
3-(4-cyanophenyl)quinoxaline-5-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-(4-cyanophenyl)quinoxaline-5-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-cyanophenyl)quinoxaline-5-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
3-(4-methoxyphenyl)quinoxaline-5-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-(4-methoxyphenyl)quinoxaline-5-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-methoxyphenyl)quinoxaline-5-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
3-aminobenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-aminobenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-aminobenzamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1279] | ||
3-aminobenzo[c][1,5]naphthyridin-6(5H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
3-Ethenylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Ethenylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Ethenylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
3-Ethylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Ethylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Ethylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
3-Ethynylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Ethynylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Ethynylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
3-Hydroxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Hydroxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Hydroxy-benzamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
3-Methoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Methoxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Methoxybenzamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [210], [1260] | ||
3-Methylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Methylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Methylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1280] | ||
3-Phenylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Phenylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Phenylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
3-Prop-1-ynylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Prop-1-ynylquinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Prop-1-ynylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1281] | ||
4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1280] | ||
4-amino-1,8-naphthalimide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-amino-1,8-naphthalimide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-amino-1,8-naphthalimide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1266] | ||
4-benzylphthalazin-1(2H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-benzylphthalazin-1(2H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-benzylphthalazin-1(2H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1272] | ||
5-amino-3,4-dihydroisoquinolin-1(2H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-amino-3,4-dihydroisoquinolin-1(2H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-amino-3,4-dihydroisoquinolin-1(2H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1278] | ||
5-aminoisoquinolin-1(2H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-aminoisoquinolin-1(2H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-aminoisoquinolin-1(2H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
5-Chloro-2-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-Chloro-2-methyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Chloro-2-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1282] | ||
5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1272] | ||
8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1283] | ||
8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1283] | ||
8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Hydroxy-2-phenyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Hydroxy-2-phenyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Hydroxy-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Methoxy-2-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-methyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Methoxy-2-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Methoxy-2-phenyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-phenyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Methoxy-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Methyl-2-phenyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methyl-2-phenyl-3H-quinazolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Methyl-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1274] | ||
8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1283] | ||
9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1280] | ||
9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1283] | ||
A-620223 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for A-620223. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-620223 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
AG-014376 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AG-014376. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG-014376 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
ANG-2684 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for ANG-2684. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ANG-2684 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
ANG-2864 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for ANG-2864. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ANG-2864 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1277] | ||
Benzo[c][1,5]naphthyridin-6(5H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Benzo[c][1,5]naphthyridin-6(5H)-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzo[c][1,5]naphthyridin-6(5H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
BPI-704001 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BPI-704001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BPI-704001 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
BZ3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BZ3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BZ3 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1284] | ||
BZ5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BZ5. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BZ5 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1284] | ||
BZ6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BZ6. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BZ6 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1281] | ||
Carba-Nicotinamide-Adenine-Dinucleotide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Carba-Nicotinamide-Adenine-Dinucleotide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carba-Nicotinamide-Adenine-Dinucleotide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [210], [1260] | ||
CEP-6800 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for CEP-6800. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEP-6800 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1272] | ||
DR2313 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for DR2313. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DR2313 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1266] | ||
EB-47 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for EB-47. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EB-47 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1284] | ||
HYDAMTIQ [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for HYDAMTIQ. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HYDAMTIQ through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
INO-1002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for INO-1002. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INO-1002 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
KR-33889 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for KR-33889. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KR-33889 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
KU-58684 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for KU-58684. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KU-58684 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1283] | ||
ME0328 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for ME0328. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ME0328 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [210], [1260] | ||
N-(4-Phenylthiazol-2-yl)isonicotinamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for N-(4-Phenylthiazol-2-yl)isonicotinamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-Phenylthiazol-2-yl)isonicotinamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1271] | ||
PD-128763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for PD-128763. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-128763 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1275] | ||
Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1272] | ||
Quinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Quinoline-8-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1273] | ||
S-070 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for S-070. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-070 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
S-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for S-111. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-111 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1270] | ||
Thieno-phenanthridin-6-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Thieno-phenanthridin-6-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thieno-phenanthridin-6-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1266] | ||
TI3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for TI3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TI3 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1284] | ||
TI4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for TI4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TI4 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1284] | ||
[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1284] | ||
NU1025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for NU1025. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NU1025 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [1260], [1265] | ||
Programmed cell death 1 ligand 1 (PD-L1)
Atezolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Atezolizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Atezolizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1286] | ||
Avelumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Avelumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Avelumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1153], [1285] | ||
Bavencio [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Bavencio. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bavencio through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1287] | ||
Durvalumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Durvalumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Durvalumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1288] | ||
RG-7446 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for RG-7446. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG-7446 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1289] | ||
CS1001 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CS1001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CS1001 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1290] | ||
KN046 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KN046. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KN046 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1291] | ||
MEDI4736 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MEDI4736. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MEDI4736 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1292] | ||
MPDL-3280A [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MPDL-3280A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MPDL-3280A through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1293] | ||
BGB-A333 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for BGB-A333. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BGB-A333 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1294] | ||
Bintrafusp alfa [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Bintrafusp alfa. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bintrafusp alfa through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1295] | ||
CX-072 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CX-072. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CX-072 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1296] | ||
GS-4224 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for GS-4224. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GS-4224 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1297] | ||
INCB86550 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for INCB86550. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INCB86550 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1298] | ||
KN035 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KN035. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KN035 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1299] | ||
M7824 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for M7824. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M7824 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [497], [1285] | ||
NM21-1480 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for NM21-1480. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NM21-1480 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1288] | ||
Pidilizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [5], [1285] | ||
ALPN-202 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for ALPN-202. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALPN-202 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [821], [1285] | ||
Anti-PD-L1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Anti-PD-L1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-PD-L1 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1300] | ||
Anti-PD-L1 CSR T cells [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Anti-PD-L1 CSR T cells. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-PD-L1 CSR T cells through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [5], [1285] | ||
BMS-986189 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for BMS-986189. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-986189 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1288] | ||
CA-170 [Phase 1]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-170. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CA-170 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [497], [1285] | ||
| Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-170. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CA-170 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1301] | |||
Cosibelimab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Cosibelimab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cosibelimab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1302] | ||
FAZ053 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for FAZ053. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FAZ053 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1288] | ||
FS118 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for FS118. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FS118 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1303] | ||
GEN1046 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for GEN1046. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GEN1046 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1304] | ||
IBI318 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for IBI318. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IBI318 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1305] | ||
INBRX-105 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for INBRX-105. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INBRX-105 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1306] | ||
KD033 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KD033. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KD033 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1307] | ||
LY3300054 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3300054. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3300054 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [5], [1285] | ||
LY3415244 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1308] | ||
MCLA-145 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MCLA-145. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MCLA-145 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1309] | ||
MSB2311 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MSB2311. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MSB2311 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1288] | ||
PD-L1 t-haNK [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for PD-L1 t-haNK. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-L1 t-haNK through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1310] | ||
RG6084 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for RG6084. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG6084 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [497], [1285] | ||
TAK-252 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for TAK-252. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-252 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1311] | ||
CA-327 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-327. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CA-327 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [1285], [1288] | ||
Prominin-1 (PROM1)
Anti-CD133-CAR vector-transduced T cells [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prominin-1 (PROM1) is a therapeutic target for Anti-CD133-CAR vector-transduced T cells. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-CD133-CAR vector-transduced T cells through regulating the expression of Prominin-1 (PROM1). | [570], [1312] | ||
ICT-121 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prominin-1 (PROM1) is a therapeutic target for ICT-121. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ICT-121 through regulating the expression of Prominin-1 (PROM1). | [570], [1313] | ||
CAR-T cells targeting CD133 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prominin-1 (PROM1) is a therapeutic target for CAR-T cells targeting CD133. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CAR-T cells targeting CD133 through regulating the expression of Prominin-1 (PROM1). | [570], [1314] | ||
Prostaglandin G/H synthase 2 (COX-2)
(S)-FLURBIPROFEN [Preregistration]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (S)-FLURBIPROFEN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (S)-FLURBIPROFEN through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1315] | ||
Aminosalicylic Acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Aminosalicylic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aminosalicylic Acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1316] | ||
Carprofen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Carprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Carprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1317] | ||
Celecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Celecoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Celecoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1318] | ||
Dapsone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Dapsone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dapsone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [327], [879] | ||
Diflunisal [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Diflunisal. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Diflunisal through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1319] | ||
Etodolac [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Etodolac. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etodolac through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1320] | ||
Etoposide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Etoposide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etoposide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1321] | ||
Etoricoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Etoricoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etoricoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1322] | ||
FENBUFEN [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for FENBUFEN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FENBUFEN through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1153] | ||
Flufenamic Acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Flufenamic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flufenamic Acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1323] | ||
Flurbiprofen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Flurbiprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flurbiprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1324] | ||
Gamma-linolenic acid [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Gamma-linolenic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gamma-linolenic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
Ibuprofen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Ibuprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ibuprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1326] | ||
IMRECOXIB [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for IMRECOXIB. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMRECOXIB through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1327] | ||
Indomethacin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Indomethacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Indomethacin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1328] | ||
Ketoprofen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Ketoprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ketoprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1329] | ||
Lumiracoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Lumiracoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lumiracoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1330] | ||
Mefenamic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Mefenamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mefenamic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1331] | ||
Meloxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Meloxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Meloxicam through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1332] | ||
Nabumetone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Nabumetone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nabumetone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1333] | ||
Naproxen [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Naproxen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Naproxen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1334] | ||
Niflumic Acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Niflumic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Niflumic Acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1335] | ||
Omega-3 Fatty acids [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Omega-3 Fatty acids. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Omega-3 Fatty acids through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1336] | ||
Phenylbutazone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Phenylbutazone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenylbutazone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1337] | ||
Rofecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Rofecoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rofecoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1331] | ||
Tenoxicam [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Tenoxicam. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tenoxicam through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1338] | ||
Tiaprofenic acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Tiaprofenic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tiaprofenic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1339] | ||
Tolmetin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Tolmetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tolmetin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1340] | ||
Valdecoxib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Valdecoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Valdecoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1341] | ||
CG-100649 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CG-100649. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CG-100649 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1342] | ||
Curcumin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Curcumin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Curcumin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1343] | ||
Darbufelone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Darbufelone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Darbufelone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1344] | ||
Omega-6-FA [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Omega-6-FA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Omega-6-FA through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1345] | ||
SC-411 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-411. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-411 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
ThermoProfen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for ThermoProfen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ThermoProfen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1346] | ||
CIMICOXIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CIMICOXIB. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CIMICOXIB through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1347] | ||
FK-3311 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for FK-3311. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FK-3311 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1348] | ||
SC-75416 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-75416. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-75416 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1349] | ||
CA102N [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CA102N. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CA102N through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1350] | ||
RWJ-67657 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for RWJ-67657. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RWJ-67657 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1351] | ||
(11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1352] | ||
(11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1353] | ||
(11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1352] | ||
(E)-2-(4-(methylsulfonyl)styryl)furan [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (E)-2-(4-(methylsulfonyl)styryl)furan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-2-(4-(methylsulfonyl)styryl)furan through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1354] | ||
(E)-2-(4-(methylsulfonyl)styryl)thiophene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (E)-2-(4-(methylsulfonyl)styryl)thiophene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-2-(4-(methylsulfonyl)styryl)thiophene through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1354] | ||
(E)-3-(4-(methylsulfonyl)styryl)thiophene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (E)-3-(4-(methylsulfonyl)styryl)thiophene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-3-(4-(methylsulfonyl)styryl)thiophene through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1354] | ||
(E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1354] | ||
(E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
(E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1356] | ||
(R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1357] | ||
(Z)-2'-des-methyl sulindac sulfide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for (Z)-2'-des-methyl sulindac sulfide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (Z)-2'-des-methyl sulindac sulfide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1358] | ||
1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1359] | ||
1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
1-(4-(methylsulfonyl)phenyl)-1H-indole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1-(4-(methylsulfonyl)phenyl)-1H-indole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(4-(methylsulfonyl)phenyl)-1H-indole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1361] | ||
1-(4-(methylsulfonyl)phenyl)-1H-pyrrole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1362] | ||
1-(4-(methylsulfonyl)phenyl)-3-phenylurea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1-(4-(methylsulfonyl)phenyl)-3-phenylurea. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(4-(methylsulfonyl)phenyl)-3-phenylurea through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1353] | ||
1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1363] | ||
2'-hydroxy-3,4,5-trimethoxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2'-hydroxy-3,4,5-trimethoxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2'-hydroxy-3,4,5-trimethoxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1364] | ||
2'-Hydroxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2'-Hydroxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2'-Hydroxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
2,3-dimethoxy-2'-hydroxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2,3-dimethoxy-2'-hydroxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,3-dimethoxy-2'-hydroxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1365] | ||
2,4'-Dimethoxy-5,3'-dipropyl-biphenyl [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2,4'-Dimethoxy-5,3'-dipropyl-biphenyl. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,4'-Dimethoxy-5,3'-dipropyl-biphenyl through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1354] | ||
2,4-dimethoxy-2'-hydroxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2,4-dimethoxy-2'-hydroxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,4-dimethoxy-2'-hydroxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
2,6-dihydroxy-1,7-dimethoxyxanthone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2,6-dihydroxy-1,7-dimethoxyxanthone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2,6-dihydroxy-1,7-dimethoxyxanthone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1366] | ||
2-(2,3,4-trimethoxyphenyl)-1H-indene [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(2,3,4-trimethoxyphenyl)-1H-indene. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2,3,4-trimethoxyphenyl)-1H-indene through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1367] | ||
2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1358] | ||
2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1368] | ||
2-(4-(methylsulfonyl)phenyl)pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(4-(methylsulfonyl)phenyl)pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(4-(methylsulfonyl)phenyl)pyridine through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1361] | ||
2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1367] | ||
2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1369] | ||
2-(p-Methylsulfonylbenzoyl)furan [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-(p-Methylsulfonylbenzoyl)furan. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(p-Methylsulfonylbenzoyl)furan through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1370] | ||
2-Benzyl-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-Benzyl-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Benzyl-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1371] | ||
2-Methyl-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-Methyl-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Methyl-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
2-Phenethyl-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-Phenethyl-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Phenethyl-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
2-Phenyl-1,2-dihydro-indazol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 2-Phenyl-1,2-dihydro-indazol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Phenyl-1,2-dihydro-indazol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1354] | ||
3 beta-O-acetyloleanolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 3 beta-O-acetyloleanolic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3 beta-O-acetyloleanolic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1372] | ||
3,4-dibenzyloxy-2'-hydroxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 3,4-dibenzyloxy-2'-hydroxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-dibenzyloxy-2'-hydroxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
3,4-dihydroxyxanthone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 3,4-dihydroxyxanthone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3,4-dihydroxyxanthone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1373] | ||
3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1374] | ||
3-benzyloxy-4-methoxy-2'-hydroxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 3-benzyloxy-4-methoxy-2'-hydroxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-benzyloxy-4-methoxy-2'-hydroxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
3-Bromo-2'-hydroxy-4-methoxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 3-Bromo-2'-hydroxy-4-methoxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-Bromo-2'-hydroxy-4-methoxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
4,5-Bis(4-chlorophenyl)-1,2-selenazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4,5-Bis(4-chlorophenyl)-1,2-selenazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-Bis(4-chlorophenyl)-1,2-selenazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1369] | ||
4,5-Bis(4-chlorophenyl)isothiazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4,5-Bis(4-chlorophenyl)isothiazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-Bis(4-chlorophenyl)isothiazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1359] | ||
4,5-Bis(4-methoxyphenyl)-1,2-selenazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4,5-Bis(4-methoxyphenyl)-1,2-selenazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-Bis(4-methoxyphenyl)-1,2-selenazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1369] | ||
4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1375] | ||
4,5-Bis(4-methoxyphenyl)isothiazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4,5-Bis(4-methoxyphenyl)isothiazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5-Bis(4-methoxyphenyl)isothiazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1359] | ||
4-((4-methoxyphenyl)diazenyl)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1376] | ||
4-(3-hydroxy-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(3-hydroxy-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(3-hydroxy-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(3-methoxy-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(3-methoxy-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(3-methoxy-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(3-nitro-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(3-nitro-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(3-nitro-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1369] | ||
4-(4-fluoro-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-fluoro-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-fluoro-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1378] | ||
4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(4-hydroxy-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(4-methoxy-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-methoxy-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-methoxy-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(4-methyl-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-methyl-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-methyl-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(4-methyl-phenyliminomethyl)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-methyl-phenyliminomethyl)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-methyl-phenyliminomethyl)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(4-nitro-benzylideneamino)-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(4-nitro-benzylideneamino)-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(4-nitro-benzylideneamino)-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-(benzylideneamino)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-(benzylideneamino)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(benzylideneamino)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
4-amino-N-(4-chlorophenyl)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-amino-N-(4-chlorophenyl)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-amino-N-(4-chlorophenyl)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1371] | ||
4-amino-N-(4-iodophenyl)benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-amino-N-(4-iodophenyl)benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-amino-N-(4-iodophenyl)benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1372] | ||
4-benzyloxy-2'-hydroxychalcone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-benzyloxy-2'-hydroxychalcone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-benzyloxy-2'-hydroxychalcone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1361] | ||
4-phenyliminomethyl-benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 4-phenyliminomethyl-benzenesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-phenyliminomethyl-benzenesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
5,3'-Dipropyl-biphenyl-2,4'-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5,3'-Dipropyl-biphenyl-2,4'-diol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5,3'-Dipropyl-biphenyl-2,4'-diol through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1372] | ||
5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1379] | ||
5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1369] | ||
5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1380] | ||
5-Ethyl-3,4-diphenyl-isoxazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-Ethyl-3,4-diphenyl-isoxazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Ethyl-3,4-diphenyl-isoxazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1381] | ||
5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1382] | ||
5-Methyl-3,4-diphenyl-isoxazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-Methyl-3,4-diphenyl-isoxazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Methyl-3,4-diphenyl-isoxazole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1383] | ||
5-Phenyl-pentanoic acid benzyl-hydroxy-amide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-Phenyl-pentanoic acid benzyl-hydroxy-amide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Phenyl-pentanoic acid benzyl-hydroxy-amide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1355] | ||
5-thia-8,11,14,17-eicosatetraenoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 5-thia-8,11,14,17-eicosatetraenoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-thia-8,11,14,17-eicosatetraenoic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1315] | ||
6,7'-oxybis(2-phenyl-4H-chromen-4-one) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 6,7'-oxybis(2-phenyl-4H-chromen-4-one). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6,7'-oxybis(2-phenyl-4H-chromen-4-one) through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1360] | ||
8alpha,19-dihydroxylabd-13 E-en-15-oic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for 8alpha,19-dihydroxylabd-13 E-en-15-oic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 8alpha,19-dihydroxylabd-13 E-en-15-oic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1384] | ||
Alpha-linolenic acid [Investigative]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Alpha-linolenic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alpha-linolenic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
| Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Alpha-linolenic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Alpha-linolenic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1385] | |||
Arachidonic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Arachidonic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Arachidonic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1386] | ||
B-Octylglucoside [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for B-Octylglucoside. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of B-Octylglucoside through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1387] | ||
Bimetopyrole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Bimetopyrole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bimetopyrole through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1388] | ||
BML3-C01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for BML3-C01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BML3-C01 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
C-myb [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for C-myb. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-myb through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1389] | ||
CLEMATOMANDSHURICA SAPONIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CLEMATOMANDSHURICA SAPONIN A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CLEMATOMANDSHURICA SAPONIN A through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1374] | ||
CLEMATOMANDSHURICA SAPONIN B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CLEMATOMANDSHURICA SAPONIN B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CLEMATOMANDSHURICA SAPONIN B through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1390] | ||
CR-4174 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CR-4174. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CR-4174 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [220], [879] | ||
CX-9051 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CX-9051. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CX-9051 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1391] | ||
DFU [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for DFU. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DFU through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1392] | ||
Eicosadienoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Eicosadienoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Eicosadienoic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
Firocoxib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Firocoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Firocoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1393] | ||
Fluoro loxoprofen [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Fluoro loxoprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fluoro loxoprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1315] | ||
Furan-3-yl(4-(methylsulfonyl)phenyl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Furan-3-yl(4-(methylsulfonyl)phenyl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Furan-3-yl(4-(methylsulfonyl)phenyl)methanone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1361] | ||
GW-637185X [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for GW-637185X. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW-637185X through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1366] | ||
Heme [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Heme. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Heme through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [210], [879] | ||
HONOKIOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for HONOKIOL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HONOKIOL through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1372] | ||
Icosapentum [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Icosapentum. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Icosapentum through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
Icosatrienoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Icosatrienoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Icosatrienoic acid through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1325] | ||
L-748780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for L-748780. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-748780 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1390] | ||
L-761000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for L-761000. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-761000 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1361] | ||
LM-4108 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for LM-4108. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LM-4108 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1394] | ||
METHYLHONOKIOL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for METHYLHONOKIOL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of METHYLHONOKIOL through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1372] | ||
Microxine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Microxine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Microxine through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1383] | ||
N-(1H-indazol-5-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for N-(1H-indazol-5-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(1H-indazol-5-yl)acetamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1395] | ||
N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1384] | ||
N-(3-phenoxy-4-pyridinyl)ethanesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for N-(3-phenoxy-4-pyridinyl)ethanesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3-phenoxy-4-pyridinyl)ethanesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1376] | ||
N-(3-phenylamino-4-pyridinyl)methanesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for N-(3-phenylamino-4-pyridinyl)methanesulfonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3-phenylamino-4-pyridinyl)methanesulfonamide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1369] | ||
Nectamazin C [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Nectamazin C. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nectamazin C through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1364] | ||
NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1364] | ||
Nitroflurbiprofen [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Nitroflurbiprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nitroflurbiprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1396] | ||
NSC-27236 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for NSC-27236. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-27236 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1397] | ||
OCOPHYLLALS A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for OCOPHYLLALS A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OCOPHYLLALS A through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1364] | ||
Ocophyllals b [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Ocophyllals b. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ocophyllals b through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1398] | ||
Oxametacin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Oxametacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxametacin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1399] | ||
Oxindole 94 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Oxindole 94. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxindole 94 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1400] | ||
PAC-10649 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for PAC-10649. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PAC-10649 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1401] | ||
PHENIDONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for PHENIDONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PHENIDONE through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1402] | ||
Prifelone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Prifelone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prifelone through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1403] | ||
Primary alcohol metabolite of celecoxib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Primary alcohol metabolite of celecoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Primary alcohol metabolite of celecoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1352] | ||
Prostaglandin G2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Prostaglandin G2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Prostaglandin G2 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [220], [879] | ||
Resveratrol Potassium3-Sulfate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Resveratrol Potassium3-Sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Resveratrol Potassium3-Sulfate through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1404] | ||
Resveratrol Potassium4,-Sulfate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Resveratrol Potassium4,-Sulfate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Resveratrol Potassium4,-Sulfate through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1375] | ||
SB 239063 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SB 239063. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB 239063 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1405] | ||
SC-558 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-558. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-558 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1406] | ||
Silicon-modified indomethacin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Silicon-modified indomethacin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Silicon-modified indomethacin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1401] | ||
TENOSAL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for TENOSAL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TENOSAL through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1407] | ||
THIOCTIC ACID [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for THIOCTIC ACID. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of THIOCTIC ACID through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1377] | ||
Wogonin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Wogonin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Wogonin through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1361] | ||
XGP-110 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for XGP-110. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XGP-110 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1401] | ||
Apricoxib [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Apricoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Apricoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1408] | ||
ATLIPROFEN METHYL ESTER [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for ATLIPROFEN METHYL ESTER. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ATLIPROFEN METHYL ESTER through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1409] | ||
CRx-401 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for CRx-401. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRx-401 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1410] | ||
DUP 697 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for DUP 697. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DUP 697 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1408] | ||
E-6087 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for E-6087. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E-6087 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1411] | ||
Flosulide [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Flosulide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Flosulide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1412] | ||
FR-123826 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for FR-123826. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FR-123826 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1413] | ||
GR-253035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for GR-253035. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GR-253035 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1389] | ||
GSK-644784 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for GSK-644784. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK-644784 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1414] | ||
GW-406381 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for GW-406381. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW-406381 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1415] | ||
INDOPROFEN [Withdrawn from market]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for INDOPROFEN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INDOPROFEN through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1416] | ||
L-745337 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for L-745337. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-745337 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1417] | ||
L-768277 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for L-768277. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-768277 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1418] | ||
Nimesulide [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Nimesulide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nimesulide through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1362] | ||
NMI-150 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for NMI-150. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NMI-150 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1419] | ||
NS398 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for NS398. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NS398 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1153] | ||
ON-09300 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for ON-09300. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ON-09300 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1153] | ||
PMI-001 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for PMI-001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMI-001 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1362] | ||
PRINOMIDE TROMETHAMINE [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for PRINOMIDE TROMETHAMINE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PRINOMIDE TROMETHAMINE through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1420] | ||
R-ketoprofen [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for R-ketoprofen. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of R-ketoprofen through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1421] | ||
RPR 200765A [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for RPR 200765A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RPR 200765A through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1422] | ||
RQ-00317076 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for RQ-00317076. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RQ-00317076 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1423] | ||
RWJ-63556 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for RWJ-63556. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RWJ-63556 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1424] | ||
S-2474 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for S-2474. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-2474 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1425] | ||
S-33516 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for S-33516. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of S-33516 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1426] | ||
SB 203580 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SB 203580. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB 203580 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1362] | ||
SC-236 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-236. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-236 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1427] | ||
SC-57666 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-57666. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-57666 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1428] | ||
SC-58125 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-58125. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-58125 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1429] | ||
SC-58451 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for SC-58451. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-58451 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1430] | ||
TEBUFELONE [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for TEBUFELONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TEBUFELONE through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1425] | ||
Tilmacoxib [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for Tilmacoxib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tilmacoxib through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). | [879], [1431] | ||
Protein arginine methyltransferase 5 (PRMT5)
GSK3326595 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for GSK3326595. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK3326595 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1433] | ||
JNJ-64619178 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for JNJ-64619178. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ-64619178 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [5], [1432] | ||
PF-06939999 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for PF-06939999. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-06939999 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1434] | ||
PRT543 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for PRT543. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PRT543 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1435] | ||
PRT811 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for PRT811. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PRT811 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1436] | ||
cmp5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for cmp5. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of cmp5 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1437] | ||
DS-437 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for DS-437. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-437 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1438] | ||
EPZ015666 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein arginine methyltransferase 5 (PRMT5) is a therapeutic target for EPZ015666. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EPZ015666 through regulating the expression of Protein arginine methyltransferase 5 (PRMT5). | [1432], [1439] | ||
Proto-oncogene c-Met (MET)
Cabozantinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Cabozantinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cabozantinib through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1441] | ||
Capmatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Capmatinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Capmatinib through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1442] | ||
Tepotinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Tepotinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tepotinib through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1443] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Amivantamab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amivantamab through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
Beperminogene perplasmid [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Beperminogene perplasmid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Beperminogene perplasmid through regulating the expression of Proto-oncogene c-Met (MET). | [5], [1440] | ||
MGCD516 [Phase 2/3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for MGCD516. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MGCD516 through regulating the expression of Proto-oncogene c-Met (MET). | [486], [1440] | ||
| Proto-oncogene c-Met (MET) is a therapeutic target for MGCD516. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MGCD516 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1445] | |||
RG3638 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for RG3638. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG3638 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1446] | ||
Savolitinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Savolitinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Savolitinib through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1447] | ||
Tivantinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Tivantinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tivantinib through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
AMG 208 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for AMG 208. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 208 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1448] | ||
AMG 337 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for AMG 337. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 337 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1449] | ||
Anti-C-met CAR-T cells [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Anti-C-met CAR-T cells. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-C-met CAR-T cells through regulating the expression of Proto-oncogene c-Met (MET). | [5], [1440] | ||
APL-101 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for APL-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APL-101 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1450] | ||
BMS-777607 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for BMS-777607. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-777607 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1451] | ||
ChronSeal [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for ChronSeal. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ChronSeal through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1452] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for CMX-2043. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CMX-2043 through regulating the expression of Proto-oncogene c-Met (MET). | [497], [1440] | ||
Emibetuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Emibetuzumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Emibetuzumab through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1453] | ||
HM-5016504 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for HM-5016504. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HM-5016504 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1454] | ||
LY-2875358 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for LY-2875358. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY-2875358 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
LY2801653 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for LY2801653. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY2801653 through regulating the expression of Proto-oncogene c-Met (MET). | [214], [1440] | ||
MK-2461 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for MK-2461. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-2461 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1455] | ||
SAR-125844 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for SAR-125844. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAR-125844 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1456] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Sym015. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sym015 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1457] | ||
Telisotuzumab vedotin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Telisotuzumab vedotin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Telisotuzumab vedotin through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1458] | ||
XL880 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for XL880. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XL880 through regulating the expression of Proto-oncogene c-Met (MET). | [933], [1440] | ||
ABBV-399 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for ABBV-399. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABBV-399 through regulating the expression of Proto-oncogene c-Met (MET). | [5], [1440] | ||
ABT-700 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for ABT-700. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-700 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1459] | ||
Altiratinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Altiratinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Altiratinib through regulating the expression of Proto-oncogene c-Met (MET). | [497], [1440] | ||
Autologous T Cells Expressing MET scFv CAR [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Autologous T Cells Expressing MET scFv CAR. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Autologous T Cells Expressing MET scFv CAR through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1460] | ||
BPI-9016 M [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for BPI-9016 M. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BPI-9016 M through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1461] | ||
CBT-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for CBT-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CBT-101 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1462] | ||
E-7050 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for E-7050. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of E-7050 through regulating the expression of Proto-oncogene c-Met (MET). | [518], [1440] | ||
EMD-1204831 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for EMD-1204831. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EMD-1204831 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1463] | ||
Hepapoietin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Hepapoietin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Hepapoietin through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1464] | ||
JNJ-38877605 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for JNJ-38877605. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ-38877605 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1465] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for LY3164530. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3164530 through regulating the expression of Proto-oncogene c-Met (MET). | [11], [1440] | ||
MK-8033 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for MK-8033. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-8033 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1466] | ||
PF-4217903 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for PF-4217903. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-4217903 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1467] | ||
REGN5093 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for REGN5093. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of REGN5093 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
RXDX-106 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for RXDX-106. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RXDX-106 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1468] | ||
SGX523 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for SGX523. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SGX523 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1469] | ||
TPX-0022 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for TPX-0022. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TPX-0022 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1470] | ||
TR1801-ADC [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for TR1801-ADC. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TR1801-ADC through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1471] | ||
XL092 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for XL092. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XL092 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1472] | ||
Mteron-F1 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Mteron-F1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mteron-F1 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1473] | ||
NPS-1034 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for NPS-1034. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NPS-1034 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1474] | ||
1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1475] | ||
1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1476] | ||
1-benzyl-1H-pyrrolo[3,2-b]pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for 1-benzyl-1H-pyrrolo[3,2-b]pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-benzyl-1H-pyrrolo[3,2-b]pyridine through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1476] | ||
3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1476] | ||
ALD-805 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for ALD-805. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALD-805 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
ALD-806 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for ALD-806. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALD-806 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1477] | ||
AM7 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for AM7. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AM7 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
Anti-cMET mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for Anti-cMET mab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Anti-cMET mab through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
APS-3010 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for APS-3010. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APS-3010 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
BAY-85-3474 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for BAY-85-3474. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BAY-85-3474 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1476] | ||
CMET Avimer polypeptides [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for CMET Avimer polypeptides. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CMET Avimer polypeptides through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
DP-3590 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for DP-3590. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DP-3590 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
GE-137 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for GE-137. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GE-137 through regulating the expression of Proto-oncogene c-Met (MET). | [683], [1440] | ||
HuMax-cMet [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for HuMax-cMet. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HuMax-cMet through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
LA-480 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for LA-480. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LA-480 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
mab 224G11 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for mab 224G11. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of mab 224G11 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
PF-00614435 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for PF-00614435. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-00614435 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1478] | ||
PHA-665752 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for PHA-665752. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PHA-665752 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
PRS-110 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for PRS-110. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PRS-110 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
RP-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for RP-1040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RP-1040 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
SU11274 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for SU11274. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SU11274 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1479] | ||
TP-801 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Met (MET) is a therapeutic target for TP-801. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TP-801 through regulating the expression of Proto-oncogene c-Met (MET). | [1440], [1444] | ||
Proto-oncogene c-Myc (MYC)
AVI-5126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC). | [1285], [1480] | ||
Resten-NG [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). | [1285], [1481] | ||
TWS-119 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). | [1285], [1482] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [5], [1483] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1484] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [5], [1483] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1466], [1483] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [5], [1483] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [241], [1483] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1485] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [5], [1483] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1486] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [414], [1483] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1486] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1250], [1483] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [5], [1483] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [624], [1483] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [590], [1483] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [624], [1483] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [624], [1483] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1487] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [210], [1483] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [709], [1483] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1488] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [624], [1483] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1489] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1486] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1490] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1488] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1491] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1486] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1492] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1486] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [624], [1483] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1493] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [586], [1483] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1492] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [1483], [1486] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [5], [1483] | ||
Retinoic acid-inducible gene-1 (RIG-1)
SB-9200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for SB-9200. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-9200 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). | [1494], [1495] | ||
CV8102 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for CV8102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CV8102 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). | [1494], [1496] | ||
MK-4621 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for MK-4621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MK-4621 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). | [1494], [1497] | ||
Ribosomal protein S6 kinase beta-1 (S6K1)
PF-4708671 [Clinical trial]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for PF-4708671. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-4708671 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [5], [1498] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for M2698. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of M2698 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [1498], [1499] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [590], [1498] | ||
ACTB-1003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for ACTB-1003. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ACTB-1003 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [1487], [1498] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for CI-1040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CI-1040 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [1498], [1500] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for KN-62. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KN-62 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [1489], [1498] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for KT-5720. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KT-5720 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [1498], [1501] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for RO-316233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-316233 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [624], [1498] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for Ro31-8220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro31-8220 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [624], [1498] | ||
SB-415286 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for SB-415286. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-415286 through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [624], [1498] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for SB-747651A. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-747651A through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [1498], [1502] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ribosomal protein S6 kinase beta-1 (S6K1) is a therapeutic target for STAUROSPORINONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Ribosomal protein S6 kinase beta-1 (S6K1). | [624], [1498] | ||
Sequestosome-1 p62 (SQSTM1)
IMX-942 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sequestosome-1 p62 (SQSTM1) is a therapeutic target for IMX-942. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMX-942 through regulating the expression of Sequestosome-1 p62 (SQSTM1). | [1503], [1504] | ||
Serine/threonine-protein kinase mTOR (mTOR)
Glasdegib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Glasdegib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glasdegib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1505] | ||
Novolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Novolimus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Novolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [211], [1483] | ||
Temsirolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Temsirolimus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Temsirolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1506] | ||
Zotarolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Zotarolimus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Zotarolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
Ridaforolimus [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ridaforolimus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ridaforolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1507] | ||
ABI-009 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ABI-009. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABI-009 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1465], [1483] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD-2014. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-2014 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
BEZ235 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BEZ235. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BEZ235 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [5], [1483] | ||
BGT226 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BGT226. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BGT226 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
CC-223 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CC-223. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CC-223 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1508] | ||
INK128 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1509] | ||
| Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1526] | |||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LY3023414. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY3023414 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1510] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ME-344. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ME-344 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1511] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for MM-141. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MM-141 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [5], [1483] | ||
OSI-027 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OSI-027. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OSI-027 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1512] | ||
PF-04691502 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-04691502. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-04691502 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1513] | ||
PF-05212384 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05212384. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-05212384 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1217], [1483] | ||
PQR309 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PQR309. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PQR309 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1215], [1483] | ||
Salirasib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Salirasib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Salirasib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
SAR245409 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SAR245409. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SAR245409 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1514] | ||
SF1126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SF1126. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SF1126 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [5], [1483] | ||
BI 860585 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BI 860585. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI 860585 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1515] | ||
DS-3078 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-3078. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-3078 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1516] | ||
DS-7423 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-7423. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-7423 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1517] | ||
GDC-0349 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for GDC-0349. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GDC-0349 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
LAM-001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LAM-001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LAM-001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1518] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [414], [1483] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for VS-5584. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VS-5584 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1519] | ||
(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1521] | ||
2-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(6-morpholino-9H-purin-2-yl)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
2-chloro-N-(6-cyanopyridin-3-yl)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-chloro-N-(6-cyanopyridin-3-yl)propanamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-chloro-N-(6-cyanopyridin-3-yl)propanamide through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1522] | ||
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1523] | ||
3-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 3-(6-morpholino-9H-purin-2-yl)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1524] | ||
4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
4-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(6-morpholino-9H-purin-2-yl)phenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
AP-21967 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AP-21967. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AP-21967 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1521] | ||
AR-mTOR-26 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AR-mTOR-26. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AR-mTOR-26 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
C-16-(S)-3-methylindolerapamycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for C-16-(S)-3-methylindolerapamycin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C-16-(S)-3-methylindolerapamycin through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1520] | ||
CU-906 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CU-906. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CU-906 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
EC-0565 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0565. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EC-0565 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
EC-0845 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0845. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EC-0845 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
EM-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EM-101. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of EM-101 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1525] | ||
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1523] | ||
HM-5016699 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for HM-5016699. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HM-5016699 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
OXA-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OXA-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OXA-01 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
P-2281 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-2281. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of P-2281 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
P-6915 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-6915. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of P-6915 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
PF-03772304 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-03772304. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-03772304 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
PF-05094037 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05094037. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-05094037 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1527] | ||
PP-242 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP-242. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PP-242 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [543], [1483] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP121. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PP121 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [551], [1483] | ||
Rapamycin complexed with immunophilin FKBP12 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Rapamycin complexed with immunophilin FKBP12. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Rapamycin complexed with immunophilin FKBP12 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1523] | ||
SB-2280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SB-2280. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-2280 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
SX-MTR1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SX-MTR1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SX-MTR1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
torin 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for torin 1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of torin 1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [551], [1483] | ||
Torin2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Torin2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Torin2 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1528] | ||
X-387 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for X-387. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of X-387 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [466], [1483] | ||
AZD8055 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD8055. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD8055 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1529] | ||
SCR-44001 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SCR-44001. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SCR-44001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [1483], [1530] | ||
TAFA-93 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for TAFA-93. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAFA-93 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [613], [1483] | ||
Signal transducer and activator of transcription 1 (STAT1)
AVT-02 UE [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 1 (STAT1) is a therapeutic target for AVT-02 UE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVT-02 UE through regulating the expression of Signal transducer and activator of transcription 1 (STAT1). | [191], [1531] | ||
Signal transducer and activator of transcription 3 (STAT3)
Acitretin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Acitretin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acitretin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1531] | ||
Napabucasin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Napabucasin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Napabucasin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1532] | ||
Atiprimod [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Atiprimod. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Atiprimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1533] | ||
GLG-801 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GLG-801. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GLG-801 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1534] | ||
Golotimod [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Golotimod. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Golotimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [5], [790] | ||
IMX-110 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for IMX-110. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IMX-110 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [5], [790] | ||
ISIS-STAT3 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS-STAT3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS-STAT3 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1535] | ||
NT219 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for NT219. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NT219 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1536] | ||
OPB-31121 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-31121. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OPB-31121 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [5], [790] | ||
WP-1066 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP-1066. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WP-1066 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [5], [790] | ||
C188-9 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for C188-9. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of C188-9 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1537] | ||
DSP-0337 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for DSP-0337. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DSP-0337 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [26], [790] | ||
OPB-111077 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-111077. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OPB-111077 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1538] | ||
OPB-51602 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-51602. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OPB-51602 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1539] | ||
TAK-114 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for TAK-114. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-114 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1540] | ||
WP1220 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP1220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WP1220 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1541] | ||
GNF-PF-1399 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GNF-PF-1399. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GNF-PF-1399 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1542] | ||
ISIS 113176 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113176. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113176 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1535] | ||
ISIS 113187 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113187. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113187 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1535] | ||
ISIS 113209 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113209. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113209 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1535] | ||
ISIS 113210 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113210. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113210 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [5], [790] | ||
ISIS 17148 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1535] | ||
ISIS 17152 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17152. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 17152 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3). | [790], [1535] | ||
Solute carrier family 45 member 4 (SLC45A4)
Sucrose [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Solute carrier family 45 member 4 (SLC45A4) is a therapeutic target for Sucrose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Sucrose through regulating the expression of Solute carrier family 45 member 4 (SLC45A4). | [1543], [1544] | ||
SRSF protein kinase 1 (SRPK1)
SPHINX31 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | SRSF protein kinase 1 (SRPK1) is a therapeutic target for SPHINX31. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SPHINX31 through regulating the expression of SRSF protein kinase 1 (SRPK1). | [426], [1545] | ||
Stress-activated protein kinase 2a (p38 alpha)
Ozagrel [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ozagrel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ozagrel through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1547] | ||
Losmapimod [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Losmapimod. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Losmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1548] | ||
Dilmapimod [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Dilmapimod. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dilmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1549] | ||
VX-702 [Phase 2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for VX-702. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VX-702 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [471], [1546] | ||
VX-745 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for VX-745. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VX-745 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1550] | ||
(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1551] | ||
2-Chlorophenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 2-Chlorophenol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Chlorophenol through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [220], [1546] | ||
3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [210], [1546] | ||
3-(Benzyloxy)Pyridin-2-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 3-(Benzyloxy)Pyridin-2-Amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 3-(Benzyloxy)Pyridin-2-Amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [210], [1546] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1552] | ||
4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1553] | ||
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [220], [1546] | ||
4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
6-(4-Fluoro-phenylsulfanyl)-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-(4-Fluoro-phenylsulfanyl)-9H-purine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-(4-Fluoro-phenylsulfanyl)-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
6-Benzylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-Benzylsulfanyl-9H-purine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Benzylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [624], [1546] | ||
6-o-tolylquinazolin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-o-tolylquinazolin-2-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-o-tolylquinazolin-2-amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1394], [1546] | ||
6-Phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-Phenylsulfanyl-9H-purine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-Phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1555] | ||
9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
9-Benzyl-6-phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-Benzyl-6-phenylsulfanyl-9H-purine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 9-Benzyl-6-phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for AG1478. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AG1478 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1556] | ||
B-Octylglucoside [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for B-Octylglucoside. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of B-Octylglucoside through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1557] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Bisindolylmaleimide-I. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for CI-1040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CI-1040 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1558] | ||
Dihydro-quinolinone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Dihydro-quinolinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dihydro-quinolinone through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1559] | ||
DP-802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for DP-802. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DP-802 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1547] | ||
GSK-280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for GSK-280. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GSK-280 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1560] | ||
GW-788388 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for GW-788388. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GW-788388 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [624], [1546] | ||
IN-1130 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for IN-1130. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IN-1130 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1561] | ||
IN-1166 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for IN-1166. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IN-1166 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1489], [1546] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for KN-62. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KN-62 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1559] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for KT-5720. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KT-5720 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1562] | ||
L-779450 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for L-779450. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of L-779450 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [590], [1546] | ||
ML-3163 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3163. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ML-3163 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1563] | ||
ML-3375 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3375. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ML-3375 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1564] | ||
ML-3403 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3403. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ML-3403 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [624], [1546] | ||
N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1565] | ||
N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1565] | ||
N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1565] | ||
N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [624], [1546] | ||
N-(4-methyl-benzyl)-4-phenoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-methyl-benzyl)-4-phenoxy-benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-methyl-benzyl)-4-phenoxy-benzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1566] | ||
Oxindole 94 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Oxindole 94. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Oxindole 94 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1565] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PD-0166326. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0166326 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1567] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PD-0173956. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PD-0173956 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1394], [1546] | ||
PHA-666859 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PHA-666859. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PHA-666859 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1547] | ||
Phenyl-(3-phenyl-1H-indazol-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Phenyl-(3-phenyl-1H-indazol-6-yl)-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phenyl-(3-phenyl-1H-indazol-6-yl)-amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [624], [1546] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for RO-316233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-316233 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1554] | ||
Ro-3201195 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ro-3201195. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro-3201195 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1568] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ro31-8220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro31-8220 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1567] | ||
RWJ-68354 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for RWJ-68354. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RWJ-68354 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1563] | ||
SB-216995 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-216995. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-216995 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1569] | ||
SB-218655 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-218655. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-218655 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1394], [1546] | ||
SB-227931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-227931. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-227931 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1570] | ||
Small molecule 34 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Small molecule 34. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Small molecule 34 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [210], [1546] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for STAUROSPORINONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [624], [1546] | ||
Talmapimod [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Talmapimod. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Talmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [220], [1546] | ||
Triazolopyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Triazolopyridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Triazolopyridine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [220], [1546] | ||
UCB-1277763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for UCB-1277763. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UCB-1277763 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1547] | ||
ZM-336372 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ZM-336372. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ZM-336372 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1571] | ||
FR167653 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for FR167653. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FR167653 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [471], [1546] | ||
PAMAPIMOD [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PAMAPIMOD. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PAMAPIMOD through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [471], [1546] | ||
R-1487 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for R-1487. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of R-1487 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1549] | ||
SB 203580 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB 203580. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB 203580 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1572] | ||
SB 235699 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB 235699. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB 235699 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1573] | ||
SB-242235 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-242235. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-242235 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1574] | ||
SB220025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB220025. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB220025 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [1546], [1575] | ||
SC-102 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SC-102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SC-102 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [210], [1546] | ||
Stress-activated protein kinase JNK1 (JNK1)
NKP-1339 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for NKP-1339. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NKP-1339 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1572] | ||
COR-D [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for COR-D. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of COR-D through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1576] | ||
2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [624], [674] | ||
2-(2-butoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-butoxypyrimidin-4-ylamino)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-butoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
2-(2-phenoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
2-(2-propoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-propoxypyrimidin-4-ylamino)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-propoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1578] | ||
Aminopyridine deriv. 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Aminopyridine deriv. 2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aminopyridine deriv. 2 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1579] | ||
AS-601245 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for AS-601245. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AS-601245 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1577] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Bisindolylmaleimide-I. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [688] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for CI-1040. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CI-1040 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1576] | ||
JNK-IN-8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for JNK-IN-8. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNK-IN-8 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [210], [674] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for KN-62. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KN-62 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1489] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for KT-5720. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KT-5720 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [1580] | ||
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [675] | ||
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [675] | ||
N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [624], [674] | ||
N-(6-ethoxypyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(6-ethoxypyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(6-ethoxypyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [675] | ||
NM-PP1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for NM-PP1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NM-PP1 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [624], [674] | ||
Phylomers [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Phylomers. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Phylomers through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [675] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for RO-316233. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO-316233 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [624], [674] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for Ro31-8220. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ro31-8220 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [674], [688] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for STAUROSPORINONE. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). | [624], [674] | ||
Sulfonylurea receptor 2 (ABCC9)
Glimepiride [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for Glimepiride. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Glimepiride through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1582] | ||
Nicorandil [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for Nicorandil. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nicorandil through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1583] | ||
Repaglinide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for Repaglinide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Repaglinide through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1584] | ||
Tolbutamide [Approved]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for Tolbutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tolbutamide through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1585] | ||
| Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for Tolbutamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Tolbutamide through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1586] | |||
BMS-191095 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for BMS-191095. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-191095 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1587] | ||
BTS-67582 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for BTS-67582. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BTS-67582 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1588] | ||
CCX915 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for CCX915. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CCX915 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1589] | ||
KRN-2391 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for KRN-2391. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KRN-2391 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). | [1581], [1590] | ||
Tankyrase-1 (TNKS-1)
PMID27841036-Compound-37 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tankyrase-1 (TNKS-1) is a therapeutic target for PMID27841036-Compound-37. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMID27841036-Compound-37 through regulating the expression of Tankyrase-1 (TNKS-1). | [950], [1264] | ||
Stenoparib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tankyrase-1 (TNKS-1) is a therapeutic target for Stenoparib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Stenoparib through regulating the expression of Tankyrase-1 (TNKS-1). | [950], [1591] | ||
Target of rapamycin complex 2 MAPKAP1 (MTORC2)
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for AZD-2014. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AZD-2014 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [210], [1592] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for ME-344. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ME-344 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [5], [1592] | ||
Palomid-529 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for Palomid-529. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Palomid-529 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [5], [1592] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Target of rapamycin complex 2 MAPKAP1 (MTORC2) is a therapeutic target for VS-5584. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VS-5584 through regulating the expression of Target of rapamycin complex 2 MAPKAP1 (MTORC2). | [835], [1592] | ||
Thioredoxin (TXN)
PX-12 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thioredoxin (TXN) is a therapeutic target for PX-12. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PX-12 through regulating the expression of Thioredoxin (TXN). | [1593], [1594] | ||
Acetate Ion [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thioredoxin (TXN) is a therapeutic target for Acetate Ion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Acetate Ion through regulating the expression of Thioredoxin (TXN). | [1593], [1595] | ||
Cacodylate Ion [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thioredoxin (TXN) is a therapeutic target for Cacodylate Ion. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cacodylate Ion through regulating the expression of Thioredoxin (TXN). | [210], [1593] | ||
Transcription factor Sp1 (SP1)
Terameprocol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transcription factor Sp1 (SP1) is a therapeutic target for Terameprocol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Terameprocol through regulating the expression of Transcription factor Sp1 (SP1). | [1596], [1597] | ||
Transforming growth factor beta 1 (TGFB1)
Pirfenidone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Pirfenidone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pirfenidone through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [963], [1598] | ||
LY2157299 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [1598], [1599] | ||
TG-C [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for TG-C. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TG-C through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [1153], [1598] | ||
Disitertide [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Disitertide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Disitertide through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [5], [1598] | ||
ABBV-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ABBV-151. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABBV-151 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [1598], [1600] | ||
SRK-181 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for SRK-181. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SRK-181 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [1598], [1601] | ||
ART-144 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for ART-144. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ART-144 through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [1598], [1602] | ||
Mannose phosphate [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transforming growth factor beta 1 (TGFB1) is a therapeutic target for Mannose phosphate. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Mannose phosphate through regulating the expression of Transforming growth factor beta 1 (TGFB1). | [1598], [1603] | ||
Tumor necrosis factor (TNF)
Adalimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Adalimumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Adalimumab through regulating the expression of Tumor necrosis factor (TNF). | [23], [1604] | ||
Certolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Certolizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Certolizumab through regulating the expression of Tumor necrosis factor (TNF). | [23], [1605] | ||
Enbrel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Enbrel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enbrel through regulating the expression of Tumor necrosis factor (TNF). | [23], [1606] | ||
Etanercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Etanercept. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Etanercept through regulating the expression of Tumor necrosis factor (TNF). | [23], [1607] | ||
Golimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golimumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Golimumab through regulating the expression of Tumor necrosis factor (TNF). | [23], [1608] | ||
Infliximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Infliximab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Infliximab through regulating the expression of Tumor necrosis factor (TNF). | [23], [1609] | ||
Lenalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Lenalidomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Lenalidomide through regulating the expression of Tumor necrosis factor (TNF). | [23], [1610] | ||
Nafamostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Nafamostat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Nafamostat through regulating the expression of Tumor necrosis factor (TNF). | [23], [1611] | ||
Pentoxifylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pentoxifylline. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pentoxifylline through regulating the expression of Tumor necrosis factor (TNF). | [23], [1612] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Thalidomide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thalidomide through regulating the expression of Tumor necrosis factor (TNF). | [23], [613] | ||
ABP 501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABP 501. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABP 501 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1613] | ||
CPL-7075 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1614] | ||
Golnerminogene pradenovac [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golnerminogene pradenovac. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Golnerminogene pradenovac through regulating the expression of Tumor necrosis factor (TNF). | [23], [1615] | ||
PF-06410293 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06410293. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-06410293 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1616] | ||
PF-06438179 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06438179. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-06438179 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1617] | ||
ABT-122 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABT-122. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABT-122 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1425] | ||
AN0128 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AN0128. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AN0128 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1618] | ||
AP-301-IH [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AP-301-IH. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AP-301-IH through regulating the expression of Tumor necrosis factor (TNF). | [23], [1619] | ||
ART621 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ART621. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ART621 through regulating the expression of Tumor necrosis factor (TNF). | [23], [518] | ||
BAICALEIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for BAICALEIN. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BAICALEIN through regulating the expression of Tumor necrosis factor (TNF). | [23], [1620] | ||
COVA322 [Phase 1/2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for COVA322. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of COVA322 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1621] | ||
DLX-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DLX-105. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DLX-105 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1622] | ||
ESBA-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ESBA-105. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ESBA-105 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1623] | ||
Ortataxel [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Ortataxel. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ortataxel through regulating the expression of Tumor necrosis factor (TNF). | [23], [1624] | ||
Pegsunercept [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pegsunercept. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pegsunercept through regulating the expression of Tumor necrosis factor (TNF). | [23], [1625] | ||
RDP58 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1626] | ||
TNF alpha kinoid [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNF alpha kinoid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TNF alpha kinoid through regulating the expression of Tumor necrosis factor (TNF). | [23], [1627] | ||
ABBV-257 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABBV-257. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABBV-257 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1628] | ||
AST-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AST-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AST-005 through regulating the expression of Tumor necrosis factor (TNF). | [23], [60] | ||
AVX-470 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AVX-470. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVX-470 through regulating the expression of Tumor necrosis factor (TNF). | [23], [60] | ||
CYT-609 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-609. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYT-609 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1629] | ||
INB03 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for INB03. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INB03 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1630] | ||
PF-05230905 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-05230905. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-05230905 through regulating the expression of Tumor necrosis factor (TNF). | [23], [963] | ||
PMI-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PMI-005. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMI-005 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1631] | ||
ABX-0401 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABX-0401. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABX-0401 through regulating the expression of Tumor necrosis factor (TNF). | [23], [28] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Celastrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Celastrol through regulating the expression of Tumor necrosis factor (TNF). | [23], [214] | ||
2-Propanol, Isopropanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). | [23], [1632] | ||
DOM-0215 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DOM-0215. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DOM-0215 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1633] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for IK-862. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IK-862 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1634] | ||
PKF-241-466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-241-466. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PKF-241-466 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1634] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-242-484. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PKF-242-484 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1187] | ||
Y-39041 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Y-39041. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Y-39041 through regulating the expression of Tumor necrosis factor (TNF). | [23], [881] | ||
ALS-00T2-0501 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ALS-00T2-0501. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALS-00T2-0501 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1635] | ||
AME-527 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AME-527. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AME-527 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1633] | ||
Camobucol [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Camobucol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Camobucol through regulating the expression of Tumor necrosis factor (TNF). | [23], [1636] | ||
CDP571 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CDP571. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CDP571 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1637] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1638] | ||
CYT-007-TNFQb [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-007-TNFQb. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CYT-007-TNFQb through regulating the expression of Tumor necrosis factor (TNF). | [23], [746] | ||
FR-133605 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for FR-133605. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of FR-133605 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1639] | ||
ISIS 104838 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ISIS 104838. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 104838 through regulating the expression of Tumor necrosis factor (TNF). | [23], [581] | ||
MDL-201112 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for MDL-201112. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MDL-201112 through regulating the expression of Tumor necrosis factor (TNF). | [23], [1640] | ||
PNU-282987 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PNU-282987. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PNU-282987 through regulating the expression of Tumor necrosis factor (TNF). | [23], [46] | ||
Segard [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Segard. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Segard through regulating the expression of Tumor necrosis factor (TNF). | [23], [1641] | ||
TNFQb therapeutic vaccines [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNFQb therapeutic vaccines. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TNFQb therapeutic vaccines through regulating the expression of Tumor necrosis factor (TNF). | [23], [1642] | ||
Tyrosine-protein kinase EIF2AK2 (p68)
ASN-11124542 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase EIF2AK2 (p68) is a therapeutic target for ASN-11124542. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ASN-11124542 through regulating the expression of Tyrosine-protein kinase EIF2AK2 (p68). | [1643], [1644] | ||
NU6140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase EIF2AK2 (p68) is a therapeutic target for NU6140. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NU6140 through regulating the expression of Tyrosine-protein kinase EIF2AK2 (p68). | [1643], [1645] | ||
Tyrosine-protein kinase UFO (AXL)
Gilteritinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Gilteritinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Gilteritinib through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1647] | ||
Bemcentinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Bemcentinib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bemcentinib through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1648] | ||
BGB-324 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BGB-324. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BGB-324 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1649] | ||
BI-505 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BI-505. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI-505 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [5], [1646] | ||
Enapotamab vedotin [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Enapotamab vedotin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Enapotamab vedotin through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1650] | ||
MGCD265 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for MGCD265. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MGCD265 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [414], [1646] | ||
ONO-7475 [Phase 1/2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for ONO-7475. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ONO-7475 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1651] | ||
| Tyrosine-protein kinase UFO (AXL) is a therapeutic target for ONO-7475. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ONO-7475 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [5], [1646] | |||
TP-0903 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for TP-0903. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TP-0903 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1652] | ||
AVB-S6-500 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for AVB-S6-500. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AVB-S6-500 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1470], [1646] | ||
BPI-9016 M [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for BPI-9016 M. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BPI-9016 M through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [5], [1646] | ||
DS-1205 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for DS-1205. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-1205 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [5], [1646] | ||
INCB81776 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for INCB81776. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of INCB81776 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1471], [1646] | ||
PF-07265807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for PF-07265807. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PF-07265807 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1653] | ||
RXDX-106 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for RXDX-106. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RXDX-106 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1654] | ||
Cu-anti-hAXL [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for Cu-anti-hAXL. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cu-anti-hAXL through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [5], [1646] | ||
DP-3975 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for DP-3975. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DP-3975 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1655] | ||
GL21.T [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for GL21.T. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of GL21.T through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1655] | ||
YW327.6S2 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for YW327.6S2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of YW327.6S2 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1656] | ||
LDC1267 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tyrosine-protein kinase UFO (AXL) is a therapeutic target for LDC1267. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase UFO (AXL). | [1646], [1655] | ||
Ubiquitin-protein ligase E3 Mdm2 (MDM2)
RG7388 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for RG7388. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG7388 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1658] | ||
ALRN-6924 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ALRN-6924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALRN-6924 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1659] | ||
AMG 232 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for AMG 232. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of AMG 232 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [5], [1657] | ||
APG-115 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for APG-115. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of APG-115 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1660] | ||
ASTX295 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ASTX295. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ASTX295 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1661] | ||
BI 907828 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for BI 907828. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BI 907828 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1662] | ||
DS-3032 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for DS-3032. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DS-3032 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1663] | ||
HDM201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for HDM201. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HDM201 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1664] | ||
JNJ-26854165 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for JNJ-26854165. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of JNJ-26854165 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [5], [1657] | ||
RG7775 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for RG7775. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG7775 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1665] | ||
ISIS 16507 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ISIS 16507. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 16507 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1666] | ||
ISIS 16518 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ISIS 16518. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 16518 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [228], [1657] | ||
MI-219 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for MI-219. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MI-219 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1667] | ||
NSC-66811 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for NSC-66811. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NSC-66811 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1668] | ||
NU-8231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for NU-8231. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NU-8231 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1669] | ||
NUTLIN-3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for NUTLIN-3. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NUTLIN-3 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1670] | ||
PLSQETFSDLWKLLPEN-NH2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for PLSQETFSDLWKLLPEN-NH2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PLSQETFSDLWKLLPEN-NH2 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). | [1657], [1671] | ||
Uridine-cytidine kinase 2 (UCK2)
Uridine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Uridine-cytidine kinase 2 (UCK2) is a therapeutic target for Uridine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Uridine through regulating the expression of Uridine-cytidine kinase 2 (UCK2). | [1672], [1673] | ||
Cytidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Uridine-cytidine kinase 2 (UCK2) is a therapeutic target for Cytidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cytidine through regulating the expression of Uridine-cytidine kinase 2 (UCK2). | [1672], [1673] | ||
Urokinase-type plasminogen activator (PLAU)
PAI-1 [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for PAI-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PAI-1 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1675] | ||
Pro-urokinase [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Pro-urokinase. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Pro-urokinase through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1153], [1674] | ||
Urokinase [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Urokinase. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Urokinase through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1676] | ||
Amediplase [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Amediplase. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Amediplase through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1504], [1674] | ||
HTU-PA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for HTU-PA. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of HTU-PA through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1677] | ||
PMID18163548C4 [Clinical trial]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for PMID18163548C4. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PMID18163548C4 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1678] | ||
Saruplase [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Saruplase. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Saruplase through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1679] | ||
UK-356202 [Clinical trial]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for UK-356202. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UK-356202 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1680] | ||
Upamostat [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Upamostat. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Upamostat through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1681] | ||
(2R)-1-(2,6-dimethylphenoxy)propan-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (2R)-1-(2,6-dimethylphenoxy)propan-2-amine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (2R)-1-(2,6-dimethylphenoxy)propan-2-amine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1682] | ||
(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
(4-guanidino-benzyl)-carbamic acid benzyl ester [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (4-guanidino-benzyl)-carbamic acid benzyl ester. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-guanidino-benzyl)-carbamic acid benzyl ester through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
(4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
(4-nitro-1H-pyrazol-1-yl)(phenyl)methanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1684] | ||
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1685] | ||
1-guanidino-7-isoquinolinesulphonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 1-guanidino-7-isoquinolinesulphonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-guanidino-7-isoquinolinesulphonamide through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1685] | ||
1-guanidino-N-phenyl-7-isoquinolinesulphonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 1-guanidino-N-phenyl-7-isoquinolinesulphonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-guanidino-N-phenyl-7-isoquinolinesulphonamide through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [220], [1674] | ||
2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1686] | ||
2-Amino-5-Hydroxy-Benzimidazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 2-Amino-5-Hydroxy-Benzimidazole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Amino-5-Hydroxy-Benzimidazole through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [210], [1674] | ||
2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1687] | ||
4-chloro-1-guanidino-7-isoquinolinesulphonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 4-chloro-1-guanidino-7-isoquinolinesulphonamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-chloro-1-guanidino-7-isoquinolinesulphonamide through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1685] | ||
4-iodobenzo[b]thiophene 2-carboxamidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 4-iodobenzo[b]thiophene 2-carboxamidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-iodobenzo[b]thiophene 2-carboxamidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1688] | ||
4-methoxy-N'-(2-phenylacetyl)benzohydrazide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 4-methoxy-N'-(2-phenylacetyl)benzohydrazide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 4-methoxy-N'-(2-phenylacetyl)benzohydrazide through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1683] | ||
5-Methylsulfanyl-thiophene-2-carboxamidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 5-Methylsulfanyl-thiophene-2-carboxamidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-Methylsulfanyl-thiophene-2-carboxamidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [210], [1674] | ||
6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [220], [1674] | ||
ATF-HI-8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for ATF-HI-8. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ATF-HI-8 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1689] | ||
ATN-658 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for ATN-658. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ATN-658 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1504], [1674] | ||
B-623 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for B-623. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of B-623 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1690] | ||
Benzamidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Benzamidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Benzamidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [210], [1674] | ||
CRA_10655 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for CRA_10655. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRA_10655 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [210], [1674] | ||
CRA_8696 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for CRA_8696. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRA_8696 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [210], [1674] | ||
Fucose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Fucose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Fucose through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [220], [1674] | ||
N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [220], [1674] | ||
Recombinant human pro-urokinase [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Recombinant human pro-urokinase. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Recombinant human pro-urokinase through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1691] | ||
Thieno[2,3-B]Pyridine-2-Carboxamidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for Thieno[2,3-B]Pyridine-2-Carboxamidine. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thieno[2,3-B]Pyridine-2-Carboxamidine through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [220], [1674] | ||
UPA-targeted oncolytic Sendai virus [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for UPA-targeted oncolytic Sendai virus. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of UPA-targeted oncolytic Sendai virus through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1504], [1674] | ||
B-428 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for B-428. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of B-428 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1692] | ||
PAI-2 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for PAI-2. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PAI-2 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1693] | ||
WX-UK1 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Urokinase-type plasminogen activator (PLAU) is a therapeutic target for WX-UK1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of WX-UK1 through regulating the expression of Urokinase-type plasminogen activator (PLAU). | [1674], [1694] | ||
Vacuolar-type proton ATPase catalytic A (v-ATPase-A)
Cruentaren [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vacuolar-type proton ATPase catalytic A (v-ATPase-A) is a therapeutic target for Cruentaren. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cruentaren through regulating the expression of Vacuolar-type proton ATPase catalytic A (v-ATPase-A). | [426], [1695] | ||
Vascular endothelial growth factor A (VEGFA)
Aflibercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Aflibercept. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Aflibercept through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1696] | ||
Bevacizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Bevacizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bevacizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1697] | ||
Brolucizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Brolucizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Brolucizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1698] | ||
Ranibizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Ranibizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Ranibizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1443] | ||
Faricimab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Faricimab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Faricimab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1699] | ||
Abicipar pegol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Abicipar pegol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abicipar pegol through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1700] | ||
MP0250 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for MP0250. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MP0250 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1701] | ||
PTC299 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for PTC299. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PTC299 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1702] | ||
RG7221 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for RG7221. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RG7221 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [518] | ||
RO5520985 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for RO5520985. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of RO5520985 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [3], [456] | ||
SNN-0029 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for SNN-0029. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SNN-0029 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [5], [456] | ||
ABI-011 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for ABI-011. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ABI-011 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1703] | ||
MP-0112 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for MP-0112. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MP-0112 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1704] | ||
Navicixizumab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Navicixizumab. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Navicixizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [5], [456] | ||
SFLT-01 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for SFLT-01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SFLT-01 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [497] | ||
ALN-VEG01 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for ALN-VEG01. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALN-VEG01 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [414], [456] | ||
Bevasiranib [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Bevasiranib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bevasiranib through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [456], [1697] | ||
WD repeat-containing protein 5 (WDR5)
OICR-9429 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | WD repeat-containing protein 5 (WDR5) is a therapeutic target for OICR-9429. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of OICR-9429 through regulating the expression of WD repeat-containing protein 5 (WDR5). | [442], [1596] | ||
References